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Neutrophils are an important cell in host defence and migrate rapidly to sites of 
inflammation when the host is compromised (e.g., in infection or wounding).  There, 
they produce and/or release inflammatory mediators (e.g., LTB4, TNF, IL-8) and 
ingest and degrade pathogens (e.g., by release of granule proteins and reactive oxygen 
species).  Neutrophils then undergo apoptosis and are cleared by phagocytes such as 
macrophages, to allow efficient resolution of inflammation.  Inducing neutrophil 
apoptosis by pharmacological means could be a therapeutic strategy to dampen 
inflammation in diseases where neutrophils are prevalent, e.g., acute respiratory 
distress syndrome (ARDS) and rheumatoid arthritis (RA).  Inhibition of cyclin-
dependent kinases (CDKs) using CDK inhibitor (CDKi) compounds induces 
mammalian neutrophil apoptosis in vitro, and can drive resolution of inflammation in 
vivo in mouse models.  Evidence indicated that this is due to inhibition of CDK9 and 
CDK7-mediated transcription of the anti-apoptotic protein Mcl-1. 
The hypothesis of this project was that CDK9, CDK7 and Mcl-1 are pivotal 
regulators of resolution of inflammation in vivo.  The model selected to test this 
hypothesis was tailfin injury of embryonic zebrafish (Danio rerio).  Zebrafish are 
optically transparent and reporter transgenic lines with neutrophils labelled by 
enhanced GFP (EGFP - Tg[mpx:EGFP]i114) and macrophages (Tg[MPEG1:mCherry]) 
have been created, permitting the imaging of the behaviour of these cells in vivo.  The 
model of tailfin transection was chosen to cause an inflammatory response in these 
animals, with neutrophil and macrophage recruitment to the tailfin. 
This response was manipulated using CDKi compounds and specific gene 
knockdowns (using morpholino and CRISPR/cas9 technologies).  It was shown that 
CDKi compounds could reduce neutrophil numbers at 24 h post-injury at the 
transected tailfin, but did not affect macrophage numbers.  The CDKi AT7519 
increased neutrophil apoptosis at 12 h post-injury.  Specific CDK9 knockdown using 
morpholinos or CRISPR/cas9 also reduced neutrophilic inflammation at the tailfin 24 
h after transection, accompanied by increased apoptosis levels at 8 h in the 
morpholino-treated group.  Inhibition of an endogenous CDK9 inhibitor, LaRP7, had 
the opposite effect and increased neutrophil numbers; and could oppose the neutrophil-
19 
 
reducing effect of AT7519 and CDK9 morpholino knockdown.  Preliminary genetic 
knockdown studies into the roles of CDK7 and Mcl-1 have been carried out.  Taken 
together, the results demonstrate CDK9 is important in the resolution of neutrophilic 
inflammation, indicating that manipulation of CDK9 activity could be a good target 






Cells of the immune system work to protect the body against infection and help to heal 
damaged tissue.  These processes are known as an inflammatory response.  Immune 
cells circulate in the blood and move to places where they are needed in host defence.  
One such cell is the neutrophil, which quickly move to sites of inflammation, where 
they “eat” and destroy bugs that invade the body using digestive substances stored 
inside the cell.  Neutrophils also release small substances that attract other immune 
cells to the inflammatory area, launching a co-ordinated response to the original 
stimulus.  After this stimulus is cleared, neutrophils undergo a death process called 
apoptosis, to avoid the inflammation carrying on for too long in an uncontrolled 
manner.  This can end up causing more damage to the tissue than the original 
inflammatory stimulus did.  There are several diseases where this happens, including 
rheumatoid arthritis (RA) and acute respiratory distress syndrome (ARDS).  For this 
reason, this project has investigated if drugs could be used to cause the death of 
neutrophils, and therefore help to resolve inflammation. 
   Specific drugs known as cyclin-dependent kinase inhibitor (CDKi) drugs have been 
shown to cause death of neutrophils.  In rodent tests they have also been shown to help 
cure models of inflammatory disease; for example in one model, the antibiotic 
bleomycin sulphate is introduced into the lung, and causes an inflammatory response 
where neutrophils are recruited.  It was thought that this was because the CDKi drugs 
inhibit a specific CDK, CDK9, which is required for the production of a pro-cell-
survival molecule called Mcl-1.  This theory was tested in this project, using 
transparent zebrafish embryos with fluorescently labelled neutrophils to carry out 
imaging of neutrophils, allowing the cell behaviour to be visualised inside a live 
animal.  This model was used to show that CDKi drugs could reduce neutrophil 
numbers after wounding of the fish tailfin, and staining for dead cells showed that 
CDKi treatment increased the number of dead neutrophils.  CDKi drugs did not affect 
the number of macrophages at the wound, which are required to take up and clear away 
apoptotic cells.  Genetic technologies were used to target genes of the CDK9 gene 
pathway.  Targeting CDK9 reduced neutrophil numbers post-wounding.  Targeting the 
LaRP7 gene, which is a negative regulator of CDK9, have the opposite effect: 
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neutrophil numbers were increased.  Preliminary studies into the role of other 
apoptosis pathway regulators (CDK7, Mcl-1) were performed.  Overall, the project 










Inflammation is vital to protect the human body from invading pathogens, and also to 
promote healing of damaged tissue.  In the vast majority of cases inflammation occurs 
and resolves without major issue in a self-contained manner.  However, in many 
disease settings inflammation is a major cause of disease pathology.  This is seen in 
diseases such as asthma, rheumatoid arthritis and sepsis (1-3).   
 The initial innate inflammatory response primarily involves cells of the 
myeloid lineage, particularly neutrophils, eosinophils and macrophages.  These cells 
are recruited soon after the host is compromised by an infection or wound, and carry 
out several functions to clear the immune challenge.  Later, cells of the adaptive arm 
of immunity (e.g. B or T lymphocytes) are recruited to carry out a more specific 
response.  The development of these cell types is outlined in Figure 1.1. 
The first sections describe what is known about mammalian inflammation; the 
last section will focus on zebrafish as an animal model for inflammation. 
 
 
Figure 1.1.  Mammalian Haematopoiesis 
The development of white blood cells, from haematopoietic stem cells, divergence 




1.1.  Inflammation at the Cellular and Molecular Level 
 
1.1.1. Granulocytes 
The inflammatory response occurs when cells in the host tissue become alerted to 
tissue damage or infiltration by pathogens.  One of the first cells to respond in this 
mammalian inflammatory response is the neutrophil.  Neutrophils arise from the 
common myeloid progenitor cell in the bone marrow, which differentiate to become 
granulocyte progenitors (Fig. 1.1.) (1).  These progenitors then become blood-
circulating neutrophils, eosinophils or basophils.  Neutrophils are the most abundant 
white blood cell (approximately 70% of circulating leukocytes, 2-7.5x109 cells/L) in 
humans (1).  They are typically thought to live in circulation for 7 – 10 h but 
inflammatory stimuli can increase this lifespan to as much as 48 h.  Other studies have 
challenged the standard dogma of neutrophil lifespan; suggesting it can be as much as 
5 days, although this is controversial (4, 5).  Neutrophils possess a multi-lobed nucleus 
and their cytoplasm is filled with primary (e.g. myeloperoxidase, phospholipase A2, 
elastins, defensins), secondary (e.g. lysozyme, nicotinamide adenine dinucleotide 
phosphate-oxidase [NADPH] oxidase, cathelicidin) and tertiary granules (e.g. 
cathepsin, gelatinase), as well as secretory granules containing plasma proteins (1, 6).  
Pathogens are phagocytosed by neutrophils and the secreted contents of the granules 
can help to destroy pathogens.  Neutrophils also secrete cytokines to send signals to 
other inflammatory cells to activate them and induce migration to tissue (e.g. tumor 
necrosis factor [TNF], interleukin [IL]-1β and IL-8) (7).  In addition, neutrophils are 
known to produce extracellular traps (NETs) which trap pathogens (8).  When 
regulation and resolution of these neutrophil responses does not occur, aberrant 
inflammation and disease occurs (see Section 2.1.2). 
 In addition to neutrophils, other inflammatory cells, i.e. eosinophils and 
basophils are also present in the blood of mammals (9).  Eosinophils are thought to be 
effective tools against parasitic infection, in particular; and high levels are also found 
in individuals during allergic reactions, especially in Western society.  They have 
many granule proteins specific to them such as major basic protein and eosinophil 
peroxidase.  Basophils release histamine and cytokines which are thought to influence 
the immune response towards a T-helper 2 phenotype by interactions with dendritic 
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cells (DCs) (10).  The lifespan of eosinophils in tissue can greatly exceed that of 
neutrophils, even as much as 6 days (9).  Basophils survive for around 60 h – 70 h (9). 
 
1.1.2. Neutrophils in disease 
Neutrophils are a vital part of host defence, and their toxic granule contents and 
phagocytic capabilities are important for the destruction of invading pathogens.  
However their actions can in fact contribute to disease and pathology, due to their 
cytotoxic cell contents, which can damage tissues.  For this reason, appropriate 
shutdown of the neutrophil response is essential.  Examples can be found in many 
different disease models.  In experimental pneumococcal meningitis in mice, over-
expression of the survival protein B cell lymphoma-2 (Bcl-2) results in lower 
neutrophil apoptosis levels, and contributes to higher brain inflammation and tissue 
damage during infection (11).  Inhibition of the pro-apoptotic p53/Puma pathway has 
been shown to extend neutrophil survival, and prevent resolution in a mouse model of 
bacterial sepsis, and increases mortality rates (12). 
In the mammalian lung, it is known that neutrophils are a key cell in acute lung 
injury (ALI) with a large neutrophil infiltrate into the lung interstitium and 
bronchoalveolar space (13).  The higher number of neutrophils present, the worse the 
disease pathology is found to be (14).  Depleting neutrophils in mouse models of ALI 
results in a reduction in inflammatory markers and prevents development of disease 
(15).  
 It is recognised that inflammation in the heart can contribute to the 
development of atherosclerosis.  Neutrophils are known to be involved in the early 
growth of atherosclerotic plaques, as neutrophil depletion correlates with a reduction 
in lesion size (16, 17).  They also contribute to later plaque rupture, when the presence 
of reactive oxygen species and proteases are known to facilitate atherothrombosis (17, 
18). 
 Recent data have even shown a role for neutrophils in the pathology of an 
Alzheimer’s disease model in mice (19).  Soluble amyloid-β was shown to cause 
activation of lymphocyte function-associated antigen-1 (LFA-1), resulting in adhesion 
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and transendothelial migration (TEM) into the brain and central nervous system.  In 
the systemic disease sepsis, the role of neutrophils is unclear; however it has been 
shown that the function of neutrophils is greatly dysregulated, with neutrophil 
accumulation at sites remote from the inflammatory response and reduced neutrophils 
at the site of inflammation (20).   
 A role for neutrophils in autoimmune diseases has also been noted.  In 
rheumatoid arthritis, neutrophils in the circulation were shown to be primed for 
reactive oxygen species (ROS) production, and become activated in the arthritic joints 
by engagement of Fc receptors on neutrophils by immune complexes like rheumatoid 
factor (21).  Mice with depleted neutrophils were resistant to the effect of transferring 
pro-atherogenic serum, and depletion of neutrophils after serum transfer was able to 
reverse the joint inflammation (22).  Therapies for the treatment of severe rheumatoid 
arthritis, including anti-TNF therapy, reduces the elevated TNF seen on neutrophils in 
rheumatoid arthritis patients; which may contribute to the efficacy of the treatment 
(23). 
It is clear that neutrophils play an important role in many diseases, and their 
persistence in inflammatory diseases may be detrimental. 
 
1.1.3. Migration of leukocytes to inflammatory sites  
Granulocytes can be attracted to inflammatory sites by numerous signals, including 
interleukin-8 (IL-8) and formyl-methionyl-leucyl phenylalanine (fMLF), which bind 
to their corresponding receptors on the leukocyte.  Pro-inflammatory lipid mediators 
(e.g. leukotriene B4 [LTB4]) are produced from the arachidonic acid biosynthesis 
pathway, and also induce granulocyte migration (24). 
Detection of these signals attracts circulating granulocytes towards 
inflammatory site, promoting their adhesion to the endothelial wall and TEM across 
the vessel wall (25) (26).  Adhesion is mediated initially by weak binding of selectin 
ligands (e.g. P-selectin glycoprotein ligand -1, PSGL-1) on leukocytes with selectins 
on activated endothelium.  Stimulation of chemokine receptors by chemokines on the 
endothelium switches integrins on the leukocyte into a high-affinity conformation, 
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allowing them to bind to intracellular adhesion molecules 1 and 2 (ICAM-1 and 
ICAM-2), and vascular cell adhesion molecule 1 (VCAM-1) (26).  This mediates 
migration via diapedesis processes to the site of inflammation, via migration through 
the border of endothelial cells (paracellular TEM), or less commonly, through 
endothelial cells (transcellular TEM).  Live imaging evidence also exists to suggest 
that in mice, neutrophils can undergo reverse TEM from inflamed tissue back into the 
vasculature (27, 28).  This has also been noted in zebrafish (29). 
 
 
1.2. Resolution of Inflammation 
 
Inflammation is vital for host defence, however it can be a damaging response 
and therefore must be carefully controlled.  One of these levels of control is that 
neutrophils must undergo apoptosis to terminate and resolve inflammation.  Apoptosis 
is a controlled, self-contained form of cell death. Apoptosis of neutrophils after they 
have completed their functions at the inflammation site is a vital part of this resolution, 
helping to dampen down the whole response.   Other types of cell death include 
necrosis (where the cell contents are released to the surroundings), NETosis (DNA is 
expelled from inside the cell) and autophagy (when intracellular lysozymes digest cell 
contents from within).   
 Resolution of inflammation is orchestrated by various pro- and anti-
inflammatory molecules.  An overall view of the inflammation and resolution 
processes are shown in Figure 1.2.  Various pro-apoptotic factors such as ROS can 
induce neutrophil apoptosis, over-riding neutrophil pro-survival factors such as 
granulocyte-macrophage colony stimulating factor (GM-CSF) or hypoxia, which is 




Figure 1.2.  Cellular events in resolution of inflammation. 
Neutrophils and monocytes are recruited from the blood, and can phagocytose and 
destroy bacteria and release pro-inflammatory mediators.  Following this, neutrophils 
undergo apoptosis and macrophage switch to an anti-inflammatory phenotype, and 
ingest apoptotic neutrophils.  Some neutrophils are also thought to migrate back to the 




1.2.1. Neutrophil Apoptosis 
Apoptosis is important from early in development.  Originally termed “programmed 
cell death”, it was described as an important part of the development of the transparent 
nematode C. elegans, allowing the direct observation of cell behaviour in development 
(30).  In zebrafish, the development of sex organs was shown to be dependent on 
apoptosis (31). 
  Aspects of the apoptotic process are shown diagrammatically in Figure 1.3.  
Apoptosis is mediated by caspases, which are endoproteases that work by cleaving 
target proteins.  Caspases are present as pro-caspases, which are activated by cleavage 
by other caspases.  Caspases 3, 6, 7, 8, and 9 have been implicated in apoptosis, while 
others (e.g. caspases 1) are involved in the activation of inflammatory cytokines (32).  
Adaptor proteins cause the caspases to cluster together, and initiator caspases start off 
a process of downstream caspases cleaving each other.  This results in release of 
cytochrome C from mitochondria, and then executioner caspases (such as caspase-3 
and caspase-7) initiate proteolysis and DNAse of intracellular proteins in an organized 
manner (33).  mRNA inside the cell is then rapidly degraded.  This degradation results 
in cell shrinkage and chromatin condensation (pyknosis).  The DNA becomes 
fragmented and the cell membrane buds into irregular blebs.  Finally the cell breaks 
up into vesicles called apoptotic bodies. These apoptotic cells are cleared away by 
phagocytes such as macrophages.  Failure of clearance results in cells proceeding to 
necrosis (34). 
 
1.2.1.1. Activation of apoptosis 
Activation of apoptosis can broadly occur by two pathways, although there is 
crossover.  The extrinsic pathway is mediated by death receptors. These are 
expressed on the cell surface and bind to death receptor ligands (35).  Examples of 
these ligands are TNF, Fas ligand (FasL) and TNF-related apoptosis-inducing ligand 
(TRAIL).  These ligands are not specific to death pathways, for example TNF also 
plays a role in inflammatory responses and activation of nuclear factor κ-light-chain-
enhancer of activated B cells (NF-κB).  TNF only becomes pro-apoptotic in 
circumstances when NF-κB signalling is blocked. When these ligands bind to their 
receptors, the death-inducing signalling complex (DISC) is recruited, resulting in 
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caspase 8 activation.  This is regulated by proteins such as DISC protein cellular 
FLICE (FADD-like IL-1beta-converting enzyme)-like inhibitor protein (c-FLIP), a 
caspase-8 homologue that lacks proteolytic activity; and inhibitor of apoptosis 
proteins (IAPs) that can block apoptosis.  Proteins like second mitochondria-derived 
activator of caspases (SMAC)/direct IAP binding protein with low pI (DIABLO) can 
inhibit the actions of IAPs. 
The second pathway is the intrinsic pathway, which results from caspase-9 
activation by apoptotic protease activating factor-1 (Apaf-1).  Apaf-1 changes 
conformation in cell stress.  Pro-apoptotic proteins such as Bcl-2 homologous 
antagonist killer (Bak) and Bcl-2 associated X protein (Bax) create pores, allowing 
cytochrome C release from damaged mitochondria, which recruits procaspase-9 via 
caspase recruitment domains.  In turn this creates an ‘apoptosome’ scaffold, in which 
caspase-9 is activated.  This then leads to the activation of executioner pathways. The 
intrinsic and extrinsic pathways of apoptosis have a degree of overlap; the extrinsic 
pathway results in activation of the intrinsic pathway. 
 
1.2.1.2. Regulators of Apoptosis 
The apoptotic pathways are regulated by many molecules, some pro-apoptotic and 
others anti-apoptotic.  In particular, the B cell lymphoma-2 (Bcl-2) family members 
regulate apoptosis by governing mitochondrial permeability and the release of 
cytochrome C into the cytosol.  Bcl-2, Bax and Bak are present on the mitochondrial 
membranes, endoplasmic reticulum and nuclear envelopes.  They permeabilise the 
mitochondrial membrane, facilitating the efflux of pro-apoptotic proteins such as 
Cytochrome C.  Myeloid cell leukaemia 1 (Mcl-1) is a pro-survival protein which 
exists mainly in the cytosol.   Mcl-1 sequesters Bax and Bak to help prevent the release 
of cytochrome C. 
 In neutrophils, the pro-survival protein Mcl-1 is highly expressed; to a much 
greater extent than other Bcl-2 family members.  This means the neutrophil relies 
heavily on Mcl-1 for cell survival (36).  Mcl-1 expression declines in isolated human 
neutrophils, eventually disappearing by 20 h post-culture which corresponds to high 
levels of apoptosis (37).   
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 As with many genes, it is highly conserved between species, with mouse 
neutrophil survival also thought to rely on Mcl-1 (38).  Mcl-1 is also expressed in 





Figure 1.3.   Apoptosis pathways in cells 
Apoptosis can be activated by the intrinsic and extrinsic pathways.  In the extrinsic 
pathway, external ligands signal to induce caspase 8 activation and activate 
executioner caspases (e.g. caspase 3), resulting in apoptosis.  The intrinsic pathway 
occurs by release of cytochrome C from mitochondria, resulting in caspase 9 activation 
and then activation of executioner caspases. Many molecules exist to promote (e.g. 
SMAC/DIABLO) or inhibit (e.g. Mcl-1) apoptosis. 
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1.2.2. Macrophages during resolution of inflammation 
 
1.2.2.1. Clearance of apoptotic neutrophils 
Apoptotic neutrophils must be cleared away by phagocytes such as macrophages to 
prevent them eventually proceeding to secondary necrosis (where the apoptotic cell 
falls apart, releasing intracellular contents).  The macrophage is attracted to find 
apoptotic neutrophils by signals such as sphingosine-1-phosphate which are released 
from neutrophils and bind macrophage receptors.  They recognise molecules such as 
phosphatidylserine (PS) on the surface of apoptotic cells, via receptors such as TIM4 
or BAI1 (40).  In addition, molecules such as annexins (e.g. annexin A1) or Protein S 
can opsonise apoptotic cells via binding to PS, facilitating recognition by receptors 
such as tyro, axl and mer (TAM) receptors (41) (2, 42, 43).  This process is an anti-
inflammatory process, switching macrophages to the ‘M2’ anti-inflammatory 
phenotype, in which pro-resolution cytokines such as transforming growth factor β 
(TGFβ) and IL-10 are released (44-46).  Apoptotic neutrophils can release factors that 
inhibit the recruitment of further neutrophils.  Annexin A1 moves to the surface of 
neutrophils in apoptosis, where it can engage formyl peptide receptor 1 (FPR1), 
helping to regulate leukocyte migration and promote further apoptosis and 
phagocytosis of apoptotic cells (efferocytosis) (47-49). 
 
1.2.2.2. Macrophages in tissue repair 
Macrophages are thought to be key cells in the process of healing and restoration of 
tissue homeostasis following inflammation (50).  Healing involves a co-ordinated 
response from macrophages and progenitors to replace tissue, promote angiogenesis 
and normal tissue oxygen, and prevent fibrosis developing.  Macrophages exist in a 
dynamic state of inflammatory (‘M1’) vs anti-inflammatory, pro-healing (‘M2’).  
Some hallmarks of M2 macrophages are up-regulation of Dectin-1, mannose receptor 
and production of ornithine and polyamines through arginase pathways, production of 
vascular endothelial growth factor (VEGF), fibroblast growth factors (FGF), platelet-
derived growth factors (PDGF), and anti-inflammatory cytokines such as TGF-β (51).  
Macrophages can be skewed to the M2 phenotype by the presence of anti-
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inflammatory factors like IL-4 or IL-13.  M2 can be subdivided into a, b and c subtypes 
based on what stimulated them in the first place and what they express, although these 
are in vitro classifications and the situation in vivo is likely to be more plastic (52).   
Growth factors promote cell proliferation in the cells around the affected area, 
and proteases like matrix metalloproteinases (MMPs) help to remodel the extracellular 
matrix.  MMP12 from macrophages destroys the receptor-binding site of CXC 
chemokines which attract neutrophils, helping to dampen down inflammation (53).  
Various MMPs also cleave monocyte-attractant CC chemokines, rendering them 
unable to signal to the monocyte although they can still bind, hence they act as 
antagonists (54).  In a similar way, decoy chemokine receptors such as D6 also 
promote resolution.  D6-deficient mice display excessive neutrophilic responses after 
myocardial infarction, resulting in tissue damage (55).  D6 has been shown to be 
important in switching macrophages to a pro-resolution phenotype.  In a zymosan-
induced peritonitis model, macrophages from D6-deficient animals had increased pro-
inflammatory mediator production (56). 
 
1.2.2.3. Macrophage production of pro-resolution mediators 
Macrophages can also produce pro-resolution lipid mediators.  Exploiting some 
naturally occurring pro-resolving molecules may be a good strategy to target some of 
these functions.  This family of proteins can be both pro- and anti-inflammatory.  The 
arachidonic acid pathway can synthesise pro-inflammatory molecules but also pro-
resolution ones such as lipoxins, and derivatives from unsaturated fatty acids, such as 
resolvins and protectins (2).  The production of these mediators is regulated by the 
cyclooxygenase (COX) enzymes, COX-1 and COX-2.  These appear to be expressed 
differently in M1 and M2 macrophages, with ‘M1’ macrophages up-regulating COX-
2, and ‘M2’ macrophages up-regulating COX-1. (57).  For this reason, anti-
inflammatory therapeutics targeting cyclooxygenases aim to target COX-2 selectively 
(58).  Lipoxin A4 (LXA4), another member of this family, can mediate its’ effects 
differently depending on the cell type it binds.  In neutrophils, LXA4 inhibits 
neutrophil migration to sites of inflammation; as well as decreasing pro-inflammatory 
actions such as NF-κB activation and cytokine production.  However in monocytes, 
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LXA4 promotes migration (2).  In has been shown that Lipoxin A4 can be pro-
resolving in vivo in models of acute lung inflammation (carrageenan-induced, and E. 
coli-induced), by indirectly promoting neutrophil apoptosis and driving clearance by 
phagocytes (59). 
 Macrophages can migrate away from the inflamed site via the draining lymph 
when the inflammatory response is resolved.  Failure to do this contributes to 
prolonged inflammation; in atherosclerotic plaques, monocyte migration away from 
the plaque was associated with regression of lesions, whereas high numbers of retained 
macrophages correlates with progression of plaques (60).  Macrophages are able to 
present antigen to adaptive immune cells, although not as effectively as dendritic cells 
(61).  This has resulted in controversy in how exactly one defines a macrophage or 
dendritic cell – it has been suggested they are all part of the same plastic spectrum 
(62). 
Due to the body of evidence suggesting that targeting neutrophil apoptosis and 
macrophage clearance might be a good strategy to induce resolution of inflammation, 
several drugs to target these events have been tested in inflammation models. 
 
 
1.2.3. Drugs to target resolution 
 
Potential therapeutics to target resolution should ideally perform some of the following 
functions:  
1. Prevention of neutrophil migration 
2. Promotion of efferocytosis 
3. Induction of neutrophil apoptosis 
 





1.2.3.1. Prevention of neutrophil migration 
Many strategies to prevent neutrophil migration have been tested.  Some drugs already 
in clinical use (e.g. the non-steroidal anti-inflammatory drugs (NSAIDs) naproxen, 
ibuprofen and oxaprozin) are known to prevent neutrophil migration to 
chemoattractants like CXC ligand 8 (CXCL8) and complement component 5a (c5a).  
An inhibitor of c-Abl kinase, ST1571, has been shown to inhibit neutrophil recruitment 
due to its effect on β2 integrin, actin polymerisation and hence migratory morphology 
of cells (63).  However, a consequence of inhibiting neutrophil recruitment is that 
patients are likely to clinically present at the peak of inflammation, i.e. when 
neutrophils will already be recruited to the site of inflammation, and for this reason 
strategies to specifically drive apoptosis may be more beneficial. 
The addition of synthetic annexin A1 derivatives in a model of 
lipopolysaccharide (LPS)-induced pleurisy in mice has been shown to reduce 
neutrophil migration to lung tissue in intestinal ischemia-reperfusion, during which the 
lung becomes inflamed (64), and also promotes neutrophil apoptosis (48).  A 2011 
paper indicates that R-roscovitine may also work by suppressing activation of 
leukocytes/endothelial cells, down-regulating adhesion molecules and preventing 
migration to inflammatory sites (65). 
 
1.2.3.2. Increasing phagocytosis of apoptotic neutrophils 
One possible drug strategy for inducing resolution of inflammation is increasing 
phagocytic clearance of apoptotic neutrophils, preventing the progression of apoptotic 
cells to secondary necrosis, as well as inducing the macrophage to switch to an anti-
inflammatory phenotype (45).  Glucocorticoid drugs have been shown to increase the 
capacity of macrophages to take up apoptotic cells (66). 
 
1.2.3.3. Driving neutrophil apoptosis 
Several pathways exist whose disruption may drive neutrophil apoptosis; for example, 
interference of pathways such as Extracellular signal-related kinase 1 and 2 (ERK1/2) 
and phosphoinositide 3-kinase (PI3K) signalling.  Treatment with the ERK inhibitor 
37 
 
PD98059 was shown to drive neutrophil apoptosis and enhance resolution of a 
carrageenan-induced pleurisy model (67).  
One strategy which is investigated within our laboratory group is the inhibition 
of cyclin-dependent kinases.  In 2006 it was shown that the CDK inhibitor, R-
roscovitine, could effectively drive neutrophil apoptosis in vitro, observed by 
increased Annexin V binding and cleaved caspase 3 expression in R-roscovitine-
treated cells (68).  There was a concurrent decrease in the expression of Mcl-1, a pro-
survival protein, which is a vital part of neutrophil survival (36).  R-roscovitine was 
then shown to reduce inflammatory cell numbers, oedema and inflammatory cytokines 
in a carrageenan-induced pleurisy model; and helped to restore normal tissue 
architecture in the lung (68).  This was reversible using the caspase inhibitor 
Carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]-fluoromethylketone (zVAD-fmk).  
R-roscovitine was also effective in reducing inflammation in other disease models, 
including bleomycin-induced lung inflammation, and serum-induced arthritis (68).  
Further work showed that R-roscovitine could overcome pro-survival signalling by 
driving apoptosis and decreasing Mcl-1 levels after human neutrophil exposure to 
bacterial products such as lipopolysaccharide, or pro-inflammatory mediators such as 
TNF (69).  The drug had no effect on Bim, a member of the Bcl-2 family that is pro-
apoptotic, thus indicating that R-roscovitine may well be effective to tip the balance of 
pro- and anti-apoptotic factors in favour of apoptosis.  
Further studies were performed to investigate which cyclin-dependent kinases 
were being targeted by R-roscovitine (70).  In neutrophils, the most highly expressed 
genes were CDK7 and 9, and CDK2 to a lesser extent.  R-roscovitine was shown to 
decrease phosphorylated RNA polymerase II, which is a downstream enzyme of 
CDK7 and 9, and is involved in transcription.  R-roscovitine has also been shown to 
similarly affect eosinophil apoptosis (71). 
 Other molecules with similar structures to CDK inhibitor drugs have been 
described to cause apoptosis.  Flavone compounds are members of the flavonoid 
family of compounds, characterised by the presence of a 2-phenylchromen-4-one (2-
phenyl-1-benzopyran-4-one) backbone.  The flavones wogonin, apigenin and luteolin 
have been shown to drive neutrophil and eosinophil apoptosis (72, 73). 
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The compound flavopiridol (FVP) is one of the most widely-tested CDK 
inhibitor drugs in lots of disease models, particularly for cancer, due to its activity 
against CDK1 (74).  The use of FVP as a therapeutic for cancer has been disappointing, 
due to low efficacy and toxicity issues.  However, FVP has other targets including 
CDK9. It has been shown to inhibit migration of neutrophils, in the setting of ConA-
induced liver injury.  Intravital imaging of the mouse cremaster muscle after 
intrascrotal TNF injection showed that FVP reduced transendothelial migration of 
leukocytes, with decreased ICAM-1 mRNA expression in endothelial cells (75).  In 
this case, FVP was given before or together with inflammatory stimuli.  However it 
has also been shown that FVP causes neutrophil apoptosis (37). 
 
1.2.3.4. The CDKi compound AT7519 
The synthetic CDK inhibitor AT7519 was generated by a high-throughput medicinal 
chemistry study, with several beneficial properties for therapeutic use (76, 77).  The 
compound was effective in causing apoptosis in cancer cell lines (77-79).  It also 
inhibited growth of xenografted neuroblastoma cells in mice (80).  In a phase I trial of 
patients with solid tumours, the drug was well-tolerated (81).    
AT7519 was shown to drive the apoptosis of isolated human eosinophils, and 
also increased eosinophil apoptosis when administered to a mouse model of allergic 
pleurisy inflammation (an eosinophil-mediated diseases, driven by challenge with 
ovalbumin) (82).  Furthermore, AT7519 was shown to drive neutrophil apoptosis in 
vitro, even overcoming the pro-survival effect of LPS (38).  This coincides with a 
reduced expression of Mcl-1.  The effect was reversible using the caspase inhibitors 
zVAD-fmk and Q-VD-OPh.  AT7519 was not shown to cause apoptosis of monocyte-
derived macrophages, despite causing a downregulation of Mcl-1 – likely due to the 
lower reliance of macrophages on Mcl-1 for survival (83).  LPS-mediated lung 
inflammation in mice could be reduced by intraperitoneal treatment with AT7519, with 
decreased inflammatory cytokines present (e.g. IL-6), an increased level of monocyte 
chemoattractant protein-1 (MCP-1), increased apoptotic neutrophils and ingested 
neutrophils inside macrophages in bronchoalveolar lavage fluid (BAL) (38).  The same 
effect was seen when AT7519 was used when the mice were infected with E. coli intra-
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tracheally (38).  Interestingly, circulating neutrophil numbers were unaffected by 
AT7519, suggesting that targeting Mcl-1 to induce apoptosis is specific to 
inflammatory neutrophils.  Furthermore, AT7519 was able to decrease bacteria titres 
in the lung and BAL, although the mechanisms for this are still not known (38). 
 
1.2.4. Cyclin-dependent kinase 9 (CDK9) as a drug target in 
inflammation 
 
1.2.4.1. Cyclin-dependent kinases 
The above evidence suggested CDKs appear to be a good target for resolution of 
inflammation.  CDKs are important in functions such as cell cycle, but also 
transcription.  The first CDK was discovered in 1982 in yeast (84-86).  It was shown 
that this CDK was important in the transition of cell cycle phases in cell division of 
the yeast Saccharomyces cerevisiae (cell division cycle [cdc] 28) and 
Schizosaccharomyces pombe (cdc2).  Subsequently, cdc2 was found to be conserved 
in human cells and was eventually renamed CDK1 (87).  Since then, the family of 
mammalian CDKs has expanded to include CDK1 – CDK20, after new discoveries 
and nomenclature of existing proteins has changed (88) (Table 1.1).   CDKs are small 
serine-threonine kinases, around 30 – 40 kDa, which partner with cyclins in order to 
perform their phosphorylation activity.  Yeast rely on a small number of CDKs and 
cyclins for functions such as cell cycle and transcription; however mammals have a 
much wider spectrum of CDKs which have evolved from the yeast CDKs and have 
taken on particular roles, in keeping with the complexity of the mammalian system 
(88).  For example, different CDKs are activated at different points of the cell cycle; 
CDK1 in mitosis phase, and CDK2 in S phase.  However, there is an element of 
redundancy; it is known that CDK1 is indispensable for cell division in yeast and 
mammals; however in mammals, CDK2 is dispensable for mitosis (but not meiosis).  
CDK2, 4 and 6 triple knockout mice still develop to mid-gestation, indicating CDK1 
alone is sufficient for cell cycle to proceed; however CDK1 knockout embryos do not 
begin to develop, or undergo embryogenesis, as evidenced when CDK1 gene mutant 
heterozygote mice are crossed (89).   
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 In addition to this functional redundancy, other proteins exist which possess 
CDK activity.  One such example PFTK1, which bears no homology to CDKs but 
interacts with cyclin D3, and knockdown of PFTK1 causes arrest of cell cycle at G1 
phase.  PFTK1 has since been designated CDK14 (90). 
On the other hand, some CDKs, specifically, CDK7, 8 and 9 have been shown 
to regulate transcription and in fact play no role in cell cycle.  The cyclin binding 
partners of CDK7, 8 and 9 (cyclin H, C and T, respectively) do not change in 
expression throughout the cell cycle, unlike the binding partners of other CDKs 








1.2.4.2. Cyclin-dependent kinase 9 (CDK9) 
CDK9 was first characterised in 1994, originally designated PITALRE (91).  CDK9 is 
a cdc2-like Ser/Thr kinase.  Its crystal structure has previously been determined (92).  
CDK9 is expressed within all mammalian tissues and particularly highly in terminally 
differentiated cells.  Two isoforms have been described with different molecular 
weights at 42 and 55 kDa, shown by Western blotting (93).  These isoforms both 
CDK Binding Partner Function Zebrafish 
homologue? 
CDK1 Cyclin A, B & E Cell cycle   
CDK2 Cyclin A, B, D & E Cell cycle  
CDK3 Cyclin A,B,C & E Cell cycle  
CDK4 Cyclin D Cell cycle  
CDK5 CDK5R1 (p35), 
CDK5R2,  cyclin D & Y 
Cell cycle  
CDK6 Cyclin D Cell cycle  
CDK7 Cyclin H Transcription, CDK 
activation kinase 
 
CDK8 Cyclin C Transcription  
CDK9 Cyclin T Transcription  
CDK10 Cyclin M Transcription, Cell 
cycle 
 
CDK11 Cyclin L Transcription, Cell 
cycle 
 
CDK12 Cyclin L1, Cyclin K1 Transcription,  
CDK13 L type cyclins, Cyclin K Transcription,  
CDK14 CDK5R1 (p35), 
CDK5R2,  cyclin D & Y 
Cell cycle  
CDK15 CDK5R1 (p35), 
CDK5R2,  cyclin D & Y 
Cell cycle  
CDK16 CDK5R1 (p35), 
CDK5R2,  cyclin D & Y 
Cell cycle  
CDK17 CDK5R1 (p35), 
CDK5R2,  cyclin D & Y 
Cell cycle  
CDK18 CDK5R1 (p35), 
CDK5R2,  cyclin D & Y 
Cell cycle  
CDK19 Cyclin C Transcription  
CDK20 Cyclin H Transcription  
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interact with the same cyclins (T1 and T2) and RNA Pol II in the same way.  However 
the 55 kDa isoform is present in only the nucleus, whereas the 42kDa isoform is 
present in both nucleus and cytoplasm (94).  Isoforms are expressed to different extents 
in different tissues; e.g. the 55 kDa isoform is the most highly expressed in lung, liver 
and brain; whereas the 42 kDa isoform was the predominant isoform in the spleen and 
testis (95).  Additionally, the 55 kDa isoform appears to be involved in the 
differentiation of hematopoietic cells, muscle cells and adipogenesis. 
The cyclin binding partners of CDK9 are the cyclin T family consisting of T1, 
T2a and T2b (96).  CDK9/cyclin T heterodimers are involved in transcription as part 
of the positive transcription elongation factor b (P-TEFb), consisting of RNA 
polymerase II and transcription factors such as transcription factor II B (TFIIB). 
The P-TEFb complex was originally described in drosophila (97, 98).  It 
stabilises the elongation of RNA transcripts, which are made by RNA Polymerase II 
(99).  RNA polymerase II cannot cause RNA elongation on its own; due to inhibition 
by the negative transcription elongation factor (N-TEF).  P-TEFb is able to displace 
N-TEF and phosphorylate the carboxyl terminal domain (CTD) of RNA polymerase 
II, facilitating elongation of RNA transcripts by RNA polymerase II (100). 
The P-TEFb complex controls transcription factors such as NF-κB, resulting 
in the production of proteins such as inflammatory cytokines and pro-survival factors 
(such as Mcl-1).  More is still being discovered about the P-TEFb complex and 
associated gene pathways; for example recent work showed the existence of a 
previously unknown binding partner, AFF1 (101).  Other endogenous inhibitors of the 
P-TEFb complex exist, for example, the 7SK small nuclear ribonucleoprotein 
(snRNP).  Part of this complex is the La-ribonucleoprotein family member 7 (LaRP7). 
(Fig. 1.4). 
P-TEFb is involved in the transcription of several important proteins in 
neutrophils; and for this reason, work in our laboratory group has considered CDK9 to 
be a potentially useful therapeutic target.  Mcl-1, the short-lived protein important in 
neutrophil survival, is transcribed as a result of CDK9 phosphorylation (102).  
Inhibiting CDK9 is associated with driving apoptosis, due to its role in transcription 
of pro-survival proteins (70).  Not only is CDK9 inhibition directly associated with 
driving apoptosis, but may also liaise with other molecules to drive apoptosis.  In a 
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cancer cell line, CDK9 inhibition alongside TNF apoptosis-inducing ligand (TRAIL) 
caused a synergistic effect, increasing the apoptosis-causing potential of TRAIL (103).  
This was due to the ability of CDK9 to drive transcription of cFLIP, in addition to 
Mcl-1, sensitizing the cells to TRAIL inhibition.  Up-regulation of CDK9 activity 
results in Mcl-1 stability, and therefore increased resistance to CDK inhibitor treatment 
in a leukaemia cell line (104). 
In addition, P-TEFb is also thought to play a role in other inflammatory 
processes such as cytokine transcription.  It is involved in TNF-inducible NF-κB 
activation, and STAT3 signalling induced by IL-6 (105).  Previous work also showed 
that CDK9 was necessary for the transcription of pro-inflammatory cytokines such as 
TNF, and even synergises with IL-6 to induce NK-κB activation (106, 107).  It also 
















Figure 1.4.  The P-TEFb pathway in mammalian cells 
The P-TEFb complex consists of CDK9 and cyclin T1, which bind to RNA polymerase 
(pol) II along with other transcription factors (e.g. TATA-binding factor, TBP).  P-
TEFb is associated with the inhibitory 7SK snRNP, of which LaRP7 is part.  
Conformational changes induce the association of P-TEFb, allowing it to bind RNA 
pol II and initiate transcription of genes such as Mcl-1. 
 
1.2.4.3. Cyclin-dependent kinase 7 (CKD7) in the P-TEFb complex 
CDK7 is also part of the initiation of this transcription complex (see Fig 1.4) (109).  
RNA polymerase II transcription is initiated by phosphorylation by the transcription 
factor II H (TFIIH), which CDK7 is part of.  This may also be a useful target for 
inhibition of transcription of neutrophil survival proteins.   
However unlike CDK9, which is preferentially involved in transcription, 
CDK7 seems to be involved in the cell cycle in mammalian cells (110).  It has both a 
CDK-activating domain (CAK), which phosphorylates cell cycle CDKs, as well as 
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forming part of TFIIH and phosphorylating RNA polymerase II.  CDK7 levels do not 
fluctuate through the cell cycle though, and therefore may be involved in regulation 
rather than driving the cell cycle (111). 
 
1.2.4.4. Difficulties of investigating the role of CDKs in mammals 
Traditionally, neutrophil biology studies have been carried out in isolated human cells 
or mouse models.  This is due to the ease of isolating human neutrophils from the 
blood, and the good homology between human and mouse genetics.  Mouse models 
make it possible to investigate diseases similar to human diseases; for example lung 
inflammation models (e.g. bleomycin- or LPS-induced, or E. coli infection), and 
serum-induced arthritis as a model for RA. 
CDK9 is clearly an important transcriptional regulator in development, as 
attempts to generate CDK9 deficient mice have been so far unsuccessful due to the 
low viability of the animals.  CDK9 knockdown has also been shown to be lethal in C. 
elegans embryos, further supporting its role as a master regulator (112).  A myeloid-
specific CDK9 knockout has yet to be been created.  Mouse embryogenesis has been 
shown to require cyclin T2 - which works together with CDK9 to form P-TEFb (113).  
A myeloid-specific Mcl-1 knockout mouse has been created, although it does exhibit 
neutropenia, making it a less useful model for studies of Mcl-1 in neutrophils during 
inflammation (83, 114).  
CDK studies using human neutrophils have typically involved the use of CDK 
inhibitor compounds of varying specificities for individual CDKs.   It is very difficult 
to achieve knockdown of any mammalian gene in primary neutrophils, due to the fact 
that they are terminally differentiated with a half-life of around 8 hours (115).  
Techniques such as small interfering RNA (siRNA) have been applied to neutrophils 
with limited success.  The best compromise is to use neutrophil-like cell lines such as 
human promyelocytic leukaemia cell-60 (HL-60) (38); or for eosinophils, the 
eosinophil-like cell line, Eosinophilic leukaemia-1 (EoL-1) (116).  However, these 
cells by their very nature have an altered survival profile, although they can be 
differentiated further to improve their neutrophil/eosinophil-like characteristics.  
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Knockdown of Mcl-1 in HL-60 cells was shown to cause increased apoptosis levels 
(38).  
 For the above reasons, the CDK9-P-TEFb-Mcl-1 hypothesis (shown 
diagrammatically on page 56) was investigated in a model more amenable to genetic 
manipulation, namely the zebrafish (Danio rerio).  Applying this hypothesis to a 
whole-animal study will give greater insight in to the importance of these genes in 
vivo.  Recent work has shown the importance of CDK9 and the P-TEFb complex in 
regulating the proliferation of cardiomyocytes after laser injury of the zebrafish heart; 
shown by morpholino targeting of CDK9 (described in Section 2.5), as well as 
pharmacological inhibition using FVP (117).  This study shows that zebrafish are a 




1.3. Zebrafish as a model of resolution of Inflammation 
 
1.3.1. Zebrafish embryos as an animal model 
Zebrafish embryos have become increasingly recognised as a useful adjunct to 
traditional mammalian systems for investigating innate immune biology, namely 
primary cells and rodent models (115, 118, 119).  They originally emerged as a tool in 
developmental biology, when it was recognised that their optically transparency and 
rapid development outside the mother makes it simple to image development in vivo.  
They develop a full range of immune cells, and are amenable to genetic and chemical 
manipulation.  The zebrafish produces large numbers of eggs, facilitating experiments 
with large n values and strong statistics.  Furthermore, as the zebrafish embryo can 
survive without a cardiovascular system for up to 7 days the feasibility of studying 
embryonic-lethal phenotypes is possible (120).  Zebrafish are relatively cheap to house 
and maintain, making them a practical animal model.   Some of the useful properties 
of zebrafish are detailed below. 
 
1.3.1.1. Live imaging of zebrafish 
The transparency of the zebrafish embryo makes them a perfect tool for in vivo 
imaging.  Before 24 h, the embryo is completely transparent, ideal for imaging early 
developmental stages. After this, pigmentation develops, which can present an issue 
for imaging specific organs or regions of the embryo; however areas such as the tailfin 
are still free of pigmentation till much later stages of development.  Lines of zebrafish 
are now widely used which lack these pigmented cells, such as casper or golden.  
Propylthiouracil (PTU) treatment at 1 dpf can delay pigmentation, however the 
potential side effects of this toxin on the immune response are unknown (115). 
 In zebrafish it is relatively simple to label cell populations and intracellular 
structures with fluorescent proteins.  This, together with the transparency of the fish, 
allows in vivo imaging of these cells/structures (121).  In addition, the wide range of 
fluorescent proteins available in recent times means that crossing different lines allows 
interactions between multiple labelled populations to be imaged within the same 
animal.  One of the major differences between studying zebrafish and mammalian 
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neutrophils and macrophages is the cell numbers present.  For example, a 3 days post 
fertilisation (dpf) zebrafish embryo will have roughly 200 neutrophils (122).  This can 
make ex vivo work with these cells technically challenging, however does allow for 
clear in vivo imaging of cells and their interactions. 
 
1.3.1.2. Zebrafish Immune Studies 
Zebrafish develop a full range of haematopoietic cells, equivalent to those seen in 
mammals (123).  However, there are some noteworthy differences, such as the 
presence of nuclei in erythrocytes (119).  From around 30 hours post fertilisation (hpf), 
myeloid cells are seen which are capable of performing functions such as phagocytosis 
(124, 125).  These cells can be imaged in vivo following the development of 
neutrophil-specific Tg(mpx:EGFP)i114 (126) and macrophage-specific 
Tg(MPEG1:mCherry), Tg(fms:mCherry) lines (127, 128).  Images of these embryos 
at 3 dpf are shown in Figure 1.5.   
 





Whilst myeloid cells are seen at early stages from 1 dpf onwards, adaptive 
immune cells do not develop from about 10 dpf onwards in zebrafish (115).  This 
allows exclusive and unimpeded imaging of the innate immune response at early 
stages, to assess cell behaviour without the confounding factor of other inflammatory 
cell types.   
Zebrafish neutrophils possess many similar characteristics to mammalian 
neutrophils, such as polymorphic nuclei, primary and secondary granules, myeloid-
specific peroxidase (a homologue of myeloperoxidase in mammals), and NADPH 
oxidase (125, 129).  They can engulf and destroy bacteria (130) and it has been shown 
ex vivo that zebrafish neutrophils are capable of producing extracellular traps (131).  
Other components are conserved, such as IL-1 and CXCL8-CXCR2 signalling to 
induce neutrophil migration (132, 133).  Rodents do not have the CXCL8 gene, making 
zebrafish a useful model to study CXCL8 function in vivo (134). Zebrafish also possess 
toll-like receptors (TLRs), and mediators such as complement and acute-phase 
proteins (135, 136). 
 Zebrafish macrophages have been shown to phagocytose bacteria and express 
L-plastin (124).  They undergo frustrated phagocytosis when apoptotic cells are too 
large to phagocytose easily, and also form granulomas in response to infection with 
Mycobacterium marinum, a close relative of Mycobacterium tuberculosis (124, 137).  
Live imaging has permitted more insights into the behaviour of these cells in vivo; for 
example, it was shown that neutrophils engulf surface-associated bacteria, whereas 
macrophages can engulf fluid-borne bacteria (130).  Macrophages are thought to play 
important roles in regeneration following tissue injury/loss (138, 139). 
  In addition to the existence of neutrophil and macrophage-like cells, there is a 
high degree of conservation between zebrafish and mammalian genes.  Importantly for 
this project, the zebrafish possesses the full complement of CDK genes with a high 
degree of homology to humans.  They have two isoforms of the Mcl-1 gene, with less 
homology to the human gene (compared to CDK gene conservation), however both 
have a role in cell survival (39, 140).  Table 1.2 details the conservation of selected 
relevant protein sequences between species, calculated using Clustal Omega sequence 





































Mcl-1a N/A 58.8% ENSDARG0
0000009779 
N/A N/A 




1.3.1.3. Models of inflammation in zebrafish  
Inflammation in zebrafish has generally been modelled by wounding or infection 
studies.  Wounding of the tailfin has been used to image recruitment of neutrophils 
and macrophages to wounds (126).  The tailfin is a good area to image due to the lack 
of pigmentation in this area.  This has been done in various guises; removing the entire 
tailfin and part of the vasculature (126), removing only the tailfin (72), and ‘nicking’ 
the tailfin (141).  This results in recruitment of neutrophils with a peak at 4-6 h post-
injury.  The injuries result in a variety of recruitment levels; around 30 neutrophils 
when the vasculature is injured, but less than 10 when the tailfin is nicked, although 
the duration of monitoring the inflammatory response was much shorter in this study 
(2.5 h) (141). However, what is clear is that the onset of the inflammatory response 
can be clearly observed, made easier with transgenic lines mentioned above.  
Macrophage recruitment is slower and rises progressively over the next 48 h post-
wounding in the vasculature-injury model (127). 
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Different methods have been used to injure the tailfin in this model; sterile 
blades have been used previously (126), but also a laser can be used to punch a straight 
line of dots along the tailfin, resulting in the tailfin ‘sloughing’ off (142).  The use of 
a laser is more precise and easier to reproduce injuries each time.  Nicking’ the tailfin 
has been carried out in the past using a 19 gauge needle and is technically challenging 
(141). 
 Other injury models have been used; for example laser injury of the heart and 
vasculature has been used to investigate inflammation and repair (143, 144) (145).  
Targeted laser ablations of cells in the brain have been used to show that Ca2+ waves 
are involved in the microglia response to this brain injury (146). 
Zebrafish wounding studies have revealed new insights into inflammation 
biology.  A wounding model was used to demonstrate for the first time that hydrogen 
peroxide is involved in attracting leukocytes to sites of inflammation (147).  Reverse 
migration of neutrophils away from inflammatory injury sites was first observed in 
zebrafish (141, 148, 149).  Primarily they reverse migrate through tissue, but it has 
been demonstrated that some neutrophils can ‘reverse migrate’ into the vasculature 
(149).  This function has now been demonstrated in rodents   It was shown that 
Hypoxia inducible factor 1α (HIF1α) expression is related to the incidence of reverse 
migration (150).  This phenomenon contributes to resolution of inflammation in this 
model.  It has been suggested these cells might play a role in influencing T cells in 
lymphatic organs (149).   
 Apart from wounding, inflammation can be induced by chemical means.  
Copper sulphate can be added to the water, destroying hair cells of the lateral line by 
causing oxidative stress (151).  In addition, infectious disease can be modelled in the 
zebrafish.  Salmonella typhimurium infection in zebrafish was used to further examine 
the role of CXCL8 in zebrafish (152).  Mycobacterium marinum injection into the 
caudal vein of zebrafish results in a similar disease to human tuberculosis, with 
formation of granulomas (153).  Labelling bacteria fluorescently allows the imaging 
of host-pathogen interactions in vivo.  These inflammation models can then be 




1.3.1.4. Genetic Manipulation of Zebrafish 
Many tools exist to alter genes in zebrafish (154).  Due to the fact that embryonic stem 
cells have not been identified, targeted cell-specific deletions (as in mouse genetics) 
have not yet been possible. Stem cell-like cells have been found in zebrafish but this 
is still controversial (155).  However, several other techniques are in common use, 
which are relatively simple to apply.  In zebrafish it is common to use both forward 
genetic approaches (large scale mutagenesis followed by identification of specific 
genes related to a particular phenotype) and reverse genetics approaches (disrupting a 
known gene then analysing the phenotype).  The benefits of some of these methods for 
gene targeting are compared in Table 1.3. 
One such approach which zebrafish are very suitable for is large-scale genetic 
forward screens.  Ethyl nitrosourea (ENU) can be used to generate random mutations 
to screen (156).  This approach was used to identify a mutant of the cleavage and 
polyadenylation specificity factor 1 (cpsf1) gene, which has a defect in haematopoietic 
stem cell development (157).   
A targeted reverse genetics approach to the creation of mutants is the use of 
clustered regularly interspaced short palindromic repeats (CRISPR) RNA-guided cas9.  
This allows targeted mutations of genes of interest, with an efficiency rate of over 80% 
(158-160).  It works by using an RNA guide to specifically bind the DNA region of 
interest.  The oligonucleotide is attached to a protospacer adjacent motif (PAM) site, 
which recruits the cas9 enzyme.  Cas9 cleaves DNA, resulting in DNA excision and 
frame shift mutations.  This technique has been widely used to knockout genes of 
interest, and also to knock in genes (158).  One recent study used vector delivery of 
CRISPR sequences to induce gene knockout in tissues; but due to the 80% efficiency 
rate (not all mutations will be frameshift), not all target cells will be affected (161). 
Other reverse genetic techniques include transcription activator-like effector 
nucleases (TALENs).  These consist of TAL effector DNA-binding domains fused to 
DNA cleavage domains, hence allowing specific excision of DNA sequences (162).  
TAL effectors are bacterial-derived proteins from Xanthomonas.  For genetic 
knockdown, microinjection of morpholinos (which are synthetic antisense 
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oligonucleotides with sequences specific for the gene of interest) results in temporary 



















Table 1.3.  Advantages and disadvantages of different knockout methods. 
Technology Features/Advantages Disadvantages 
Forward genetics  
mutagenesis screens 
Unbiased target discovery, 
may reveal previously 
Laborious/time 




unknown targets of 
interest. 
Genetic redundancy (e.g. 
genome duplication) may 
mask potential 
phenotypes 
Reverse genetics  
Morpholino-mediated 
gene knockdown 
Immediate loss of gene 
function, does not require 
raising several generations  
Simple and quick to use 
Possibility of off-target 
effects and toxicity 













Heritable knockout in 
desired location 
RNA guided DNA 
endonuclease mediated- 
RNA/DNA hybridisation 
of 20bp motif 
Easy to use, highly 
efficient 
Relatively new 
technology – any 
possible side-effects are 
not fully known yet and 







Heritable knockout in 
desired location 
Protein guided DNA 
endonuclease, each TAL 
effector recognises a 
single DNA base  
Laborious to engineer 





Heritable knockout in 
desired location 
Protein guided DNA 
endonuclease, each zinc 
finger recognises a DNA 
base triplet 
Laborious to engineer 
modules of TAL 
effectors 
Least specific gene 
editing method, as each 
zinc finger can bind 
different DNA triplets 
with different affinities 
 
The creation of transgenic lines in zebrafish for in vivo studies of fluorescently-
labelled cells is a well-established method.  It has been made easier to create new lines 
by the use of ‘tol2’ approaches, which utilise the tol2 transposon element to promote 
DNA incorporation into cells, at a higher efficiency rate (20%) than previous methods 
such as BAC recombineering (164).  However these approaches require the 
identification of cell-specific promoters, which does not yet exist for all cells.  In 
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addition, ablation of these cells can be carried out by inclusion of the bacterial 
nitroreductase enzyme (NTR) gene, which catalyses the pro-drug metrodinazole (Mtz) 
to a cytotoxic product; or the Killer Red gene, a light-activated inducer of ROS which 
is toxic to cells (165, 166). 
 
1.3.1.5. Chemical Manipulation in Zebrafish 
One of the benefits of using zebrafish embryos is the ability to do large-scale drug 
testing, and systems to allow automation of these vast screens may well be used widely 
in the future (115).  Chemical manipulation of the inflammatory response post-
wounding has primarily been carried out by immersion of the embryo in the drug, 
diluted to the appropriate concentration (167).  Drugs can also be injected directly into 
the embryo, allowing the concentration which is actually taken up into the embryo to 
be more carefully controlled compared to incubation.  Several examples exist of drug 
manipulation of tailfin inflammatory responses; for example it was shown that Class 
III antiarrhythmic methanesulfonanilides inhibited leukocyte recruitment to sites of 
tailfin injury (141).  The pan-hydroxylase inhibitor dimethyloxalogylglycine 
(DMOG), which inhibits an endogenous inhibitor of HIF1α, was shown to delay 
resolution of inflammation post-wounding (150).  HIF1α is involved in extending 
neutrophil lifespan during conditions of hypoxia seen during inflammation. 
 Some studies have been carried out using CDKi compounds in zebrafish, to 
examine if they also drive neutrophil apoptosis in this in vivo setting, as seen in human 
cell lines and rodent models.  Renshaw et al showed that the CDKi R- roscovitine 
reduces neutrophil numbers after tailfin wounding (which also transected the tailfin 
vasculature) (168).  Meanwhile, the caspase inhibitor zVAD-fmk and the pro-
inflammatory stimuli LPS had the opposite effect, with higher neutrophil numbers at 
24 h post-wounding, and less apoptotic neutrophils, compared to control.  The flavone 
wogonin, which has structural similarities to CDKi compounds, was also able to 
reduce neutrophilic inflammation post-wounding (72).  This was reversible using the 




1.4. Hypothesis  
 
The hypothesis of the project was that the P-TEFb pathway and Mcl-1 transcription 
are vital in regulating resolution of inflammation in vivo. 
The aim of the study was to test this hypothesis by using genetic and pharmacological 
manipulations of the CDK9/CDK7, P-TEFb, Mcl-1 transcription pathway in vivo in a 
zebrafish inflammation model.  From previous work with human neutrophils in vitro, 
these genes have been shown to be important in neutrophil lifespan (37, 68, 70), and 
the zebrafish offers a unique opportunity to probe the role of these genes in vivo.  
Figure 1.6 depicts aspects of the P-TEFb pathway and the green boxes highlight what 
is known about the role of these genes in vitro in human neutrophils, in vivo in mouse 
systems, and what is still unclear.  Briefly, some research questions at the start of the 
project, and which chapter they were addressed in, were as follows: 
(a) What is a good zebrafish injury model to probe the role of CDKs in neutrophil- 
and macrophage-mediated inflammation?  Chapter 3 
(b) What is the neutrophil and macrophage response profile in this model? Chapter 
3 
(c) Can the inflammation be increased by addition of bacterial products like 
lipopolysaccharide (LPS)?  Chapter 3 
(d) Do the zebrafish neutrophils share functional characteristics with mammalian 
ones? Chapter 3 
(e) Do cyclin-dependent kinase (CDKi) drugs affect resolution of neutrophilic 
inflammation in zebrafish, and the general neutrophil population?  Chapter 4 
(f) Do CDKi drugs affect apoptosis of neutrophils in zebrafish inflammation? 
Chapter 4 
(g) How are macrophages affected by CDK inhibition?  Chapter 4 
(h) Does genetic targeting of specific genes in the P-TEFb pathway (specifically 
CDK9, CDK7, Mcl-1 and the negative regulator LaRP7) affect neutrophils and 
macrophages during inflammation, and in the entire embryo?  Chapter 5 



















Figure 1.6. What is known about the P-TEFb pathway 
CDK7 initiates mRNA transcription and CDK9 and RNA Polymerase II are 
important for elongation.  This results in the transcription of several important genes 
in neutrophils such as Mcl-1, TNF and IL-6.  The green boxes highlight genes of 
interest and where their role has been investigated with respect to their role in 
resolution of inflammation and neutrophils in particular models. 
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The materials and methods described in this chapter relate to the general techniques 
applied throughout this study.  Further details of specific reagents, including 
manufacturer, is given in Appendix A; and recipes for solutions are in Appendix B. 
 
2.1. The zebrafish tailfin injury model 
 
2.1.1. Zebrafish application and ethical review 
All experiments were carried out in accordance with the accepted standards of humane 
animal care under the regulation of the Animal (Scientific Procedures) Act UK 1986 
and EU Directive 2010/63/EU; animals were held in a UK Home Office approved 
facility.  The animals used in these experimental studies were under the age of 5 days 
post fertilisation.   
 
2.1.2. Zebrafish lines used in the study 
Throughout the project, various genetically modified lines were used to aid the 
visualisation of inflammation. 
 Tg(mpx:EGFP)i114 or Tg(mpx:mCherry)i114 (126) were used to image 
neutrophil populations in vivo. 
 Tg(MPEG1:mCherry), Tg(MPEG1:EGFP) (128) and Tg(fms:mCherry) (127) 
were used to image macrophages. 
The above lines were a kind gift from Professor Stephen Renshaw, University of 
Sheffield.  In the project, new lines and mutants were also generated.  CDK9 
homozygote and heterozygote knockout fish were generated using CRISPR-Cas9 
technology (158). Tg(LysC:mcl1a:cmlc2:EGFP) and Tg(LysC:mcl1b:cmlc2:EGFP) 
fish were created using the Tol2 transgenesis system, in which the cardio-myosin light 
chain promoter linked to EGFP is driven by Lysozyme C linked to Mcl-1a or Mcl-1b, 
respectively.  Wild-type (WIK strain) were used for microinjecting plasmids (169) and 




2.1.3. Zebrafish husbandry and breeding 
Adult fish (classified as older than 90 days) (170) were housed according to standard 
operating procedures and maintained with a 14 hour (h):10 h light:dark photoperiod 
cycle at an ambient temperature of 28.5°C.  The onset of the light cycle triggers 
spawning of these photoperiodic organisms.  Eggs were collected by pair-mating one 
female and one male fish overnight and collecting the eggs in a sieve the next morning.  
The eggs were maintained at 28.5°C in an incubator until use.  Experiments were 
conducted at 22°C but stored at 28.5°C between time points.  All animals were used 
under the age of 5 days post fertilisation, which is the age when procedures carried out 
on the embryos require a Home Office licence.  Staging of zebrafish to ensure they 
were always at similar developmental stages was conducted by eye, according to the 
guidelines of Kimmel et al (171).  Collected eggs were maintained in either “systems 
water” containing 0.03% salt or Embryo Medium (see Appendix B for recipes) with 
0.5 mg/L of the antifungal/antibacterial methylthioninium chloride (methylene blue) 
in deionised water, in 9 cm Petri dishes. Systems water or embryo medium was 
replenished every 24 h. 
 
2.1.4. Zebrafish tailfin injury 
Zebrafish (3 days post fertilisation [3 dpf]) were injured in a similar manner to the one 
described by Renshaw and colleagues (126).  The fish were anaesthetised by 
immersion in 4.2 % MS-222 buffered tricaine solution (v/v, see Appendix B), 
equivalent to 20 µM, in a petri dish (60 mm x 15 mm) (172).  Tricaine has been 
determined to be the most safe and effective anaesthetic for use in zebrafish (173). 
When the fish had ceased movement and was assessed to be anaesthetised (tested by 
stimulus and ataxia but with a good cardiovascular flow, as determined by Denvir et 
al (172), it was laid on an inverted petri dish using a 3 mL pastette.  Excess water was 
removed using tissue paper to make the transection process easier.  The transection 
process was performed using a dissecting scope (Leica MZ16F).  The median tailfin 
was fully transected using a sterile scalpel (Fig. 2.1, green line) and the fish were then 
kept in 1 mL of embryo medium in a well of a 48 well plate.  The wound was briefly 
examined using a dissecting scope to assess if the wound was in the correct place.  This 
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model was selected for the project (Chapter 1, Fig 3.1), but other models were also 
tested.  
In one model, the zebrafish embryo tailfin was fully transected in the same way 
as just described, but also involved cutting off the end of the body and embryonic 
vasculature system (Fig. 2.1, red line).  A more mild injury was tested, involving 
nicking the side of the tailfin with a 19 G needle (Fig. 2.1, blue line).  The area of the 
tailfin vasculature is more clearly highlighted using a purple line in Figure 2.1.  No 
observable detrimental effects were observed with each wound type; such as alteration 
in heart rate, blood flow or gross morphology.  The fish recovered from anaesthesia 
and showed normal swim behaviour.  Any animals that appeared unhealthy were 




Figure 2.1.  Tailfin transection of 3 dpf zebrafish. 
Dotted lines depict transection sites.  The purple line demonstrates more clearly the 
vasculature in the tailfin area.  Red line: transection damaging vasculature; green 




2.1.5. Mounting embryos for imaging 
For imaging using fluorescence microscopy, embryos were anaesthetised in 4.2% 
tricaine (v/v, see Appendix B) and imaged in embryo medium in a petri dish, or laid 
on the surface of a petri dish in a drop of embryo medium.  For confocal microscopy, 
the embryos were mounted in agarose.  Briefly; a solution of 1.5% agarose in system 
water was made and microwaved until boiling, then 1 mL was cooled for 1 minute 
(min) to 50°C in a 1.5 mL microcentrifuge tube.  Each embryo was submerged in the 
agarose and positioned.  A pastette was used to transfer an embryo into a well of an 8 
well chamber cover glass slide.  To each well, 500 µL of 4.2% embryo 
medium/Tricaine anaesthetic was added to help keep the embryo wet and under 
anaesthesia.   
 
2.1.6. Imaging, measurement and analysis of inflammation 
For general tailfin transection assays, images were taken on a Leica fluorescent 
dissecting stereoscope at 40x magnification (for whole embryo imaging) or 80x 
magnification (for imaging the tailfin), with EGFP (Ex. 488) and Texas Red filters 
(Ex. 596).  An example image at 40x magnification is shown (Fig. 2.2, A).  Images 
were taken on a Leica DFC300 FX Digital Colour Camera connected to LAS (Leica) 
software.  Afterwards, ImageJ software (NIH, Bethesda) was used to create a selection 
area of 0.5 mm length.  This was consistently applied to the same area at the fish tailfin, 
namely with the right hand vertical line placed where the notochord/vasculature ends 
(Fig 2.2, B).  All the cells to the right of the left-hand vertical line of the box were 
counted.  For whole embryo cell counting, the ImageJ multi-point tool was used.  
Images were taken in different focal planes to ensure that all cells were counted (as 
some cells might be obscured by cells directly above/below). 
Confocal imaging or time lapse imaging was carried out using a Leica sp5 
microscope.  EGFP was excited at 488 nm; mCherry at 587 nm, and TUNEL at 570 
nm.   The images were taken at 100x magnification to image the inflammatory 
response, or at 400x magnification to acquire images of fixed, Terminal 
deoxynucleotidyl transferase dUTP nick end labelling (TUNEL)–stained embryos (as 






2.2. Analysis of zebrafish neutrophil characteristics and function 
 
2.2.1. Digestion of whole embryos for fluorescent activated cell sorting 
(FACS) 
As many embryos as possible were used for a reasonable yield after sorting; in these 
studies about 500 embryos were used.  Tg(mpx:EGFP)i114 embryos were transferred 
using a pastette into a 1.5 mL microcentrifuge tube.  They were euthanized by 
immersion in 100% Tricaine stock solution (see Appendix B) for 15 min, until it was 
that activity and cardiovascular function had ceased.  The approved Schedule 1 method 
Figure 2.2. Tailfin transection and counting of cells 
Tg(mpx:EGFP)i114 zebrafish with a transected tailfin.  Images taken at 40x (A) and 
80x (B) magnification. 
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is detailed by Home Office A(SP)A’86 guidelines).  The embryos were then briefly 
washed in Tris Buffered Saline (TBS, see Appendix B) and then 1 mL of Trypsin was 
added to disassociate the cells of the embryo.  The embryos were put on a shaking heat 
block for 1 h at 37°C.  Vigorous pipetting was carried out twice per tube, to help in the 
dissociation process.  The resulting solution was then passed through a 40 μM filter in 
a 50 mL conical centrifuge tube, then centrifuged at 300 g for 5 min and resuspended 
in a flow cytometry tube in 300 μL of media (Roswell Park Memorial Institute [RPMI] 
cell medium [supplemented with 10% Foetal Bovine Serum [FBS], to aid the solution 
easily passing through the BD FACS Aria cell sorter]).   
 
2.2.2. Isolation and digestion of adult zebrafish kidneys for FACS 
The kidney of the adult Tg(mpx:EGFP)i114 zebrafish was digested and neutrophils 
isolated, to examine if a greater yield could be achieved than with digestion of embryos 
alone (Section 3.3.6).  The adult zebrafish was killed by the Schedule 1 method as 
detailed by Home Office A(SP)A ’86 guidelines (Section 2.2.1), followed by 
destruction of the brain.  The fish was then supported and inverted, in a wet, tissue 
paper-moulded groove in a petri dish. A stereo dissecting microscope (for details, see 
Appendix A) was then used to visualise the inverted fish during the dissection process.  
Dissecting scissors were used to open the peritoneal cavity, and the intestinal tissue 
was removed by cutting the oesophagus and anus.  The soft kidney was carefully 
removed using fine forceps, teasing it away from the peritoneal cavity (174).  The 
kidney of Tg(mpx:EGFP)i114 zebrafish can easily be identified using EGFP 
fluorescence.  Neutrophils labelled with EGFP could be visualised throughout the 
kidney of these animals.  The kidney was dissociated by the addition of the kidney 
tissue to 1 mL of RPMI supplemented with 10% FBS, followed by gentle pipetting up 
and down.  This was sufficient for good tissue dissociation.  The mixture was then 
filtered through a 40 µM filter and collected in a 50 mL conical centrifuge tube, and 





2.2.3. Fluorescence-activated cell sorting (FACS) of EGFP+ zebrafish 
neutrophils 
Embryos or kidneys were digested as described in Sections 2.2.1 or 2.2.2.   The cell 
populations in 300 μL RPMI in flow cytometry tubes were sorted on a BD FACS Aria 
IITM cell sorter, based on EGFP fluorescence (Ex. 488).  The sort takes approximately 
40 min.  The gating is shown in Chapter 1 (Fig. 3.7).  The cells are collected in a 1.5 
mL cytocentrifuge tube and used for imaging or ex vivo stimulation 
 
2.2.4. Imaging of zebrafish embryo EGFP+ neutrophils isolated by FACS 
FACS-isolated EGFP+ cells were imaged in media in an 8 well chamber cover glass 
slide using a fluorescent microscope (EVOS FL Cell Imaging System).  Time lapse 
images of these cells were made on the same microscope. 
 
2.2.5. Stimulation of sorted EGFP+ neutrophils using N-Formyl-Met-
Leu-Phe (fMLF) 
Shape change of sorted EGFP+ neutrophils was assessed after fMLF stimulation (see 
page 89).  fMLF is a potent chemotactic stimuli for neutrophils, inducing cell 
polarisation and therefore a shape change which can be measured by increase in 
forward scatter (175).  The sorted EGFP+ neutrophils were centrifuged at 300 g for 5 
min and resuspended in 75 μL of Phosphate-Buffered Saline (PBS, see Appendix A) 
containing Ca2+ and Mg2+ in a 2 mL microcentrifuge tube in a 37°C shaking heat block 
(300 rpm).  An additional 60 μL of PBS containing Ca2+ and Mg2+ was added, along 
with 15 μL of fMLF (10 nM) or PBS as a control.  The tubes were incubated for a 
further 30 min at 37°C, then 75 μL of cells were added to 250 μL of PBS (without 
Ca2+/Mg2+) and placed on a flow tube on ice.  The samples were then processed on an 
LSR Fortessa Flow Cytometer, and forward and side scatter profile was analysed. 
 




2.3.1. Incubation of zebrafish embryos with compounds 
Zebrafish at 3dpf were transected as described in Section 2.1.4.  At 4 h after the initial 
transection, each embryo was added to an individual well of a 48 well plate containing 
500 μL of embryo medium (see Appendix B) with the appropriate concentration of 
compound or dimethyl sulfoxide (DMSO) vehicle control (≤1% DMSO, unless 
specifically stated otherwise).  The compound concentrations used were listed in Table 
2.1 below.  The fish are repeatedly imaged at different time points over the 48 h post-
transection (see Section 2.1.5), and inflammation is determined (see Section 2.1.6).  
Only healthy animals with normal swim behaviour are included in the analysis, as 
determined by eye (see Section 2.1.4). 
 
Table 2.1. Compound incubation of 3 dpf zebrafish embryos 
Drug Concentration Used 
AT7519 10 µM, 20 µM 
Wogonin 25 µM, 50 µM 
Luteolin 50 µM, 100 µM 
Apigenin 50 µM, 100 µM 
FVP 1 µM, 3 µM 
SNS-032 10 µM, 20 µM, 50µM 
zVAD-fmk 100 µM 
QVD-OPh 1 µM, 10 µM, 50 µM 
 
2.3.2. Microinjection of zebrafish embryonic yolk sac with compounds 
The zebrafish embryo was anaesthetised in 4.2% (v/v) Tricaine (see also section 2.1.4).  
The embryo was then laid in the groove of a microinjection tray exposing the ventral 
surface for microinjection (Fig. 2.3, B).  Excess water was removed to ensure the 
embryo does not float away when the needle is inserted.  Then, 3 µL of compound or 
control solution (see Table 2.2) was loaded into a microcapillary needle, using 20 µL 
microloader tips.  The loaded microcapillary needle was inserted in the needle holder 
of a Narishige IM-300 microinjector and held in place in a Narishige micromanipulator 
for reproducible microinjections.  The microcapillary needle was calibrated by 
injecting a single pulsed bolus of experimental solution (for typical microinjector 
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settings, see Appendix A) into mineral oil on a 1 mm stage micrometer slide (Pyser 
SGI).  The diameter of the bolus was measured using the 1 mm ruler on the 
micrometer.   The injection time of the microinjector was adjusted as necessary until 
the bolus measured 0.1 mm.  A bolus of this size corresponds to a 500 pL volume.  The 
volumes listed in Table 2.2 were injected into the yolk sac of the embryo, using a 
Narishige microinjector and micromanipulator.  This region is indicated in Fig. 2.3.  
The settings used for the needle puller, necessary to shape capillary needles, are listed 
in Appendix A.  After injection, the animals were each isolated and maintained in a 
single well of a 48 well plate in 1 mL of system water.  Over the 48 h post-transection 
the fish are serially imaged (see Section 2.1.4 and 2.1.5), and inflammation is counted 
(see Section 2.1.6).  Unhealthy animals are removed from analysis as necessary (see 
Section 2.1.4).   
 
 
Table 2.2. Compound injection into zebrafish yolk sac 
Figure 2.3. Microinjection into zebrafish yolk sac 
Compounds such as AT7519 were injected into the zebrafish yolk sac (A).  Fish 
were laid in a microinjection tray in the correct orientation for microinjection (B). 
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1.5nL 10mM 0.5 ng 
zVAD-fmk Tocris 
Bioscience 
2nL 100mM 93.5 ng 
FVP Sigma Aldrich 0.5nL 10mM 2.2 ng 
 
2.4. Staining zebrafish for apoptosis 
 
2.4.1. Fixing and preparing embryos for staining 
Embryos were euthanized using 100% Tricaine by Schedule 1 methods (see Section 
2.1.4).  The embryos were transferred using a pastette into a 1.5 mL microcentrifuge 
tube, then briefly washed in TBS.  The TBS was removed, then 1 mL of 
paraformaldehyde solution (PFA, 4%) was added to the tube.  The tubes were kept at 
4°C overnight.  After 12 h of fixation, the PFA was removed.  Alternatively, fixation 
was carried out for 1 h at room temperature.  If staining was carried out on the same 
day, the embryos were washed 3 times with TBS prior to beginning the staining 
protocol.  If the embryos were stored long term, the PFA was removed and 1 mL of 
100% methanol was added to the tubes.  They were then stored at -20°C.  Prior to use, 
the embryos must be rehydrated by successive 5 min incubations in 75% 
Methanol/25% TBS, 50% Methanol/50% TBS then 25% Methanol/75% TBS.  The 
embryos are then washed 3 times in TBS. 
 
2.4.2. Tyramide signal amplification (TSA) and terminal 
deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) 
staining 
TUNEL staining was carried out in fixed Tg(mpx:EGFP)i114 conjunction with 
Tyramide Signal Amplification (TSA), in order to amplify the EGFP signal.  The 
protocol is carried out with components from the Tyramide Signal Amplification 
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(TSA) Kit and the ApopTag® Red In Situ Apoptosis Detection Kit (for details, see 
Appendix A).   
2.4.2.1. TSA Staining 
The embryos were washed in 500 µL of Amplification Diluent from the TSA kit.  They 
were then incubated in a 1 in 50 dilution of Fluorescein:Amplification Diluent.  The 
tubes were wrapped in foil and incubated for 10 min at 28°C degrees.  The embryos 
were washed 3 times for 10 min in TBS.  The fluorescein stain was checked on a 
fluorescent stereomicroscope (see Appendix A). The embryos were then fixed for 20 
min at room temperature (RT) in 4% PFA. 
2.4.2.2. TUNEL staining 
The TUNEL staining protocol began with a Proteinase K digestion.  The embryos were 
incubated for 90 min at room temperature in 10 ng/mL of Proteinase K.  The embryos 
were then washed twice for 5 min in TBS with 0.1% Tween20 (TBS-T), then fixed in 
4% PFA for 20 min at room temperature (20°C).  Another 3 washes with TBS-T were 
carried out followed by an incubation in 1:2 acetone:ethanol for 7 min at -20°C.  Three 
5 min washes in TBS-T were performed, then 50µL of Equilibration Buffer 
(ApopTag® Red kit) was added to each tube for 1 h at RT.  The equilibration buffer 
was then removed, and to each tube 16 µL terminal deoxynucleotidyl transferase (TdT) 
enzyme and 30µL Reaction Buffer (both from ApopTag® Red kit) was added.  The 
tubes were incubated for 90 min at 37°C.  The liquid was then removed and 200 µL of 
Stop Buffer (ApopTag® Red kit) was added for 3 h at 37°C.  The embryos were then 
washed for 3 times for 5 min in TBS-T.  To each tube 62 µL anti-Dig Rhodamine and 
68 µL of Blocking solution (both from ApopTag® Red kit) was added, and the tubes 
were incubated overnight on a shaker at 4°C.  The next morning, 4 washes for 30 min 
in TBS-T were performed, then 4% PFA was added for 30 min at RT.  Four final 
washes for 5 min in TBS-T were carried out.  The embryos were then stored in 80% 
glycerol at -20°C until they were imaged.   For imaging the embryos were also 





2.5. Morpholino knockdown of genes of interest 
 
2.5.1. Design of morpholino sequences 
Morpholinos were ordered from Gene Tools LLC.  These are 25 base-pair synthetic 
oligonucleotide sequences which block either mRNA splicing or translation.  To 
design these sequences, the ENSEMBL ID of each transcript was entered into the 
Design Tool of the Gene Tools website (http://www.gene-tools.com/).  For ATG-
morpholinos, the morpholino is designed across the start codon of the gene and 
therefore block translation.  For splice-targeting morpholinos, the desired potential 
target exons were listed and morpholinos are designed which span this exon-intron 
boundary.  Optimal morpholino design should have a 40-60% Guanine (G)-Cytosine 
(C) content.  The sequences should not have long stretches of self-complementarity, 
or more than 4 G nucleotides in a row (due to water solubility issues).  Table 2.3 lists 
the target, sequence, fluorophore and details of previous publications of the 
morpholinos.  Mismatched controls (similar sequences with random base pair changes) 
are also injected, to prove that the phenotype seen is due to the specific effect of the 


















Table 2.3. Morpholinos microinjected into zebrafish eggs throughout the project 
Target Type of 
Morpholino 
Sequence 3’ Fluorophore Previously 
published? 
CDK9 Splice blocking a 
Exon 3/Intron 3 
GGTGCATTTTCTT
ACCCCTTCTTTC 
Lissamine  (117) 













CDK7 Splice blocking 











Lissamine  (39) 
Mcl-1b ATG CTGTTTTCAATTCC
ACATAAACGCC 






LaRP7 Splice blocking a 
Exon 3/Intron 3 
TCATCTCCATACT
AAACCAAACTGT 
Lissamine  (117) 









Lissamine  (117) 
 
2.5.2. Preparation of morpholino injection solution 
Morpholinos were diluted to a stock solution of 1 mM in sterile water and kept at room 
temperature.  They were then diluted further in sterile water for microinjection 
(microinjection technique is detailed in Section 2.3.2).  The amount of morpholino 
injected into the zebrafish eggs in a volume of 1 nL are listed in Table 2.4, along with 
the dilution from the 1 mM stock solution. For each morpholino several amounts of 
morpholino were tested to ascertain the optimal amount, in which knockdown was 
achieved but the fish were healthy and not developmentally stunted (171).  For the 
purpose of clarity, only the optimum amount used is shown here.  Success of 





Table 2.4.  Amount of morpholino injected into zebrafish eggs 




CDK9 Splice blocking 
Exon 3/intron 3 
455.1pg 1 in 20 
CDK9 Splice blocking 
Exon 1/intron 1 
455 pg 1 in 20 
CDK9 Mismatched control 461.1 pg   1 in 20 
CDK9 ATG 130.7 pg  1 in 70 
CDK7 Splice blocking 
Exon 11/Intron 11 
1.8 ng  1 in 5 
CDK7 Mismatched control 1.8 ng  1 in 5 
Mcl-1a ATG 4.6 ng 1 in 2 
Mcl-1b ATG 4.6 ng 1 in 2 
Mcl-1 Mismatched control 4.4 ng 1 in 2 
LaRP7 Exon 3/intron 3 911.5 pg 1 in 10 
LaRP7 Mismatched control 923.5 pg 1 in 10 
CDK9 + CDK7 Splice- blocking 303.4 pg + 1.2 ng 1 in 30 (both) 
 
CDK9 + LaRP7 Splice-blocking 303.4 pg + 455.75 pg 1 in 30, 1 in 20 
Mcl-1a + Mcl-1b 2.3 ng + 2.3 ng 1 in 4 (both) 
 
2.5.3. Microinjection of morpholinos into zebrafish eggs 
Morpholinos were microinjected into newly–laid zebrafish eggs, up to the 8-cell stage 
(171).  The microinjection equipment was set up as described in Section 2.3.2.  The 
volume of the injected bolus was determined to calculate the amount of morpholino 
added.  Multiple eggs were laid into the grooves of a microinjection tray, using a 
pastette, and 1 nL of the morpholino was injected into the yolk sac of the zebrafish 
egg, shown in Figure 2.4 (A).  Morpholinos do not need to be injected into the single 
cell of the developing embryo, unlike DNA injections, as the morpholinos can easily 
be taken up in the cytoplasmic stream of the yolk sac into the developing cells.  The 
eggs were raised in petri dishes till 3 days post fertilisation.  They were screened using 
a fluorescent microscope for positive uptake of the fluorescently-labelled morpholino, 






2.5.4. Western blot to assess morpholino knockdown 
Embryos were euthanized by Schedule 1 methods, fully described in Section 2.2.1.  
Briefly, embryos at 3 dpf were immersed in 100% Tricaine for 5 min.  Each was then 
transferred by pastette into a 1.5 mL microcentrifuge tube.  A solution was prepared 
of 790 μL Radioimmunoprecipitation Assay (RIPA) buffer plus 10 μL Protease 
Inhibitor Cocktail.  To each tube 30 μL of this solution was added, and the embryos 
were dissociated with a pestle. The solution was then sonicated for 30 seconds (s) at 5 
μW using a sonicator.  The tubes were incubated for 30 min on ice, following which 
they were centrifuged for 15 min at 13,000 g.  The supernatant (approximately 30 μL) 
is collected and transferred into a fresh 0.5 mL microcentrifuge tube.  It was then stored 
at -20°C or ran immediately on a 5-12% Tris-Glycine gel.   
Figure 2.4.  Microinjection of morpholinos into the zebrafish egg 
The red arrow indicates the area of cytoplasmic streaming where the morpholino is 
injected (A).  Brightfield (B [i]) and EGFP fluorescent (B [ii]) images of an egg 
successfully injected with an EGFP fluorescent morpholino. 
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A protein assay was carried out using the Pierce Bicinchoninic acid assay 
(BCA) Protein Assay kit.  The kit consists of a BCA Working Reagent (50:1 Reagent 
A:Reagent B).  Various BSA protein standards were made up in the range 125 – 2000 
μg/mL as per manufacturer’s instructions, by serial dilutions in distilled, deionised 
(dd)H20 from a protein stock of known concentration.  Then, 200 μL of the Working 
Reagent was added to 10 μL of standards or samples in a 96 well plate.  The plate was 
covered with a lid and mixed on a plate shaker for 30 s then covered with foil and 
incubated for 30 min at 37°C.  The plate was then measured at room temperature at 
562 nm on a plate reader.  A standard curve of Optical Density (OD) vs. protein 
concentration was created on a Microsoft Excel spreadsheet.  This was used to 
calculate the unknown values of protein concentration of samples, based on the OD of 
the samples. 
  Sample buffer (4x) containing reducing agents (see Appendix B) and ddH20 
was added to the sample to make a volume of 40 μL, all containing the same amount 
of protein (confirmed from the protein assay standard curve).  The samples were then 
incubated at 95°C for 5 min in a heat block to denature the protein.  The Benchmark 
pre-stained protein ladder was used to estimate protein size.  Following this, the 
samples and 1 well of protein ladder were loaded and run on a 4-12% sodium dodedcyl 
sulphate (SDS)-Polyacrylaminde gel electrophoresis (PAGE) gel to separate the 
proteins, at 110 V for 45 min in Running Buffer (recipe in Appendix B).  The protein 
was then transferred onto a polyvinylidene fluoride (PVDF) membrane (pre-activated 
for 5 min in methanol) in Transfer Buffer (recipe in Appendix B) at 80 V for 1 h at 
4°C.  The membrane was then incubated in a 50 mL conical centrifuge tube containing 
15 mL of 5% dried milk powder in TBS-T.  The membrane was then incubated 
overnight on a roller in a 1 in 1000 dilution of the appropriate primary antibody (see 
Table 2.5).  The membrane was washed 3 times in TBS-T then incubated in the 
appropriate secondary antibody for 1 h (see Table 2.5).  The membrane was then 
washed 3 times in TBS-T then developed using an Electrochemiluminescence (ECL) 
kit.  Briefly, 1 mL of Solution A was mixed with 1 mL of Solution B (both from the 
ECL kit) in a 50 mL conical centrifuge tube.  The membrane was then developed onto 
a film, in the dark room using a developer.  The size of the protein band was estimated 
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by comparing it to the size of the closest protein ladder bands, which are of known 
size. 
 
Table 2.5. Antibodies used for western blotting 
Antibody Type Protein Band Size 
CDK9 Rabbit Polyclonal 43 kDa 
CDK7 Rabbit Polyclonal 42/37 kDa 
Mcl-1 Rabbit Polyclonal 40/32 kDa 
LaRP7 Rabbit Polyclonal 67 kDa 
Goat Anti-Rabbit Horse Radish Peroxidase-
conjugated secondary  
N/A 
Goat Anti Mouse Horse Radish Peroxidase-
conjugated secondary 
N/A 
Β-Actin Mouse Monoclonal N/A 
 
 
2.6. Heritable gene knockdown of CDK9 in zebrafish using clustered 
regularly interspaced short palindromic repeats (CRISPR)/cas9 
gene editing 
 
2.6.1. Design of gRNA guide oligonucleotide sequences 
The use of the CRISPR/cas9 for gene editing is previously described in zebrafish  
(158-160).  The gRNA guide oligonucleotide sequences were designed with an online 
CRISPR Design Tool (http://www.genome-engineering.org/crispr/?page_id=41).  It is 
an algorithm based on a previously published analysis which selects good targets from 
a 23-1000 bp long region of interest.  Good targets are DNA sequences which are 
followed by a PAM sequence (5’-NGG, 5’-NAG), as these are the sites targeted by the 
Cas9 enzyme.  From this, two guide sequence templates were synthesised, as shown 
in Figure 2.5.  The guide sequence and T7 primers were diluted to 200 μM stocks in 
ddH20.  The guide and T7 primer sequences were then annealed together by mixing 
them together in a solution where they were both at 15 μM concentration.  The tube 
was then heated in a PCR machine for 5 min at 95°C, then cooled down to 22°C by 
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setting the machine to decrease temperature at 0.1°C per s.  The reagents from the 
MEGAscript T7 kit are thawed to room temperature (except the enzyme mix which 
should be kept on ice).  Each transcription reaction is done in a polymerase chain 
reaction (PCR) tube with 2 μL of ATP, CTP, GTP and UTP solutions; 2 μL of 10X 
Reaction Buffer, 2 μL of Enzyme Mix, and 2 μL of the annealed product.  The tubes 
were mixed thoroughly and incubated for 3 h at 37°C. 1 μL of TURBO DNAse is 
added and mixed well, then the tubes were incubated at 37°C for 15 min.  The 
MEGAclear kit was then used to further purify the RNA from the in vitro transcription 
reaction.  The RNA sample was brought to a total volume of 100 μL with Elution 
Solution and then 350 μL of Binding Solution Concentrate was added and mixed 
gently again using a p1000 pipette.  A further 250 μL of 100 % ethanol was added to 
the sample and mixed gently.  The sample was then applied to a filter cartridge inside 
a collection and elution tube.  The tube was centrifuged for 1 min at 13,000 g till the 
solution passed through the filter.  The flow-through was discarded and the filter was 
washed by adding 500 μL of Wash Solution and centrifuging for 1 min at 13,000 g, 
then discarding the flow-through.  This step was repeated, then a further 30 s 13,000 g 
centrifuge step was carried out to remove any remainder of the Wash Solution.  The 
RNA was eluted from the filter by placing the filter into a new collection/elution tube 
and applying 50 μL of Elution Solution to the filter.  The tube was incubated in a heat 
block set at 65°C for 10 min.  The eluted RNA was then recovered by a 1 min 
centrifugation at 13,000 g.  This elution step was repeated with another 50 μL of 
Elution Solution (to maximise RNA recovery).  The DNA concentration in 1 μL of 
DNA solution was measured using a Nanodrop machine (for details, see Appendix A).  
With the Guide #2 template, the yield was consistently between 200-300 ng/μL.  With 
the Guide #1 template, the yield was consistently around 50 ng/μL.  This indicated that 
Guide #2 was probably the best template, however both Guide #2 and Guide #1 RNA 
were still used for microinjection into zebrafish eggs. 
 
2.6.2. Cas9 in vitro transcription 
An aliquot of Cas9 mRNA was provided as a kind gift from the laboratory group of 
Dr David Lyons.  It was synthesised as previously described (159).  Briefly; wild-type 
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Cas9 from Streptococcus pyogenes had nuclear localisation sequences and a C-






GCTGACT-3’. The PCR product was then subcloned into the vector 
pCR8/GW/TOPO/TA and then recombined into the vector pCS2+/GW using LR 
Clonase II.  The Cas9 was then linearized using NotI, then transcribed in vitro using 
the SP6 mMESSAGE mMACHINE kit.   
 
Table 2.6. Primer Sequences 
Primer Sequence 
T7 TAATACGACTCACTATAG 
CDK9 Forward GCCGAAAGAAAACGCGAAGT 

























Figure 2.5.  Designing CRISPR guide sequences 
Two gRNA anti-sense guide sequences were synthesised for in vitro transcription.  
In italics is the conserved gRNA scaffold, containing sites necessary for Cas9 
enzyme recruitment.  In bold is the region of the gene of interest which will be 
targeted, upstream of a PAM site in the gene. In red is the T7 primer binding site, 
necessary for recruitment of the T7 primer during in vitro transcription (A).  The 
CDK9 genomic DNA sequence of the target areas.  In bold are exons; in orange are 
primers designed for PCR and genotyping of the knockout region.  In green is the 
Guide #1 site, in blue the Guide #2 site.  The red lines indicate the restriction 
enzyme cut sites for Hpy99I (Guide 1) and Hpy188I (Guide 2) (B). 
79 
 
2.6.3. Microinjection of gRNA oligonucleotide and cas9 mRNA into 
zebrafish eggs 
The following injection solution was prepared:  2 μL of Cas9 mRNA, 1 μL Phenol 
Red, gRNA oligonucleotide at a concentration of 15 ng/μL, and then made up to 10 
μL with ddH20.  This solution (1 nL) was injected into the single cell of newly laid 
zebrafish eggs, as shown in Figure 2.6 (see sections 2.3.2 and 2.5.3 for further 




2.6.4. Genotyping of CRISPR/cas9-injected animals and subsequent 
generations 
Genotyping PCR assays were performed on whole single zebrafish embryos, or tail fin 
clips isolated from adults.  Briefly, this was done by anaesthetising the adult fish in 4.2 
Figure 2.6.  Microinjection of gRNA oligonucleotide and cas9 mRNA into 
zebrafish eggs 
The red arrow indicates the region where the CRISPR/cas9 mRNA is injected (A).  
Image shows microinjection into the single cell, with the egg orientated so the 
single cell faces to the right to facilitate penetration by the needle. 
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% Tricaine in system water (see Section 2.1.4), and then laying the fish on wet tissue 
paper and removing the tip of the tailfin with a sterile scalpel (see Figure 2.7).  This 
area is sufficient to allow extraction of enough genomic DNA (gDNA) for genotyping. 
Each tailfin sample was added to a PCR tube that was stored on dry ice, which helps 
the tissue to stick to the side of the tube.  The embryos were euthanised in Tricaine 
(see Section 2.2.1), rinsed in PBS then singly distributed in PCR tubes.  Excess liquid 
was removed.  To each tube, 50 μL of a solution of 1:50 Proteinase K (20 mg/mL):TE 
Buffer was added.  The tubes were then incubated overnight in a PCR machine at 55°C.  
This isolates the gDNA (170).   The CDK9 primers in Table 2.6 were used to amplify 
the region in which a mutation would be predicted to occur in Guide #1 or Guide #2 
injected animals.  This is demonstrated in Figure 2.6.  Each PCR tube was set up as 
follows to make a 25 μL reaction: 2 μL of genomic DNA, 12.5 μL of OneTaq Quick-
Load 2x Master Mix with Standard Buffer, 0.5 μL of each forward and reverse primer 
(diluted to 10 μM) and 9.5 μL ddH20.  The PCR settings used were as follows: 
 
   94°C  2 min Initial Denaturation 
   94°C  30 s 
   58°C  30 s 
   68°C  1 min 
   68°C  1 min Final Extension 
   4°C    Hold 
 
For genotyping, 12.5 μL of this PCR product was digested with 0.5 μL of Restriction 
Digest Enzyme Hpy99I (for Guide #1 template) or Hpy188I (for Guide #2 template), 
1.5 μL of ddH20 and 2 μL of Cutsmart Buffer.  These enzymes cut within the Guide 
#1 or #2 target sites, shown in Figure 2.5. 
 
2.6.5. Running agarose DNA gels 
Agarose DNA gels were run to check the size of the PCR bands and restriction digest 
bands.  A solution of TAE buffer and 2% Agarose was heated in the microwave till 
simmering.  2 µL of Sybr Safe Gel Stain was added per 100 mL of gel, then it was 







the first and last wells of each row, to allow assessment of the band size of the samples.  
The samples were loaded into the other wells.  The gel was run at 100 V for roughly 





2.7. Creation of Mcl-1 over-expressing zebrafish using Tol2 gateway 
cloning 
 
2.7.1. Cloning Mcl-1 into middle entry clone (pMe) 
Vectors containing Mcl-1a and Mcl-1b fused to pEGFP-C1, and a vector containing 
the Lysozyme C (LysC) promoter, were given as a kind gift from Professor Stephen 
Renshaw, University of Sheffield. The Mcl-1a and Mcl-1b vectors were in an 
unsuitable vector for Tol2 cloning, so PCR was performed to amplify these areas of 
the plasmid and clone them into another vector.  
The dried plasmid was shipped to Edinburgh on filter paper, then the patch 
containing the plasmid was cut out and the paper soaked in 30 µL of nuclease free 
water.  The plasmid was transformed into TOP10TM E. coli by adding 2 µL of this 
solution to an aliquot of Top10TM chemically competent cells on ice for ½ h.  The cells 
Figure 2.7.  Fin clip of an adult zebrafish, for genotyping 
An adult female zebrafish, with a red line to show the region of caudal fin which is 
removed using a scalpel for genotyping. 
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were put on heat for 40°C for 30 s, so the bacteria take up the plasmid.  The tubes were 
returned to ice for 1-2 min then 250 µL of SOC medium was added.  The tubes were 
put on a 37°C shaker for 50 min and 150 µL of this solution was added to a Petri dish 
of Agar supplemented with kanamycin antibiotic (500 µL of 50 mg/mL Kanamycin in 
500 mL of Agar).  From each plate (Mcl-1a, Mcl-1b and LysC) 4 clones were picked 
by dipping a pipette tip in the clone and dropping the tip in a bacteria culture tube 
containing 5 mL of the same concentration of Lysogeny Broth (LB) medium and 
kanamycin.  The tubes were kept overnight in a bacteria culture shaker at 37°C and 
then 700 µL of the culture was added to 300 µL of Glycerol for long term storage.  The 
rest was centrifuged down repeatedly in a 2 mL microcentrifuge tube at 6800 g for 3 
min, till only the bacterial pellet remained.  This pellet was used to prepare plasmid 
DNA using the Qiagen Spin-Miniprep Kit.  First, 250 µL of Buffer P1 from the kit 
was used to resuspend the bacterial cells, then next 250 µL of Buffer P2 was added 
and the tube was mixed by inverting it 10-12 times until the solution turned blue.  The 
solution was incubated for 5 min then 350 µL of Buffer N3 was added, and the tube 
was mixed by inverting 10-12 times till the solution turned colourless.  The tube was 
centrifuged for 10 min at 17,900 g, then the supernatant was applied to the QIAprep 
spin column.  The supernatant was centrifuged at 17,900 g for 1 min then the flow-
through was discarded.  This was repeated till all the supernatant was gone and 
afterwards 500 µL of Buffer PB was added to the spin column and the tube centrifuged 
at 17,900 g for 1 min, and the flow-through was discarded.  This step was repeated 
with 750 µL of Buffer PE.  The spin column was transferred to a fresh collection tube 
and centrifuged for 1 min at 17,900 g to remove residual wash buffer.  The spin column 
was placed in a fresh 1.5 mL microcentrifuge tube and the DNA was eluted by adding 
60 µL of ddH20 to the column, incubating at room temperature for 1 min, and 
centrifuging for 1 min at 17,900 g. 
PCR was used to amplify 4 different sequences; 1: Mcl-1a, 2: Mcl-1b, 3: 
peGFP-C1:Mcl-1a and 4: peGFP-C1:Mcl-1b.  The PCR reaction consisted of 5 µL of 
10x buffer, 1 µL of PFU DNA Polymerase, 1 µL of dNTPs, 1 µL of DNA, and 2 µL 
of the appropriate forward and reverse primers, diluted to 10 µM, and 40 µL of ddH20.  
For each condition the following primers were used: 1: Mcl-1a forward and reverse 
primers, 2: Mcl-1b forward and reverse primers, 3: peGFP-C1 forward primer and 
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Mcl-1a reverse primer, and 4: peGFP-C1 forward primer and Mcl-1b reverse primer 
(see Table 2.7).  The following settings were used: 
 
   94°C  2 min Initial Denaturation 
   94°C  30 s 
   60°C  30 s 
   72°C  1 min 
72°C  1 min Final Extension 
   4°C    Hold  
 
The PCRs were checked on a gel as in Section 2.6.5., with the exception that 6x loading 
dye was added to the samples, as the PFU DNA Polymerase did not contain loading 
dye already in a master mix.  The PCR product was excised from the gel under UV 
light and digested using a QIAquick gel extraction kit (Qiagen), according to the 
manufacturer’s protocol.  The gel slice was weighed and 3 volumes of Buffer QG were 
added per 1 volume of gel.  After the gel slice was dissolved, 1 gel volume of 
isopropanol was added to the sample and mixed.  A QIAquick spin column was added 
to a 2 mL collection tube.  The DNA was applied to the column and centrifuged for 1 
min at 17,900 g, then the flow-through was discarded and 0.4 mL of Buffer QG was 
added to the QIAquick column.  The column was centrifuged for 1 min at 17,900 g, 
then the flow-through was discarded.  A wash step was performed by addition of 0.75 
mL of Buffer PE (from kit) to the column and a 1 min 17,900 g centrifugation was 
performed.  The column was left at room temperature for 5 min then centrifuged for 1 
min to remove any residual wash buffer.  The column was placed into a fresh 1.5 mL 
microcentrifuge tube. The DNA was eluted by addition of 50 µL ddH20 to the column, 
incubation at room temperature for 1 min, then centrifuged for 1 min at 17,900 g.  The 
DNA product was measured on the Nanodrop machine (See Appendix A for details), 
and the amount of ng needed for the BP reaction for each was calculated using the 
following formula:  
Ng = (x fmoles)(Base pairs)(660 fg/fmoles)(1ng/106 fg) 
A BP reaction was set up to clone the PCR fragment into the Entry Vector 







of DNA for 50 fmoles, along with 3 µL of 50 µg/µL vector and TE buffer up to 8 µL.  
2 µL of BP Clonase was added to each tube, and then a 2 h incubation was performed 
at 25°C.  The plasmid was transformed into E. coli as before and the cells were plated 
onto a kanamycin plate and incubated overnight at 37°C (described earlier in this 
section).  Clones were picked and incubated overnight at 37°C.  The DNA was 
prepared as before using the MiniPrep kit (described earlier in this section).  The DNA 
was sent for sequencing to Eurofins Genomics using the Seq Smart DNA sequencing 
kit along with the M13 and T7 primers.  M13 and T7 sites are present on the plasmid, 
facilitating sequencing.  Appropriate restriction digests were performed at each step, 
to examine band size and ensure they were as expected. 
 
2.7.2. LR reaction to create destination vector (pDest) 
The LR reaction was carried out to combine the p5e LysC vector, the pMe vector 
(containing Mcl-1a, Mcl-1b, peGFP-C1:Mcl-1a OR peGFP-C1:Mcl-1b), p3e-PolyA 
and pDest vector).  For the LR reaction, 1 µL of each vector (10 fmoles) and 1 µL of 
LR clonase was added together with TE buffer, up to 8 µL.  This was incubated at 
25°C overnight, then 1 µL of Proteinase K was added per reaction and the tubes were 
incubated for 10 min at 37°C. 
 
2.7.3. Microinjection of vector and mRNA 
Finally, an injection solution of 2 µL Danieau’s Solution, 2 µL Rhodamine/Dextran 
solution, 1 µL Tol2 transposase mRNA (a kind gift from the lab of Dr Yi Feng), 2 µL 
of DNA, and 3 µL of ddH20 as prepared and then 1 nL was microinjected into the 1 







Table 2.7. Primers used in Cloning of Mcl-1a and Mcl-1b 
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1-4: Sequences in red: Kozak Sequence; Sequences in bold: Mcl-1-specific sequence; 
Sequences in Italics: attB1 sequence (forward primers) or attB2R sequence (reverse 
primers) 
Primer Sequence 
1. Mcl-1a Forward Primer GGGGACAAGTTTGTACAAAAAAGCAGGCTGCCGC
CACCATGGCTCTGAGTTTGGATTTTAG 
2. Mcl-1a Reverse Primer GGGGACCACTTTGTACAAGAAAGCTGGGTTCACC
GGATGAGGAAGGC 




4. Mcl-1b Reverse Primer GGGGACCACTTTGTACAAGAAAGCTGGGTTCACC
GTATCCAATAGGCAAG 
M13 Primer GTAAAACGACGGCCAGT 




2.8. Neutrophil Isolation from human peripheral blood and treatment 
with R-roscovitine 
This technique was performed with kind assistance from Dr Calum Robb.  Around 40-
160mL of blood was collected from donors in 50 mL microcentrifuge tubes with sterile 
sodium citrate (final conc. 0.38%).  The blood was centrifuged at 300 g for 20 min and 
platelet-rich plasma removed.  Leukocytes were separated from erythrocytes by 
dextran sedimentation over 25-30 min using pre-warmed (37°C) 0.6% 
(weight/volume) dextran T500.  The upper leukocyte-rich layer was aspirated and 
volume adjusted to 50 mL using pre-warmed 0.9 % saline.  The leukocytes were 
pelleted by centrifugation at 350 g for 6 min.  Polymorphonuclear leukocytes 
underwent separation from mononuclear leukocytes using a discontinuous isotonic 
Percoll gradient (9:1 percoll:10 x Phosphate Buffered Saline [PBS] ratio). The 
gradients were as follows: 81%, 70% 55% Percoll in 1x PBS (without cations). 
3 mL of 70% isotonic Percoll was layered on 3 mL of 81% isotonic Percoll in a 15 mL 
microcentrifuge tube.  The leukocytes were re-suspended in 3 mL 55% Percoll.  The 
gradients were centrifuged at 720g for 20 min.  Mononuclear cells are in the upper 
55:70% interface, and polymorphonuclear leucocytes at the 70:81% interface.  Cell 
yield was calculated using a haemocytometer.  Leukocytes were washed twice in pre-
warmed 1x PBS (without cations), by filling the microcentrifuge tube containing cells 
with 50 mL of 1x PBS, then centrifuging at 300g for 5 min and discarding the 
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supernatant.  Cell viability staining was performed using trypan blue to check that a 
purity of at least 98% neutrophils was obtained.  Cells were re-suspended at 5x106 
cells/mL in Iscove’s modified dulbecco’s medium (IMDM) with 50 U/mL penicillin 
and 50 U/mL penicillin/streptomycin (10%) Pen/Strep) plus 10% autologous serum.  
The isolated neutrophils were cultured in flat-bottomed 96 well plates at 5x107 
cells/mL in IMDM with 10% autologous serum and 10% Pen/Strep in a humidified, 
5% CO2 incubator at 37ºC.   75 μl of 5x10
6 cells/mL cell suspension to each well of a 
flat-bottomed 96 well plate.  To treat with drug or control, 15μl of R-roscovitine, (at 
10x concentration) or DMSO control and 60μl of IMDM/10% serum were added to 
the 75 μl of cells.  The plate was covered and incubated at 37oC in an incubator at 5% 
CO2 for 6 h. 
Cytospins were prepared from the cells and stained to study their morphology. 
100 μL of cell suspension was added into a cytospin chamber, and the chamber 
cytocentrifuged for 3 min at 30 g.  The slide was removed and air-dried for 5 min.  The 
slide was fixed in methanol for 2 min then drained and stained with an acid dye (Diff-
Quik solution #1) for 2 min).  It was then stained immediately with a basic dye (Diff-
Quik solution #2).  The slide was drained, rinsed with dH20, and then dried and a drop 
of DPX mountant media was applied to the cells and a coverslip placed on top.  Slides 
were viewed using a light microscope at 40x or 100x objectives. 
The cells were resuspended in the 96 well plates, then 50 µL of cell suspension 
was transferred from each well into a flow cytometry tube with 250 µL Annexin V 
buffer.  The tubes were incubated on ice for 5-10 min.  Immediately prior to analysing 
the samples using a flow cytometer, 1µL of PI (1 mg/mL solution) was added to each 
sample.  Samples were analysed on a flow cytometer using FL-1/FL-2 channel 
analysis. Viable cells are dual AnnV/PI negative; apoptotic cells are AnnV positive, 







2.9. Graphing, data analysis and statistical analysis 
Graphs were created using Graphpad Prism 5, and the statistical analysis was also 
carried out using this software.  The tests carried out were one-way or two-way Anova 
followed by post-hoc Newman-Keuls, or unpaired T-tests, as appropriate and indicated 
in the Results.  Significance was determined as a p value of less than 0.5 (p≤0.5).  
FlowJoTM software was used to analyse flow cytometry data. 
For image analysis, ImageJ Fiji (NIH Bethesda) was primarily used for analysing 
stereofluorescent and confocal images. Furthermore, Leica LAS Lite software was 
also used to analyse confocal images.  
Tests were conducted to assess the effect of intra-observer and inter-observer 
variability.  Some tailfin wound images were selected at random, and the neutrophils 
were counted using the method shown in Figure 2.2 (Chapter 2: Methods) and Figures 
3.1 and 3.2 (Chapter 3: Establishing the Zebrafish Tailfin Transection Injury Model).  
Then, the same images were counted a day later (Intra-Observer test 2) and by a third 
party (Inter-Observer test, Fig, 2.8).  This revealed no statistical difference (p ≥ 0.05) 
in the cell numbers counted in each group, indicating that counting cells by eye was a 








































































Figure 2.8.  Intra-observer and inter-observer testing on tailfin 
neutrophils after wounding 
Zebrafish neutrophils at the injury site post-wounding were counted in a 
selection of random images, then re-counted a day later (Intra-Observer test 2) 
then by a third party (Inter-Observer test).  The differences between each group 










The early stages of this project involved establishing a suitable inflammatory model in 
the zebrafish with which to investigate the innate inflammatory response, and 
specifically to manipulate neutrophil apoptosis and macrophage efferocytosis.  Often 
injury of the tailfin is used as an excellent model, as it is thin and transparent and 
therefore amenable to visualisation and image analysis.  This is regarded as a sterile 
inflammation model, but it is possible to elicit a non-sterile inflammatory response by 
including infectious agents in the water or by microinjection.  Previously other sources 
of stimulation have been used; for example, lipopolysaccharide (LPS) (168) and live 
Pseudomonas aeruginosa (141) have also been used alongside tailfin transection to 
increase inflammation. 
The tailfin transection model was pioneered by Renshaw et al in 2006 (126).  
The group created a transgenic fish with fluorescently-labelled neutrophils 
(Tg[mpx:EGFP]i114).  These animals have transgenic expression of green fluorescent 
protein (EGFP) driven by expression of the myeloperoxidase promoter.  In these 
animals, they transected the end of the embryonic tailfin and body, including part of 
the vasculature system (126).  This induces an inflammatory response with rapid 
neutrophil recruitment to the site of wounding.  The profile of this injury includes a 
‘peak’ of neutrophils (roughly 20 cells) at 4-8 hours (h), which subsequently resolves 
by 24 h (126).  An alternative model developed by Brown et al involved using a needle 
to ‘nick’ the tailfin, which induces a more subtle response with around 8 neutrophils 
recruited at 2 h after transection, measured by MPO staining (141).  Variations on this 
theme were tested in the initial stages of this project, to ascertain the most suitable 
model for the manipulations that would subsequently be carried out.  Consideration 
was also given as to which defined area to use for measuring the inflammatory 
response (i.e. should the area in which cell numbers were counted encompass the 
whole tailfin area or just the exact site of the wound?).   
After the initial zebrafish neutrophil inflammation studies in the transgenic 
embryos made by Renshaw et al (126), fish were developed in which macrophages are 
specifically labelled.  This was relatively difficult compared to development of the 
neutrophil-specific lines, due to the lack of a characterised macrophage-specific 
marker (176).   The first line to be made was the Tg(fms:mCherry) line.  This line was 
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initially used in this project, as it was already available in the zebrafish facility.  In 
Tg(fms:mCherry) fish, macrophages are labelled by the M-CSF receptor promoter; but 
some other cells are also labelled, including xanthophores (yellow pigment cells) 
(127).  This is not necessarily a problem, as distinction can be made based on the fact 
that macrophages are migratory whereas xanthophores are not.  Later in this project, 
access to the Tg(MPEG1:mCherry) line became available (128).  Macrophage-
expressed gene 1 (MPEG1), is a macrophage-specific promoter, involved in perforin 
expression (177). 
The phenotypic and functional characteristics of these labelled neutrophils and 
macrophages has been carried out in a variety of ways, such as whole-mount in-situ 
hybridisation and quantitative PCR to check what genes these cells express (176, 178).  
Another approach has been flow cytometric sorting of zebrafish neutrophils from 
whole embryos, to allow comparison of ex vivo zebrafish neutrophils to ex vivo 
mammalian neutrophils.  Isolation of zebrafish neutrophils has been successfully 
performed (178) in order to carry out phenotyping assays; such as characterisation of 
cells with strong EGFP expression (EGFPhi) and those with weak EGFP expression 
(EGFPlo) populations which exist in the Tg(mpx:EGFP)i114 line.  The EGFPlo but not 
the EGFPhi population express colony stimulating factor 1 receptor (CSF1R), 
indicating that macrophages may express a small amount of myeloperoxidase (which 
is considered a neutrophil marker); or that these EGFPlo cells are a multipotent 
precursor cell.  Isolating a population of cells in this way allows functional and 
phenotypic assays to be performed, although this is somewhat limited in zebrafish by 
the cell numbers that can be obtained, particularly from embryos, although this can be 
circumvented by obtaining large embryo numbers.  More cells can be obtained by 
digesting the site of haematopoietic development (the kidney).  Several assays exist 
that can be used to investigate granulocyte phenotype and function.  These include 
antibody staining for specific markers (i.e. Ly6G) or the measurement of shape change 
(cell polarisation) by stimulation with formyl-methionyl-leucyl-phenylalanine (fMLF) 
(175).  fMLF is a potent neutrophil chemoattractant which induces neutrophils to 
migrate by binding to the G-protein seven transmembrane formyl peptide receptor 1 
(FPR1) (179).  FPR1 ligands (N-formylated peptides and annexin A1 among others) 
are secreted by pathogens or released passively by dying host cells.  Bacteria actively 
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release N-formylated peptides; and in cells dying via necrosis, where intracellular 
DNA is released, maternal mitrochondrial peptides are also released (which are rich in 
formylated DNA).  It seems logical that they are pro-inflammatory, as mitochondria 
are thought to have arisen from proteobacteria becoming incorporated into eukaryotic 
cells.  In this project, tests were conducted to develop the previously described 
zebrafish model (126) as a suitable model to test the study objectives of this project.  
fMLF was selected for testing the effect of stimulation on isolated zebrafish 
neutrophils.   
 Taken together, the initial studies allowed the rest of the project to proceed 
with confidence that there was a justification for using zebrafish as an animal model 
of neutrophilic inflammation.  An inflammatory model was selected, and the 
neutrophil and macrophage response was characterised; paving the way for future 
manipulations and comparisons to be made to normal, baseline responses. 
 
3.2. Research Questions 
 What is a suitable and reliable zebrafish injury model for modelling neutrophil-
driven inflammation? 
 How should the area of inflammation be quantified? 
 What is the normal profile of neutrophil and macrophage response to 
wounding? 
 Can this be enhanced by other stimuli (i.e. non-sterile inflammation)? 







3.3.1. Testing three different injury models 
To set up this model, three alternative injuries were trialled (section 3.1.4, Fig. 3.1, 
2.1).  Firstly; the entire tailfin of Tg(mpx:EGFP)i114 was removed without damaging 
the vasculature using a scalpel, resulting in cell recruitment to the wound site (Fig. 3.1, 
A).  In the second model, the tailfin was removed along with a portion of the 
vasculature using a scalpel (Fig. 3.1, B), resulting in a larger recruitment of neutrophils 
and a ‘plug’ of cells where the vasculature was damaged.  In the third model, the tailfin 
was ‘nicked’ using a needle, resulting in a lower recruitment of neutrophils (Fig. 3.1, 
C).  The recruitment of neutrophils in each injury was quantified (Fig. 3.1, D) 
The tailfin transection model without vasculature damage was selected to carry 
through the project, as it produced a more reproducible injury with smaller error bars 
after quantification compared to the vasculature injury model (Fig. 3.1, A, D).  The 
approved wound technique used in these studies will be called “tailfin transection”, as 




















Figure 3.1. Comparison of the position of different zebrafish tailfin 
transections  
Images depicting the position of full transection without damaging the vasculature 
(A), full transection including vascular injury (B), and a small ‘nick’ to the edge of 
the tailfin (C) in brightfield [i] or in Tg(mpx:EGFP)
i114
 fish with green neutrophils 
at 4 h post transection (taken using a fluorescent stereoscope with a GFP filter (Ex. 
488) [ii].  Yellow line indicates area of transection with scalpel or nick with 19G 




3.3.2. The area of tailfin measured to assess inflammation 
Next, analysis was carried out to determine how the inflammatory wound cells should 
be counted (Fig. 3.2).  This was done using defined areas created using ImageJ 
software, which was considered important so that counting was consistent throughout 
the project.  The following areas (depicted in Fig. 3.2, A) were counted: b – length 
0.16 mm from the tip of the body (i.e. cells directly at the wound), and c – length 0.5 
mm from the tip of the body (i.e. cells at the wound plus cells migrating to the wound).  
This area was kept consistent by saving a 0.16 mm or 0.5 mm length box on ImageJ, 
and applying the box to all the images (taken at 8x magnification), by placing the right-
hand line of the box at the edge of the pigmented area at the end of the fish body (this 
is marked with a red line (Fig. 3.2, A[i]). 
Both areas (b and c) were quantified (Fig 3.2, B).  From this, it was concluded 
that c (0.5 mm, incorporating both a and b) was the best area to count, as it shows a 
pronounced inflammatory response, which would likely be more amenable to 
manipulation.  In addition, the area depicted by a is clearly a site of dynamic 
inflammation, as direct comparison of these images shows; so therefore a should be 
included (A).  At 0 h, there are 5 cells (i.e. resident neutrophils) in the area designated 
a; however by 4 h there were 8 cells in the same area.  This indicated it might be 
important to include this area, to incorporate cells that are migrating to the wound but 
have not quite reached the wound site yet.  The motility of cells in this area is also 
observed when performing live imaging of neutrophil migration to the wound (Video 
1).  Further quantification of tailfin wounding inflammation was therefore quantified 





















3.3.3. Quantifying the neutrophil response to tailfin transection 
Next, the inflammatory response was characterised by wounding, then imaging at 
different time points after transection (examples in Fig. 3.3, A) and quantifying as 
shown (Fig. 3.3, B).  This quantification (Fig. 3.3, C) revealed that neutrophil numbers 
rise sharply after the initial transection, peaking at around 4 h after the initial 
transection (13 ± 2).  The inflammation continues over the next 24 h and even appears 
to increase further at around 44 h post-transection (17 ± 2 neutrophils) before starting 
to decline at 48 h, which was the age limit of imaging the fish according to Home 
Office guidelines.  The inflammatory response for 15 h after transection is also shown 













Figure 3.2.  Comparison of area used to measure zebrafish tailfin transection 
model 
Images of transected Tg(mpx:EGFP)
i114
 fish were taken immediately after 
transection at 0 h (A [i]) and again at 4 h (A[ii]).  The red line indicates the 
transection.  The cells in the area with length 0.16mm (from red line to orange line, 
b) and 0.5mm (from red line to yellow line, c) were counted and compared to 
measure the inflammatory response (B). 15 fish were quantified in this example 
from  independe  experim nts.  Data expressed as mean ± S.E.M. *p ≤ 0.05, 











Figure 3.3. Neutrophil migration to wound sites of Tg(mpx:EGFP)
i114
  
zebrafish after tailfin transection 
Tg(mpx:EGFP)
i114
 fish with labelled neutrophils are wounded at the 0 h time point 
and then imaged serially over different time points (A) [i]-[vi], and quantified by 
counting the area shown [as determined in Fig. 3.2.] (B, C).  (B) adapted from Lucas 
et al, FASEB J, 2013, to show the area used for quantifying inflammatory cells.  
Embryo 3 dpf, 4 hpi. ≥40 fish in 3 individual experiments. Data expressed as mean 
± S.E.M.  *p ≤ 0.05, 0 h v all other time points; assessed by one-way ANOVA 






3.3.4. Selecting a macrophage-specific line for use in tailfin transection 
model 
The same tailfin transection assay was carried out using the macrophage-labelled lines, 
Tg(fms:mCherry) and Tg(MPEG1:mCherry) (Fig 3.4, Section 1.3.1.2).  Due to non-
specific expression of the fms promoter, it can be difficult to count cells in these fish; 
there can be significant numbers of non-macrophage cells, for example in the 4 h time 
point image, in which macrophages (orange arrows) and resident non-macrophages 
(green arrows) are labelled (Fig 3.4, A[ii]).  
Quantification revealed there may be over-estimation when counting the 
Tg(fms:mCherry) line, as numbers of macrophages counted at 24 h were higher in 
these animals compared to Tg(MPEG1:mCherry) – there were 26 ± 2 cells in the 
fms:mCherry group rather than 19 ± 4 (Fig. 3.4, D).  
Macrophage numbers in the Tg(MPEG1:mCherry) peaked at 24 h post-
transection then decreased over the next 48 h (Fig. 3.5).  In general, the number of 
macrophages was always higher than neutrophil numbers.  For example, at 12 h post-
transection in this group of animals, there were a mean of 12 ± 2 neutrophils at the 


















Figure 3.4.  Macrophage migration to wound sites in Tg(fms:mCherry) and 
Tg(MPEG1:mCherry) zebrafish after tailfin transection 
Fish were wounded at the 0 h time point and then imaged serially over different 
time points in Tg(fms:mCherry) (A) [i]-[iii] or Tg(MPEG1:mCherry) fish (B) [i]-
[iii]. Green arrows in (A[ii]) indicate non-specific fms expressing-cells which don’t 
migrate; orange arrows indicate macrophage cells which have migrated to the 
wound area.  The inflammation was quantified by counting the area shown 
(everything to the right of the yellow line) (C).  The macrophage numbers in 
Tg(fms:mCherry) and Tg(MPEG1:mCherry) fish after injury were directly 
compared (D).  *Indicates a p value of ≤ 0.05. ≥26 fish, from 3 independent 










 Figure 3.5. Comparison of neutrophil and macrophage recruitment following 
tailfin transection 
An overlay graph comparing the numbers of neutrophils and macrophages recruited 
to the site of tailfin transection over different time points in the first 24 h post 
transection.  Experiments were carried out in Tg(mpx:EGFP)
i114
 and 
Tg(MPEG1:mCherry) zebrafish for measurement of neutrophils and macrophages, 
respectively.  ≥ 40 fish per group, from 3 independent experiments. Data expressed 






3.3.5. Addition of lipopolysaccharide (LPS) after zebrafish tailfin 
transection 
After establishing these inflammation profiles, the transection experiment was 
performed, but with the addition of lipopolysaccharide immediately after transection. 
Various concentrations of LPS were tested but did not show any effect on the 
neutrophil numbers after wounding in the Tg(mpx:EGFP)i114 fish (Fig. 3.6).  For 
example, at 24 h post-transection, there was a mean of 11 ± 2 neutrophils in the control 
group compared to 10 ± 1 in the LPS-treated group.  Further wounding experiments 






















Figure 3.6.  Tailfin transection and Lipopolysaccharide (LPS) Treatment 
The tailfin of Tg(mpx:EGFP)
i114
 zebrafish was transected and LPS added to the 
water at 4 h post-transection, at a variety of concentrations (shown here is the 
highest, 50 µg/mL), and imaged at different time points post-transection (A) and 
quantified (B).  ≥8 fish per group, from 2 independent experiments.  Data expressed 








3.3.6. Sorting of EGFP+ embryonic neutrophils and stimulation with 
fMLF 
The similarities between mammalian and zebrafish neutrophils were explored by ex 
vivo stimulation.  This was done by flow sorting cells from whole embryos (500 
embryos were used here to obtain populations of roughly 3000 neutrophils).  It is easy 
to distinguish a EGFP+ population in a population of total embryonic cells (Fig. 3.7, 
A[ii]) compared to wild-type animals (A[i]).  Imaging of these cells revealed that they 
migrate with a neutrophil-like morphology (Fig. 3.7, B, Video 3). 
Sorted cells were stimulated ex vivo with fMLF.  This stimulation caused an 
increased in forward scatter in the sorted EGFP+ cells (Fig. 3.8, A, B[ii]) compared to 
untreated cells (Fig. 3.8, A, B[i]).  Isolation of EGFP+ neutrophils was also carried out 
by digesting 5 whole kidneys (the kidney is the site of haematopoietic development in 
zebrafish), and then flow sorting cells based on EGFP expression.  Higher yields were 





















Figure 3.7. Fluorescence-activated cell sorting (FACS) of embryonic EGFP
+
 
neutrophils ex vivo 
Flow sorting was carried out on embryos from wild type (A[i]) and 
Tg(mpx:EGFP)
i114
 (A[ii]) fish, with the “P4” gate demonstrating a EGFP
+
 
population in [ii]. Brightfield (B [i]) and EGFP
+
 cells (B [ii]) were imaged on a 
cover glass slide, with white arrows indicating a healthy cell and grey a potential 
apoptotic cell.  Approximately 500 embryos were used to obtain around 3000 cells 














Figure 3.8.  Stimulation of isolated zebrafish neutrophils ex vivo with fMLF 
Sorted EGFP
+
 cells from 500 embryos were stimulated ex vivo with fMLF, or were 
untreated; and forward scatter was assessed in both groups, shown as a histogram 






Observations from Chapter 3 
 Tailfin transection of the tailfin without damage to the body and vasculature is 
an ideal model for imaging neutrophil and macrophage accumulation (Fig. 
3.1). 
 The inflammatory response seen after tailfin transection is reproducible and 
allows a significant inflammatory response with manageable numbers. 
 The best area of inflammatory response to measure was determined to be the 
area with length of 0.5 mm from the end of the body (Fig. 3.2). 
 Neutrophil recruitment in the zebrafish peaks at around 4 h after tailfin 
transection, and macrophage recruitment peaks at around 24 h after transection.  
There is a second peak of neutrophil recruitment at 44 h post-transection. 
 Inflammatory cell numbers in this tailfin injury model do not fully return to 
baseline level within 48 h post-transection. 
 The area for counting these inflammatory cells should take into consideration 
migrating cells (both to and from the site of the wound), as well as cells directly 
at the wound. 
 Addition of this variant of LPS did not affect neutrophilic responses after 
wounding in this model, when added at 4 hours post injury (hpi). 
 The Tg(MPEG1:mCherry) zebrafish is a better model for macrophages 
compared to Tg(fms:mCherry), in which non-macrophage cells can also be 
labelled (Fig. 3.4). 
 EGFP+ neutrophils from zebrafish can be isolated and used for in vitro 
experimentation, for example imaging and stimulation. 
 The flow-sorted zebrafish neutrophils respond to fMLF, by increasing their 
size.  This response occurs in a similar manner in mammalian neutrophils. 
 
Following these initial studies, a “tailfin transection” model, which removed only the 
tailfin portion of the median fin, without damaging the vasculature (Fig. 3.1, A[i]), was 
chosen for further experiments.  This injury produced a reproducible wound with 
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consistent inflammation levels (Fig. 3.3).  The most severe transection (Fig. 3.1, B), 
pioneered by Renshaw et al (126), was deemed difficult to count, due to the fact that 
large ‘clumps’ of cells accumulate at the area of vasculature wounding, to heal this 
area and ‘plug’ the damage to the blood vessel. 
The milder ‘needle nick’ model (Fig. 3.1, C) was deemed to be not severe and 
acute enough; i.e. the effect of the genetic and pharmacological manipulations might 
not be seen if not enough cells are recruited.  The numbers of neutrophils recruited in 
the ‘nick’ model have previously been shown to be quite low and also quite variable 
(between 0 to 8 cells) (141).  Furthermore, in prior work by Brown et al in which they 
‘nick’ the tailfin with a needle, it was concluded that Pseudomonas aeruginosa 
incubation was necessary in addition to wounding, in order to cause a greater number 
of leukocytes to migrate to the wound (141).  This “nick” model is subtle although the 
authors report a clear statistical difference by both genetic and pharmacological 
manipulation of the inflammatory response, and it allowed the successful conclusion 
to a specific scientific question to be reached in a non-GM zebrafish line (141). 
In conclusion, the tailfin transection model chosen results in an inflammatory 
response which is severe enough to manipulate, but also allows ease of quantification 
without the huge inflammatory response seen when the vasculature is damaged.  The 
presence of so many cells can make it difficult to identify individual cells when 
tracking and counting.  A similar model to the tailfin transection used in this study has 
been recently published, showing it to be a robust assay for drug screening of inhibitors 
of neutrophil recruitment (180).  
In the tailfin transection model chosen, around 15 neutrophils are recruited at 
4 h post-transection (Fig. 3.3, C).  There are about 20 neutrophils recruited at the peak 
of inflammation in the tailfin/vasculature transection model (126); not dissimilar to the 
numbers recorded in the model chosen for this study (which does not damage the 
vasculature).  In this study the authors counted only cells which were directly in the 
vicinity of the wound.  Hence, the fact that the numbers of cells counted in this study 
are not hugely different from the Renshaw et al study can likely be attributed to the 
fact that the area chosen for counting in this study takes into account cells not directly 
associated with the wound.  It was deemed important to include cells not immediately 
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next to the wound (i.e. area ‘a’ in Fig. 3.2), as the area next to the wound is a site of 
dynamic migration of neutrophils, and therefore these cells can be described as 
‘inflammatory’. (Fig. 3.2, Video 2).  This is clear from the fluctuations in cell numbers 
in area ‘a’ over time. 
The recruitment of macrophages over time is more gradual, peaking at 24 h 
post transection (Fig. 3.3, C).  This is in keeping with the standard dogma that 
neutrophils migrate faster than macrophages.  In this study, macrophage numbers post-
transection are consistently higher than neutrophil numbers.  This is in contrast to 
previous studies, where macrophage numbers are lower and increase over time to 
become greater in number at the wound than neutrophils (127).  Again, this is likely 
due to the differences in the area selected for counting, and also perhaps reflects the 
increased presence of macrophages during homeostasis; whereas neutrophils are 
primarily recruited during inflammation.   In this study, the macrophages were counted 
using the same area that was chosen for counting neutrophils (Fig. 3.2).  As the acute 
neutrophil response was deemed to be the focus of the study, the macrophage response 
was assessed in direct relation to this area. 
One notable difference in the injury model of this study, compared to previous 
injury models, is that resolution does not fully occur by 48 h post-transection, which 
was the limit to which imaging was carried out.  There are still residual inflammatory 
cells present at 48 h post-transection.  This might be due to the fact that in the more 
severe model used by Renshaw et al., the injury is so acute that neutrophil migration 
and subsequent resolution occur much more quickly, as it is important for the overall 
survival of the embryo to heal the damaged vasculature speedily (126).   
Interestingly, a ‘second wave’ of neutrophil infiltration seems to occur at 32-
48 h post-transection.  This is an observation that has been previously noted in 
mammals (181).  This might reflect an infiltration of ‘M1’ macrophages at 24 h, 
releasing pro-inflammatory mediators such as IL-8 or TNF (182).  Future studies 
would undertake an analysis of such cytokines and chemokines. Conversely, the 
increase in macrophages towards the 44-48 h time point could be attributed to a later 
infiltration of ‘M2’ macrophages, whose presence helps to dampen down 
inflammation and promote healing (52).  Testing this hypothesis in the future could be 
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an interesting study; for example by examining the expression of markers of M1 and 
M2 macrophages by immunostaining. 
The Tg(fms:mCherry) line was used for initial macrophage experiments but 
then results were then confirmed using the Tg(MPEG1:mCherry) line, due to the better 
specificity of the latter.  Tg(fms:mCherry) zebrafish have labelled mCherry 
macrophages via expression of the macrophage colony stimulating factor (M-CSF) 
receptor promoter, whereas in Tg(MPEG1:mCherry) fish, macrophages are labelled 
via expression of the macrophage expressed gene 1 (MPEG1, perforin) (127, 128).  It 
is possible to differentiate which cells are macrophages in the Tg(fms:mCherry) line, 
by comparing which cells have migrated after transection and which were resident 
xanthophores already present.  However, the concern remained that non-specificity 
could obscure accurate counting; for example if a macrophage was present within the 
same plane of focus as the xanthophore cells.  It is also quicker to carrying out counting 
when non-specific, non-migratory cells do not have to be excluded from the final count 
for each image, by returning to compare to the 0 h time point image each time. 
 These zebrafish lines have been well studied and used as a model of neutrophil 
and macrophage inflammatory responses.  However, at the beginning of the project, 
some experiments were performed to define important characteristics of the zebrafish 
leukocytes to justify their use as a model for mammalian leukocytes.  Work on 
mammalian neutrophils is typically done in vitro with cells directly isolated from 
blood, or ex vivo with cells from animals treated with inflammatory stimuli. 
In this project, cells were isolated from whole zebrafish embryo, and imaging 
and phenotyping assays were carried out.  This revealed that zebrafish neutrophils 
exhibit some characteristics of mammalian neutrophils; for example the neutrophils 
respond to stimulation with fMLF by increasing their forward scatter.  Sorted 
neutrophils also migrate with a similar morphology to sorted human neutrophils.  The 
use of flow sorting itself to isolate populations of human neutrophils has been shown 
not to cause neutrophil activation (175).  These data (showing zebrafish neutrophils 
respond to fMLF) indicate that the neutrophils from zebrafish are similar to 
mammalian neutrophils, alongside other published evidence showing that the 
neutrophils have multi-lobed nuclei and can perform phagocytosis (125).  In the future, 
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a similar assay will be performed for sorted macrophages.  One example of a potential 
assay is measurement of the induction of ROS which can be stimulated by reagents 
such as phorbol myristate acetate (PMA) (183).   
Some ex vivo assays were difficult to perform, such as antibody staining of 
sorted cells.  This was due to limitations in the total cell numbers that can be isolated, 
and the washing steps involved in staining protocols results in continual loss of cells.  
Zebrafish neutrophils can be harvested in larger numbers from adult zebrafish kidneys 
(kidneys are the site of haematopoietic development in zebrafish) (119).  However, 
this poses the problem that the adult neutrophils are presumably fully developed cells, 
which may differ from the embryonic neutrophils on which all the future imaging 
experiments were to be performed. 
Previously, use of LPS has been shown to increase inflammation levels post-
wounding (168).  However, in this system it did not have any effect.  There could be 
several reasons for this; firstly many types of LPS exist which differ slightly depending 
on the exact isolation procedure (184).  These elicit different responses upon addition 
of cell cultures or animal models.  Hence it is difficult to compare this experiment 
directly to other studies, without knowing exactly which type of LPS was used.  To 
further these experiments, varying doses of several types of LPS should be tested.  
Perhaps the more severe vasculature transection model allows for increased access of 
LPS to the wound site, helping to aggravate the response (168).  It may also be that it 
is necessary to pre-treat with LPS before transection to see an effect. 
One challenge with this model, common to many in vivo models, is the issue 
of reproducibility.  With practise it is possible to injure the animal in roughly the same 
place each time, but there will be some variability in the exact position of the injury.  
This can be improved using a laser to position the line of injury more exactly; however 
variability always occurs naturally in vivo.  However, the use of sufficient n numbers 
will reduce variability.  Laser injury and scalpel injury of the tailfin has been shown to 
result in similar numbers of neutrophils being recruited when the tailfin was transected; 
however there are more macrophages at 48 h post-transection in the scalpel-transected 
animals compared to laser-transected (Nicolette Mineo, unpublished data).  Laser 
injury, possibly with a cauterised wound, works on the basis of a line of laser ‘dots’ 
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being made down the tailfin, resulting in sloughing of the excess tissue.  Perhaps this 
type of injury requires more ‘M2’ macrophages for healing compared to the scalpel 
transection injury, as it consists of lots of small wounds. 
 These initial studies provided the framework for future experiments in which 
tailfin transection was used to cause an inflammatory response, which could be 










The zebrafish embryo is a good model for drug and chemical screening, due to the 
numbers of embryos produced from a single cross, allowing large-scale screenings.  
This facilitates experiments with large sample sizes consisting of individual zebrafish 
(n values); and due to the transparency of the embryo, the effect of chemicals on 
different organs can easily be assessed (185).  Furthermore, vast automated screening 
is also a possibility in some of these systems by automated measurements of 
parameters such as fluorescence intensity (122, 186).  Drugs identified in zebrafish 
screens are now advancing to therapy in human disease, for example, the small lipid 
mediator dmPGE2, which was identified in a zebrafish screen, is now in clinical trials 
for patients who are undergoing hematopoietic stem cell transplantation (187).  
 In this study, CDK inhibitor (CDKi) compounds were tested in the zebrafish 
tailfin injury model (established in Chapter 3) to examine the role of CDKs in the 
resolution of innate inflammation.  For this, the CDKi compound AT7519 was selected 
as it is a small molecule inhibitor with good CDK9 specificity; the half maximal 
inhibitory concentration (IC50, i.e. the amount needed to inhibit a biological process 
by half) of AT7519 for CDK9 is ≤10 nm.  AT7519 is in Phase I and II clinical trials 
as a potential cancer treatment for chronic lymphocytic leukaemia (CLL) and mantle 
cell lymphoma (77, 81, 188), and appears to be well tolerated by humans. 
Previous work from our laboratory group has shown the CDKi R-roscovitine 
(which inhibits multiple CDKs, including CDK9, CDK2 and CDK5), causes 
neutrophil apoptosis in vitro and drives resolution of inflammation in vivo in mouse 
models (e.g. bleomycin-induced lung inflammation) (68).  R-roscovitine has 
subsequently been used in zebrafish and was shown to cause a reduction in 
neutrophilic inflammation at sites of zebrafish tailfin injury (168).  AT7519 is more 
CDK9-specific and has also been shown to be more potent than R-roscovitine in terms 
of driving neutrophil apoptosis.  AT7519 also drives resolution in mouse models of 
inflammation, for example in the ovalbumin-induced pleurisy allergy model, and 
endotoxin- or E. coli-induced lung inflammation (38, 82).  For these reasons, it was 
selected as the main compound of choice for experiments in this study.   
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 Other compounds have gained interest which also work in a similar manner to 
traditional CDKi drugs, by out-competing ATP in the ATP-binding pocket of CDK9.  
Some examples are found in the flavone group of chemicals, which are a class of 
flavonoids which possess a 2-phenylchromen-4-one backbone (189).  The flavone 
wogonin is a compound isolated from Scutellaria baicalensis, and is an active 
ingredient in the Chinese herbal medicine sho-saiko-to (190).  Wogonin has been 
shown to drive apoptosis of cancer cells by inhibition of CDK9 and down-regulation 
of Mcl-1 (191).  These compounds also increase sensitivity of cells to other anti-cancer 
drugs which inhibit other Bcl-2 family members such as Bcl-2 and Bcl-xL (192).  
Work from our group showed that wogonin can also cause neutrophil apoptosis in vitro 
and resolve mouse models of neutrophilic inflammation (e.g. LPS-induced lung 
inflammation), and eosinophilic allergic airway inflammation. (38, 73).  It was also 
shown that wogonin drives neutrophil apoptosis in zebrafish tailfin injury (72).   A 
related compound, flavopiridol (FVP), has also been shown to accelerate neutrophil 
apoptosis and drives a reduction in Mcl-1 protein levels (37).   
 Some of these pharmacological compounds were tested to see if they could 
drive resolution of inflammation after zebrafish tailfin transection. The treatment was 
administered at 4 h because this is when the initial inflammatory response after 
transection peaks (Chapter 3, Fig. 3.3).  This is to mimic a clinical setting – patients 
with inflammatory disease are likely to present once inflammation has been 
established.   This would show whether the model is useful and relevant for 
investigating CDKs and their role during inflammation, and if targeting CDKs will 
have an effect in this system.  As the zebrafish can be readily used for continuous in 
vivo imaging of inflammation, it allows for new insight into the mechanism by how 
the CDKi drugs may drive resolution.  Furthermore, this could prove to be a valuable 




4.2. Research Questions 
 
 Do CDKi compounds affect the total number of neutrophils in the zebrafish 
embryo (i.e. haematopoiesis) and neutrophil numbers at the tailfin in a 
zebrafish tailfin wounding inflammation model? 
 Do CDKi compounds affect neutrophil apoptosis during inflammation? 
 Do CDKi compounds affect macrophages during inflammation? 
 Do existing compounds with structures similar to CDKi (e.g. flavones) also 






4.3.1. Incubation of Tg(mpx:EGFP)i114 zebrafish embryos with AT7519 
post-tailfin transection 
Tg(mpx:EGFP)i114 zebrafish embryos, which had undergone tailfin transection 4 h 
earlier, were incubated with 20 µM AT7519.  Images were taken at various time points 
before and after treatment to allow assessment of the effect of AT7519 on the 
neutrophil inflammatory response.  There was no statistical difference (p ≥ 0.05) in the 
neutrophil numbers at the wound site after 24 h of treatment with AT7519 (20 ± 2 
cells) or the vehicle control DMSO (≤1%, 16 ± 2 cells, Fig 4.1, A, B).  For clarity, 
only one of the AT7519 concentrations tested is shown (20 µM).  
As solubility can be an issue with some compound treatments, the experiment 
was repeated with the addition of 2% DMSO to the compound to ensure the drug was 
dissolved as much as possible.  A dose-response test revealed 2% was the highest 
DMSO concentration the embryos could be bathed in, without compromising their 
health; higher concentrations resulted in unresponsiveness or death (data not shown).  
Again no statistical difference (p ≥ 0.05) in neutrophil numbers at the wound site was 
discernible at 24 h after treatment in the AT7519-treated group (12 ± 1 cells) compared 






















Figure 4.1.  Incubation of zebrafish embryos with the CDK inhibitor, AT7519 
Tg(mpx:EGFP)
i114
 3dpf zebrafish embryos were incubated with 20 µM AT7519 (A 
[i]) or ≤1% DMSO (A [ii])
#
, and representative images were taken at 24 h after 
transection and quantified (B). 24 h DMSO vs 24 h AT7519; p ≥ 0.05. 
Zebrafish were also incubated with 2% DMSO + 20 µM AT7519 (C [ii]) or DMSO 
alone (C [i]); representative images were taken at various time points after 
transection and treatment at 24 h and then quantified (D).  
n/s: p ≥ 0.05, analysed by ANOVA.  ≥16 fish per group in 3 independent 
experiments.  Data expressed as ± S.E.M. 
Preliminary AT7519 incubation study data (A, B) were obtained from Masters by 
Research (Biomedical Sciences) Thesis of Ms Laura Hoodless, 2012  
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4.3.2. Microinjection of AT7519 into Tg(mpx:EGFP)i114 zebrafish 
embryos post tailfin-transection 
AT7519 was administered by microinjection into the zebrafish yolk sac at 4 h post-
tailfin transection.   
At 24 h after transection, there was a significant (p ≤ 0.05) reduction in 
neutrophils at the wound site in the embryos injected with 0.5 ng of AT7519 compared 
to control, as demonstrated by the example images and when quantified over different 
time points (Fig.  4.2, A, B, C[i]).  Specifically, there was a mean of 12 ± 1 cells in the 
DMSO group, and 8 ± 1 cells in the AT7519 group after 24 h (Fig. 4.2, C[ii]).  This 
was apparent not only by examining neutrophil numbers at 24 h, but also by calculating 
the percentage change in neutrophil numbers from 4 to 24 h (Fig. 4.2, C[iii]), which 
reveals changes in individual animals.  The percentage reduction in neutrophil 
numbers in the DMSO group was a mean of 12% compared to 52% in the AT7519 
group.  The AT7519 data were also re-calculated by removing from the analysis fish 
deemed as “non-responders”.  This was deemed as fish with less than 13 neutrophils 
at the wound site at 4 hpi (Fig. 4.2, D).  This calculation resulted in an enhanced 
inflammatory response (16 ± 1 neutrophils at 4 h) and 14 ± 2 neutrophils in the DMSO 
group at 24 h compared to 7 ± 1 in the AT7519 group. 
The number of neutrophils in the entire animal at 24 h after drug treatment was 
counted by inspection of images of the tailfin of these fish (Fig 4.3, A) then counting 
total cells (Fig 4.3, B).  There was no statistically significant difference between the 
DMSO (116 ± 5 cells) and the AT7519-treated groups (130 ± 10 cells). 
The total embryonic neutrophils numbers were also examined by flow 
cytometry, by measurement of the percentage of EGFP+ cells in a pool of embryos.  
This revealed no significant difference (p ≥ 0.05) in total neutrophil numbers between 
DMSO and AT7519-treated (Fig 4.3, C).  In the DMSO group, a mean of 0.26% of the 












Figure 4.2.  Microinjection of zebrafish embryos with AT7519 
The yolk sac of Tg(mpx:EGFP)
i114
 3 dpf embryos is microinjected with AT7519 or 
DMSO 4 h after tailfin transection.  Example images from DMSO- (A) and 
AT7519-treated (B) fish are shown from 24 h after transection.  Cell numbers at the 
wound site are shown (C [i, ii]) and the percentage change per individual embryos 
from 4 h to 24 h is shown (C [iii]). ≥ 20 fish per group in 4 independent experiments. 
Data expressed as ± S.E.M. *p ≤ 0.05 analysed by ANOVA followed by post-test 
Newman Keuls.  
#









Figure 4.3.  Total neutrophils in Tg(mpx:EGFP)i114 zebrafish after 
microinjection with AT7519 or DMSO 
The total neutrophils in images of the whole embryo were counted 24 h after 
treatment with 0.5 ng of DMSO [i] or AT7519 [ii] (A), and then quantified (B). ≥10 
fish per group from 3 independent experiments.   Whole embryos treated with 
DMSO or AT7519 were digested and the percentage of EGFP+ total cells in the 
entire embryo digest was measured (C).  ≥20 fish per group from 3 independent 
experiments.  n/s: p ≥ 0.05, analyzed by unpaired t-test. Data expressed as ± S.E.M. 
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4.3.3. Pre-injection with AT7519 before tailfin transection of 
Tg(mpx:EGFP)i114 zebrafish embryos 
Next, the embryos were pre-injected with 0.5 ng AT7519 or DMSO 0.5 h before tailfin 
transection.  The fish were imaged immediately after transection and at 4 h post-
transection (Fig. 4.4, A).  The cells at the inflammation site were quantified, showing 
that AT7519 pre-treatment significantly (p ≤ 0.05) inhibited neutrophil influx to the 
wound site after transection, compared to control; with 14 ± 1 cells at the wound site 
in the DMSO-treated group at 4 h, compared to 10 ± 1 in the AT7519 group (Fig. 4.4, 

































 3dpf zebrafish embryos were injected with 0.5 ng DMSO [i] or 
AT7519 [ii], then the tailfin was transected 0.5 h later.  The embryos were imaged 
at 0 h and again at 4 h (A), and quantified (B).  *p ≤ 0.05, 4 h DMSO vs 4 h AT7519, 
analysed by ANOVA then post-test Newman-Keuls.  ≥40 fish per group from 3 
independent experiments.  Data expressed as ± S.E.M. 
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4.3.4. Effect of AT7519 microinjection on Tg(MPEG1:mCherry) 
zebrafish embryos 
The effect of AT7519 and DMSO on macrophage recruitment to sites of wounding 
was assessed by microinjection of 0.5 ng of AT7519 or DMSO into 
Tg(MPEG1:mCherry) embryos with fluorescent macrophages. 
The fish were injured using the tailfin transection model and treated with 
DMSO/AT7519 at 4 h post-wounding, following which the embryos were imaged at 
various time points.  The example images shown are from the 24 h post-injury time 
point (Fig. 4.5, A), and the macrophage numbers at 0, 4 and 24 h were quantified (Fig. 
4.5, B), showing no significant difference (p ≥ 0.05) in macrophage numbers at the 
wound between DMSO (16 ± 1 cells) and AT7519-treated groups (15 ± 1 cells).  The 
























Figure 4.5.  Tailfin transection of Tg(MPEG1:mCherry) zebrafish 
The tailfin of Tg(MPEG1:mCherry) were transected and then microinjected with 
0.5 ng DMSO (A [i]) or AT7519 (A[ii]) at different time points after transection.  
Shown here are the 24 h post-transection images.  The macrophages at the tailfin at 
different time points post-injury were quantified (B).  ≥ 22 fish per group from 3 




4.3.5. TUNEL staining of tailfin transection zebrafish embryos 
microinjected with 0.5 ng AT7519 or DMSO 
Apoptosis of neutrophils was measured by terminal deoxynucleotidyl transferase 
dUTP nick end labelling (TUNEL) performed in conjunction with tyramide signal 
amplification (TSA).  This labelled apoptotic cells red, and neutrophils green, and the 
transected region of the tailfin was then imaged.  An example is shown in Figure 4.6 
[A].  The staining must be carried out on fixed embryos; which means the same 
embryos cannot be tracked over time. 
The number of apoptotic neutrophils (cells which are both EGFP+ and 
TUNEL+ positive) at different time points post-transection after DMSO/AT7519 
treatment was quantified (Fig. 4.6, B[i]).  At 12 h post-transection (but no other time 
point), there was a significantly (p ≤ 0.05) increased number of apoptotic neutrophils 
in the AT7519 (a mean of 3 EGFP+ TUNEL+ cells) compared to the DMSO control (a 
mean of 1 EGFP+ TUNEL+ cell).  The 12 h time point post-transection (i.e. 8 h post-
AT7519 treatment) is highlighted separately as there is a significant (p ≤ 0.05) 
difference in apoptotic neutrophils in the tailfin at this time (Fig. 4.6, B[ii]).  Shown 
are example images from 12 h post transection in DMSO (Fig. 4.6, C[i]) and AT7519 
(Fig. 4.6, C[ii]) – treated fish. 
The percentage of total EGFP+ neutrophils which were also TUNEL+ was 
calculated (Fig. 4.6, D[i]).  At 12 h post-transection, there was a significantly (p ≤ 
0.05) higher percentage of apoptotic neutrophils in the AT7519-treated group (23%) 



























Figure 4.6.  TUNEL staining of zebrafish embryos microinjected with DMSO 
or AT7519 
TSA/TUNEL staining was performed on Tg(mpx:EGFP)
i114
 zebrafish, labelling 
neutrophils in green, and apoptotic cells in red.  In this tailfin transection example 
(A [i], a neutrophil is designated by a green arrow, apoptotic cells by a red arrow, 
and apoptotic neutrophils (double positive) by a green and red arrow (A [ii]).  The 
number of double positive cells over different time points was quantified (B [i]) and 
the 12 h post-transection time point was highlighted as one of interest (B [ii)].  An 
example image of the 12 h post-transection time point is shown in animals treated 
with DMSO (C [i]) and AT7519 (C [ii]) at 4 h post-transection.  The number of 
double positive cells as a percentage of the total EGFP
+
 neutrophil population was 
calculated (D [i]), and the 12 h time point is highlighted (D [ii]). ≥16 embryos per 
group in 3 independent experiments. *p≤0.05 12 h DMSO vs 12 h AT7519, 
unpaired t test. Data expressed as ± S.E.M. 
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4.3.6. Effect of AT7519 on uptake of neutrophils by macrophages 
Tg(mpx:EGFP)i114 fish were crossed with Tg(MPEG1:mCherry) fish to create 
embryos in which neutrophils and macrophages could be visualised together in the 
same animals.  The embryos were transected and imaged at various time points before 
and after microinjection with 0.5 ng DMSO or AT7519 at 4 h.  In the example is the 
24 h time point in DMSO or AT7519 –treated groups (Fig. 4.7, A). 
The number of co-localised cells at the injury site was counted (Fig. 4.7, B).  
This gave an impression of the level of phagocytosis of neutrophils by macrophages 
at the site of wounding.  There was a statistically significant increase (p ≤ 0.05) within 
each group (DMSO or AT7519) of uptake of neutrophils between 0 h and 24 h.  In the 
DMSO-treated group, there was a mean of 1 co-localised EGFP+ neutrophil within a 
macrophage.  At 24 h, this rose to 3 co-localised cells.  In the AT7519-treated group, 
there was a mean of 1 neutrophil inside a macrophage at 0 h and by 24 h there was 2.  
However, there was no statistical difference (p ≥ 0.05) between DMSO and AT7519 























Figure 4.7.  Colocalisation of EGFP
+





 x Tg(MPEG1:mCherry) zebrafish embryos treated with 
DMSO and AT7519 after tailfin transection. 
Example images shown from embryos 24 h post-tailfin transection, treated with 
DMSO (A[i]) or AT7519 (A[ii]). Green and red arrows indicate co-localisation of 
EGFP
+
 neutrophils and mCherry
+
 macrophages.  The numbers of co-localised cells 
at 0 h, 4 h, and 24 h were quantified and graphed (B).  ≥10 fish in each group in 3 
independent experiments. Data expressed as ± S.E.M.  p ≤ 0.05, DMSO/AT7519 0 
h vs 24 h, analysed by ANOVA followed by post-hoc Newman-Keuls test. 
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4.3.7. Effect of bath treatment with flavopiridol on neutrophilic 
inflammation after tailfin wounding 
Another CDKi compound, FVP, was tested which is known to have potent activity 
against CDK9.  Similar to before, the Tg(mpx:EGFP)i114 embryos were incubated with 
1 µM of FVP or DMSO (<1%) at 4 h post-transection.  The concentration shown was 
obtained by carrying out dose-response experiments (data not shown). The embryos 
were then imaged at various time points after the tailfin transection; example images 
at 24 h are shown here (Fig. 4.8, A). 
Neutrophilic inflammation was significantly (p ≤ 0.05) reduced after 24 h (but 
no other time points) in FVP-treated embryos (9 ± 1 neutrophils at 24 h), compared to 
DMSO vehicle control (13 ± 1 neutrophils at 24 h, Fig. 4.8, B[i]).  The individual 
numbers at the 24 h time point are shown in Figure 4.8, B[ii].  The embryos were also 
injected with FVP or DMSO at 4 h post-transection, but this did not have a significant 
effect (p ≥ 0.05) on neutrophil numbers at the injury site; the DMSO group had a mean 
























Figure 4.8.  Treatment of zebrafish embryos with flavopiridol (FVP) or DMSO 
following tailfin transection. 
3 dpf Tg(mpx:EGFP)
i114
 embryos were incubated with FVP (1 μM) or DMSO 
(<1%), at 4 h post-transection.  Example images at 24 h post transection and 
treatment are shown for DMSO (A[i]) and FVP-treated (A[ii]) animals, and these 
data are quantified in (B [i]). The 24 h time point is also shown with each circle 
corresponding to cell numbers in an individual animal (B [ii]) ≥31 fish per group.  
2.19 ng of FVP or DMSO in a 0.5 nL volume was also administered to the 
embryonic yolk sac by microinjection and inflammation at the wound site was 
quantified (C).  ≥13 fish per group in 3 independent experiments.  Data expressed 
as  ± S.E.M. *p ≤ 0.05, DMSO 24 h vs FVP 24 h, analysed by ANOVA followed 
by post-hoc Newman Keuls test. 
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4.3.8. Effect of flavone compounds on zebrafish embryos after tailfin 
transection 
The flavone compounds wogonin, luteolin and apigenin were tested in the tailfin 
transection model in Tg(mpx:EGFP)i114 embryos by bath treatment.  At 24 h following 
tailfin transection and wogonin (50 µM) incubation, neutrophil numbers at the wound 
site were significantly reduced (compared to the DMSO control), as demonstrated in 
the example images (Fig. 4.9, A).  At 24 h post-injury, there were 17 ± 2 neutrophils 
in the DMSO (≥ 1%) control group, compared to 9 ± 1 in the wogonin-treated (Fig. 
4.9, B[i]). 
Tg(mpx:EGFP)i114 fish were also pre-injected with the pan-caspase inhibitor 
zVAD-fmk 0.5 h prior to wogonin incubation at 4 h following tailfin transection (Fig. 
4.9, B[ii]).  ZVAD-fmk was able to reverse the resolution driven by treatment with 
wogonin alone after 24 h of treatment.  In the wogonin-treated group, there was 2 ± 1 
neutrophils and in the zVAD-fmk + wogonin group, there was a mean of 10 ± 2 
neutrophils; similar to the control DMSO group which had 12 ± 2 neutrophils.  In the 
zVAD-fmk alone group, there was a mean of 10 ± 2 neutrophils, not significantly 
different from the DMSO group. 
The embryos were also transected and incubated with the flavone compounds 
luteolin and apigenin, but there was no significant difference (p ≥ 0.05) between 




















Figure 4.9.  Bath treatment of zebrafish embryos with the flavones wogonin, 
luteolin and apigenin after tailfin transection 
3dpf Tg(mpx:EGFP)
i114
 zebrafish embryos underwent tailfin transection and were 
treated at 4 h with 50 µM of wogonin or DMSO (≤ 1%) and imaged at various time 
points.  Shown here is the 24 h post-transection time point (A) in DMSO [i] and 
wogonin [ii] – treated fish, which was quantified as shown in (B).  Zebrafish 
embryos were also incubated with wogonin, or injected with Z-VAD-fmk, or both 
together (B [ii]).  The embryos were incubated with the flavones apigenin or 
luteolin, also at 50 µM, and inflammation was measured at different times post-
transection (C). Data expressed as ± S.E.M. ≥ 30 fish per group in 3 independent 
experiments. *p ≥ 0.05, DMSO 24 h vs wogonin 24 h, analysed by ANOVA 
followed by post-test Newman-Keuls 
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4.3.9. Treatment of zebrafish embryos with the CDKi R-roscovitine after 
tailfin transection 
Zebrafish embryos were also treated with a compound previously studied in this 
model, R-roscovitine.  Zebrafish embryos at 3 dpf underwent tailfin transection and 
were then incubated by bath treatment with 20 µM of R-roscovitine at 4 h post-tailfin 
transection.  Example images of the 24 h post-treatment time point are shown (Fig. 
4.10, A).   
 Treatment with R-roscovitine did not significantly (p ≥ 0.05) affect 
neutrophilic inflammation at the site of injury after 24 h compared to control, with 17 
± 1 neutrophils in the DMSO-treated group, and 15 ± 2 neutrophils in the R-





























 embryos at 3 dpf were incubated with 20 µM R-roscovitine or ≤ 
1% DMSO at 4 h post-tailfin transection, and imaged at various time point post-
transection.  Example images are of the 24 h time point in DMSO [i] and R-
roscovitine [ii] – treated fish (A).  The neutrophils at the wound at different time 
points after transection were quantified (B). Data are shown as ± S.E.M.  n/s: p ≥ 




4.3.10. Effect of R-roscovitine on isolated human neutrophils 
Human neutrophils were isolated from peripheral blood and treated with R-
roscovitine; to test if the compound was effective in human neutrophils, as it had no 
effect on zebrafish neutrophils (Fig. 4.10).  Apoptosis of these neutrophils was 
assessed by flow cytometry using annexin V (AnnV, which binds phosphatidylserine 
on the outer membrane of apoptotic cells) and propidium iodide (PI) staining (labels 
necrotic cells by binding extracellular DNA). 
These studies showed that 3.67% of neutrophils were apoptotic after 6 h in the 
control group, compared with 31.7% apoptotic neutrophils in the R-roscovitine 
treatment (Fig. 4.11, A).  This was also clear when the cells were stained with 
DiffQuickTM - in the R-roscovitine-treated group, more cells were present which had 
typical apoptotic morphology (e.g. cell shrinkage and nuclear condensation).  This is 
shown in the representative images of control and R-roscovitine-treated groups [i and 
ii, respectively] with a healthy neutrophil indicated by a white arrow and an apoptotic 




















Figure 4.11.  Treatment of human neutrophils with R-rosovitine 
Flow cytometry plots are shown of isolated human neutrophils were treated with R-
rosocovitine (20 µM), [ii]) or left untreated [i].  Cells which were stained with 
annexin V-FITC (AnnV) were designated apoptotic; propidium iodide (PI)-positive 
cells were counted as necrotic, and unstained cells as viable. 1000x magnified 
images were taken of haematoxylin and eosin (H & E) – stained cytospin slides, 
with the white arrow showing a viable cell, and a black arrow labelling an apoptotic 
cell.  Representative flow plots and images are depicted here (Images adapted from 





Observations from Chapter 4 
 Treatment of zebrafish embryos by incubation with AT7519 in the embryo 
medium does not affect neutrophilic inflammation at wound sites, even with 
an increase in % DMSO. 
 Microinjection of AT7519 into zebrafish embryos at 4 hours post transection 
resulted in reduced accumulation of neutrophils at the injury site at 24 h post-
transection. 
 After AT7519 injection, macrophages accumulated at the wound at a similar 
manner to the DMSO control-injected fish. 
 Injection of AT7519 did not affect the total number of neutrophils in the 
zebrafish embryos. 
 AT7519 increases the number of apoptotic cells at the wound site at 12 h post-
transection (8 h post AT7519 treatment). 
 There is not a significant different in numbers of neutrophils co-localised with 
macrophages after AT7519 treatment in fish which have undergone tailfin 
transection. 
 FVP reduces neutrophil numbers following wounding, when it is incubated in 
the embryo medium with Tg(mpx:EGFP)i114 zebrafish. 
 Wogonin, but not luteolin or apigenin, drives resolution of zebrafish tailfin 
transection inflammation in a caspase-dependent manner following bath 
treatment. 
 R-roscovitine has no effect on neutrophilic inflammation in this model when 
incubated with the fish in embryo water, but drives human neutrophil apoptosis 
in vitro. 
 
Using a combination of incubation and microinjection administration, these 
pharmacological manipulation studies showed the importance of CDKs in regulation 
of neutrophilic inflammation; as the CDKi compounds AT7519, FVP and wogonin all 
reduced neutrophilic inflammation at the tail injury site.  Further experiments revealed 
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AT7519 increased neutrophil apoptosis in zebrafish in vivo, agreeing with previous 
findings showing that it drives apoptosis of isolated mammalian neutrophils (38). 
One important point that was resolved during these experiments was the 
importance of route of administration of these compounds.  This is probably related to 
the solubility of the compounds.  The lack of expected effect of AT7519 on neutrophils 
in zebrafish when administered in the bathing water prompted further investigation, 
and testing of a different route of administration (Fig. 4.1, 4.2).  Therefore, the 
compound was microinjected directly into the fish, via the yolk sac; which is the source 
of nutrition for the embryo at this early stage of development.  This was necessary 
despite the fact that AT7519 is known to be a water-soluble drug (77).  However, the 
solution that embryos are bathed in contain a mix of salts (see Appendix B (170)), and 
it is not known how this might affect solubility.  In addition, in incubation experiments, 
the compounds must enter the fish by routes such as the skin, gut, or gills, and it might 
be that a high amount of the drug does not reach the inflammatory site.  Past studies 
have shown that drugs which were inactive when placed in the water were then shown 
to be effective when microinjected into the yolk sac in a drug screen for bradycardia 
(193).  This demonstrates that there is likely to be an issue with solubility and drug 
delivery with some compounds.  Hence, in these studies, AT7519 was also 
microinjected.  In terms of large-scale drug screens, a bath incubation treatment is the 
simplest method for carrying out drug experiments.  However microinjecting drugs is 
still relatively fast (when compared with rodent drug injections), and still allows for a 
large n value of embryos to be treated in a single day. 
The food source for the early embryo at 3 dpf is the yolk sac rather than external 
food sources (171), meaning that the likelihood of effective drug absorption is perhaps 
higher in microinjected animals.  Other possible sites of injection include injecting 
directly into the vasculature, but this can be technically challenging.  A possible 
refinement to this experiment in the future would be to include a fluorescent dye along 
with the drug, in order to definitively image the areas of the fish where the drug is 
present after treatment.  However care would have to be taken to control for any side-
effects of the dye.  In addition, the gastrointestinal tract is fully open at 4 dpf, meaning 
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that some compounds would work more effectively at 4 dpf rather than 3 dpf, as used 
in the project. 
Conversely, FVP affected neutrophilic inflammation to a greater extent when 
incubated with the embryos, rather than microinjected (Fig. 4.8).  It is already known 
that FVP can affect cardiomyocyte proliferation when incubated with zebrafish 
embryos (117), so is likely to be absorbed well.  The lack of effect from microinjection 
may be attributed to the lack of optimisation of concentrations – perhaps the 
microinjected concentration was not comparable to the amount used in the incubation 
experiments. 
 In contrast, R-roscovitine did not have an effect on neutrophil numbers post-
wounding (Fig. 4.10); although previously this compound has been shown to reduce 
neutrophil numbers after zebrafish tailfin transection at the same concentration, when 
also administered at 4 h post-injury (168).  One explanation is that the injury caused 
here was not severe enough to allow the effect of the drug to be apparent.  Also, 
damaging the vasculature perhaps allows good drug absorption directly to the site of 
wounding.  Microinjection of R-roscovitine may prove to yield a bigger effect than 
incubation, in a similar manner to the AT7519 study.  A more wide screen of 
concentrations and time points may also be insightful – perhaps this concentration was 
not optimal, or the effect was seen at an earlier time point. 
Due to the finding that R-roscovitine was not effective in enhancing resolution 
in the Tg(mpx:EGFP)i114 tailfin transection model used here, the compound was tested 
to examine if it was effective in inducing apoptosis on isolated human neutrophils.  
The fact that R-roscovitine could still induce human neutrophil apoptosis indicated 
there was no issue with the activity of the drug itself; therefore route of delivery and 
the age of the embryo are important factors to consider. 
On the other hand, AT7519 effectively reduced neutrophil numbers post-
wounding when injected at 4 h post-injury (Fig 4.2).  It also prevented recruitment of 
cells when it was administered immediately at the onset of inflammation (Fig. 4.4).  
However, in terms of translational medicine for patients, compounds that target 
inflammation are probably unlikely to be administered until the inflammatory response 
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is underway and already established.  In the case of zebrafish tailfin injury, this peak 
is 4 – 6 h. 
In previous work in the model used by Renshaw et al, neutrophil inflammation 
had to reach a certain level (30 neutrophils) to be treated with the compound 
Tanshinone IIA and included in future analysis (122), to ensure that only zebrafish 
which have a robust neutrophil response are included (occasionally some fish do not 
respond to tailfin injury by showing leukocyte migration to the wound, or respond 
poorly).  In the current study, a similar analysis was not undertaken – it was deemed 
inappropriate to exclude healthy animals from the overall analysis, as it would narrow 
the field of animals studied to only ones with very specific phenotypes. 
AT7519 did not affect total embryonic neutrophils, indicating the neutrophil-
reducing effect is specific to inflammatory neutrophils (Fig.4.3).  Two methods to 
measure this were carried out (counting images and flow cytometry), as direct counting 
of total cells by eye can be challenging due to the numbers of neutrophils present, and 
some cells are obscured by pigmentation in the embryo in certain areas (such as the 
head).  In the future, due to difficulties with imaging cells in a whole organism in 3 
dimensions (if some cells are obscured by pigmentation, or reside in a different focal 
plane but directly above or below other cells), other techniques could be employed for 
whole embryo cell counting.  For example, there now exist automated imaging tools 
that can quantify all cells in an embryo in multiple embryos. 
TUNEL staining was carried out to examine if apoptosis is a mechanism by 
which neutrophil numbers are increased after AT7519 treatment.  TSA-stained EGFP+ 
cells were counted as neutrophils, and neutrophils that also had evidence of TUNEL 
staining were classed as apoptotic neutrophils.  This was displayed in Figure 4.6 as 
apoptotic neutrophil numbers and also as percentage of total neutrophils which were 
also TUNEL+; because the cell numbers recruited in the wound injuries are relatively 
low and at any given ‘snapshot’ in time it is difficult to image apoptotic neutrophils 
when there are so few neutrophils to begin with.   Hence, depicting these data as a 
percentage allows an overall picture of the levels of neutrophil apoptosis relative to 
the entire neutrophil population at the injury site.  It appeared that AT7519 may 
mediate its effects on neutrophils by increasing levels of apoptosis.  At 12 h post-
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transection, there is an increased level of neutrophil apoptosis (TSA- and TUNEL-
stained cells).  This is in keeping with the time course studied; by 24 h, the effect of 
driving apoptosis in this model becomes reflected in the reduced neutrophil numbers.  
One important aspect of future work would be to use another method of assessing 
apoptosis, to confirm these observations.  TUNEL staining is a well-validated method 
in this model (122), however perhaps other methods could be utilised, such as 
MitocaptureTM, a dye which allows apoptosis to be assessed by measuring change in 
mitochondrial potential (70, 194).  In isolated human and mouse neutrophil studies, 
annexin V/propidium iodide binding, measured by flow cytometry, is traditionally 
used to measure apoptosis (Fig. 4.11) (68).  However, such a technique would be 
challenging in this model due to the difficulties associated with isolating sufficient 
numbers of cells and to then perform a staining protocol with several washing steps, 
where cells are being lost constantly. 
 Although CDK9 inhibitors affect neutrophil apoptosis, the effect on other cell 
types cannot be discounted and must be fully investigated.  For example, one study 
shows that FVP affects endothelial cells to assist resolution in a liver inflammation 
model (concanavalin A-induced hepatitis), by inhibiting TNF induced endothelial 
cell/leukocyte interaction (75). 
To strengthen the studies undertaken here, some work looking at molecules 
downstream of CDK9 could be examined.  For example; EGFP+ neutrophils from 
embryos treated with AT7519 could be sorted using fluorescence activated cell sorting 
(FACS), and the expression of anti-apoptotic proteins (such as Mcl-1) could be 
measured by qPCR or western blotting.  This would help to confirm that CDKi 
compounds are affecting neutrophils directly.  
Although it has been suggested here that apoptosis is a mechanism by which 
AT7519 can drive resolution after zebrafish tailfin injury, the effects of the compound 
on reverse migration cannot be excluded.  It has been shown that the compound 
Tanshinone IIA can drive neutrophil reverse migration in this model (122).  This will 
be a source of further investigations in this project – to assess the contribution of 
apoptosis vs cells that leave the wound site. 
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Any increase in apoptosis of neutrophils should be accompanied by effective 
phagocytosis; as apoptotic neutrophils can proceed to secondary necrosis, where the 
release of toxic intracellular components can lead to damage to tissues (195).  
Treatment with AT7519 did not affect recruitment of macrophages or alter their 
numbers during the resolution phase. 
Even though AT7519 does not affect macrophage recruitment to the site of 
injury, the effect of the compound on macrophage functionality (specifically uptake of 
neutrophils) was unknown.  To further assess the effect of AT7519 on macrophage 
functionality, Tg(mpx:EGFP)i114 x Tg(MPEG1:mCherry) embryos were treated with 
AT7519 and were imaged at different time points.  Neutrophils that appeared to be 
engulfed by macrophages were counted.  However, apoptosis and subsequent 
efferocytosis is rapid and hard to image using still imaging, when there are so few 
neutrophils to begin with (as is the case in zebrafish).  The uptake of neutrophils by 
macrophages from 4 to 24 h does not appear to be accelerated by the addition of 
AT7519 (Fig. 5.7).  However, it will be important to fill in the gaps in between these 
times as apoptosis levels appeared to peak earlier (12 h), and time lapse imaging may 
be more useful still, although the use of time lapse is less practical to do experiments 
with large n values.  In the future, tracking software could be applied to the time-lapse 
videos to obtain measurements of other parameters such as neutrophil migration speed 
and directionality post-wounding (121).  Also, a stain for apoptosis should be included, 
to ensure that it is in fact phagocytosed apoptotic neutrophils that exist inside these 
macrophages.  This comes with the disadvantage that the staining procedure is a 
terminal one, meaning that time lapse imaging cannot be carried out in conjunction 
with the apoptosis stain.  Hence, a combination of still imaging and time lapse should 
be employed in the future. 
 In these types of studies new roles can be found for previously existing 
compounds.  Wogonin is a herbal Chinese medicine, found to reduce Mcl-1 in cancer 
cells by CDK9 inhibition, and may be a potential anti-cancer treatment.  Therefore in 
our laboratory group wogonin and the related flavones luteolin and apigenin were 
tested in neutrophils, which are known to be sensitive to Mcl-1 (72).  These compounds 
are known to have CDKi-like structures, so were tested to investigate if they work in 
a similar manner to the other CDKi.  Wogonin was shown to drive neutrophil apoptosis 
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in vitro.  In this project, these compounds were then tested in the in vivo setting of the 
zebrafish.  This showed wogonin effectively reduced inflammation in vivo, but luteolin 
and apigenin did not.  These experiments were only performed using bath treatment 
so this warrants further investigation.  This reduction in neutrophil numbers was 
reversible by microinjection of zVAD-fmk, a caspase inhibitor, suggesting wogonin 
mediates its effects by driving apoptosis.  However, injection of zVAD-fmk does not 
increase neutrophil numbers higher than control levels when injected alone; suggesting 
that it only works on cells in which the caspases have become activated (for example, 
by the addition of a pro-apoptotic agent such as a CDKi compound). 
These findings translated into the in vivo mammalian setting, in which wogonin 
was subsequently shown to attenuate allergic airways (ovalbumin-induced) 
inflammation and LPS-induced lung inflammation (38, 73).  This is a good example 
of how drug studies in zebrafish can eventually translate into mammalian systems. Pre-
testing in the zebrafish allows the reduction in the usage of higher organisms such as 
mice.  It also shows how it can be useful to revisit existing therapeutics, which might 
have structural similarities to synthetic compounds and may have previously unknown 
useful properties in disease.  These compounds may be already tested in humans, often 
for many years, and are known to be safe.  The use of zebrafish also allows large-scale 
studies of the effect of drugs and compounds in vivo.  Toxicology tests can rapidly be 
carried out by a simple bath treatment, with parameters such as mortality and gross 
changes in morphology being analysed.  Using a large number of embryos means 
several different concentrations can be tested in one experiment, making it much 
quicker to determine the concentration ranges which do not have detrimental effects 
on overall fish health. 
Taken together, these studies allowed the identification of selected CDK 
inhibitors, known to have activity against CDK9, which can drive resolution in the 











The P-TEFb complex is a transcription complex, activated by the activity of CDK7 
and 9, resulting in the transcription of anti-apoptotic proteins such as Mcl-1, amongst 
others (Chapter 1, Fig. 1.4).  In this chapter, several genes of the P-TEFb complex are 
targeted to assess what affect this has on inflammation. 
In mammalian primary neutrophils it is very challenging to directly 
knockdown genes of interest, due to the fact that neutrophils are terminally 
differentiated and non-proliferative, as well as having a short lifespan and being prone 
to undergo apoptosis (196, 197).   These problems can be circumvented using zebrafish 
as an animal model, both in vitro but more importantly as an in vivo model.  One of 
the significant benefits of using zebrafish as an animal model is their excellent 
amenability to genetic manipulation and in vivo imaging of any manipulation.  This 
has been carried out using morpholinos and more recently, transcription activator-like 
effector nucleases (TALENs) and clustered regularly interspaced short palindromic 
repeats (CRISPR)/cas9 technologies. (158, 162, 198). 
Morpholinos cause a transient knockdown of a specific gene target, whereas 
TALENs and CRISPR/cas9 causes stable, heritable targeted knockouts of 
mutagenized genes, as the region of interest is excised.  Both morpholino and CRISPR 
technologies were employed in this project, to target members of the P-TEFb pathway.  
Zebrafish possess the components of this pathway including CDKs 7 and 9, and RNA 
polymerase II; and also two isoforms (a and b) of the anti-apoptotic gene Mcl-1 
transcribed by P-TEFb (199, 200).  These genes share significant homology with 
mammalian CDKs in terms of protein sequence (see Chapter 1, Introduction, Table 
1.2).  A recent study in zebrafish has shown that the activity of this complex is 
important in the proliferation of cardiomyocytes following injury (117).  However, 
aside from this, these genes have not been extensively studied in zebrafish.  
To date, in mice, a CDK9 knockout is embryonic lethal (201), but potential 
exists to generate a myeloid-specific knockout.  CDK9, a multi-functional kinase, has 
been targeted in the zebrafish previously to investigate its role in erythropoiesis, 
possibly due to its behaviour as a binding partner to Ldb-1, a transcriptional co-factor 
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important in mammalian haematopoiesis (202).  CDK9 morpholinos have also been 
used to target the translation process; for example, a morpholino was used to target 
CDK9 just upstream of the polyA tail, preventing CDK9 translation (203). 
Alongside CDK9, another component of the P-TEFb pathway is CDK7, 
previously demonstrated to be present in human neutrophils and implicated as 
potentially important in human neutrophil survival (70).  In this study, the authors 
showed that CDK7 was shown to be highly expressed in neutrophils, and was down-
regulated by R-Roscovitine treatment.  Knockout of CDK7 in mice is embryonic lethal 
but the Cre-recombinase system has been used to cause knockout in adult tissues (such 
as skin, liver and kidney) with little detrimental effect on adult physiology (204).  
CDK7 also exists in zebrafish, but has itself not been targeted directly in zebrafish; 
merely its binding partners.  A dominant negative form of Cyclin H (the CDK7 binding 
partner) has been cloned and the mRNA injected into zebrafish eggs.  This resulted in 
stunted development of zebrafish (defective eye and head development and small size) 
(205), indicating CDK7 has a role in embryonic development. 
Downstream of CDK9 and CDK7 is the transcription of the pro-survival 
protein Mcl-1.  Mcl-1 has two isoforms in zebrafish (known as Mcl-1a and Mcl-1b) 
compared to a single gene in mammals (39, 140).  Knocking down these isoforms 
individually using morpholinos was shown to have no effect on the phenotype of 
zebrafish, even when the highest possible concentration of morpholino was injected; 
but knocking down both together was shown to be lethal (39). In the double Mcl-1a 
and Mcl-1b knockdown, only 50% of embryos survived longer than 8 hours post 
fertilisation (hpf).  Knocking out Mcl-1 in a myeloid-specific manner results in an 
almost complete deficiency of neutrophils (98% reduction compared to wild type) in 
mice (206).  The Mcl-1 knockout mouse is embryonic lethal (207). 
 Negative regulation of the P-TEFb complex also exists in mammals and 
zebrafish.  LaRP7 is a component of the 7SKsnRNP, required for its stability and 
function (208-210).  The 7SKsnRNP complex recruits and sequesters P-TEFb in a 
catalytically inactive form.  In these genetic studies, LaRP7 was also chosen as a target 
as it should have the opposite effect to targeting CDK9, as it is a negative regulator of 
P-TEFb.  Knockout of LaRP7 eventually results in embryonic death in mice at day 16, 
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likely due to cell cycle dysregulation in primordial germ cells (211).  CDK9 and 
LaRP7 have been targeted genetically in zebrafish in relation to their role in 
cardiomyocyte proliferation post-injury (117). 
 Together, these studies should provide direct genetic evidence whether or not 
the mechanism by how CDK inhibitors affect neutrophilic apoptosis and inflammation 
is mediated through inhibition of CDK9 and CDK7 via the P-TEFb pathway.  The use 
of zebrafish circumvents some of the difficulties of using mouse knockouts in this 




5.2. Research Questions 
 
 What effect does genetically targeting CDK9 (using morpholinos and/or 
CRISPR/cas9) have on the development and morphology of zebrafish 
embryos? 
 How does targeting CDK9 in zebrafish affect haematopoiesis and the 
neutrophil and macrophage response to tailfin wounding? 
 Does targeting CDK7 affect neutrophil and macrophages during 
inflammation? 
 Does knocking down LaRP7 have the opposite effect on inflammation to 
knocking down CDK9? 
 Does targeting the a and b isoforms of Mcl-1 also affect neutrophil and 
macrophage inflammation? 
 Are CDK9, CDK7, LaRP7and Mcl-1 key regulators of innate inflammation 






5.3.1. Effect of CDK9 knockdown on zebrafish gross morphology and 
development 
Zebrafish eggs at 0 dpf were microinjected with splice site morpholinos for the CDK9 
exon 3/intron 3 boundary (CDK9 morpholino a) or the CDK9 exon 1/intron 1 
boundary (CDK9 morpholino b).  Details of concentrations used for all morpholinos 
are detailed in section 2.5.2.  A translation-blocking morpholino targeting the ATG 
start codon was also used, along with control oligonucleotide sequences.   Western 
blotting at 3 dpf showed that splice-blocking [i] and translation blocking [ii] in 
zebrafish embryos resulted in partial CDK9 knockdown (Fig. 5.1, A).  The band size 
of CDK9 protein was 42 kDa.  There also appeared to be a partial reduction in the Mcl-
1 40 kDa isoform. 
The fish injected with 455 pg of either the a or b splice morpholinos exhibited 
normal body morphology with no visible growth defects, however injection of 130.7 
pg of the ATG morpholino resulted in embryos which were small (compared to control 
groups), with a deformed body-axis and peri-cardial oedema. (Fig. 5.1, B).  There was 
also a reduced survival in eggs at 1 dpf in the ATG morpholino group (46 % ±8) 
compared to the splice morpholino a (73 % ±6) and control groups (82 % ±2, Fig. 5.1, 



















Figure 5.1. Effect of CDK9 knockdown on zebrafish gross morphology and 
development 
Western blotting was performed to assess CDK9, Mcl-1 and β-actin expression in 
digested embryos at 3 dpf.  The embryos were untreated or had been microinjected 
with a CDK9 splice-blocking morpholino a or b or a mismatched control sequence 
[i] or a translation-blocking ATG morpholino and control [ii] at 0 dpf (A). Gross 
morphology of 3 dpf zebrafish embryos (B) injected at 0 dpf with a mismatched 
control morpholino sequence [i], CDK9 splice-blocking morpholino a [ii], and the 
ATG morpholino [iii].  Representative images taken at 40x magnification.  The 
percentage survival of eggs in dishes of mismatch control, CDK9 splice or ATG 
morpholino-injected embryos was calculated from 3 dishes of 50 embryos from 3 




5.3.2. Effect of CDK9 knockdown in zebrafish embryos after tailfin 
transection 
Zebrafish eggs at 0 dpf were injected with morpholinos specific for the CDK9 
exon/intron boundaries, or a similar control sequence.  The details of each morpholino 
are given in Chapter 2, Table 2.3, and are designated as a or b.  The highest amount of 
morpholino was injected which resulted in morphologically healthy animals which 
swim normally, with no visible growth defects (in this case, 455.1 pg) (172). 
 Example images are shown of zebrafish at 3 dpf previously injected with 
splice-morpholino a or a mismatch control sequence (Fig. 5.2, A). 
For splice-morpholino a, knockdown of CDK9 resulted in a statistically 
significant (p ≤ 0.05) reduction in neutrophils (16 ± 5 neutrophils in the control group 
compared to 9 ± 1 in the CDK9 knockdown group) at 24 h post-transection (Fig. 5.2, 
B[i]).  At 4 h post-transection the difference between the morpholino a and control 
group were not significant. 
Splice-morpholino b microinjection resulted in embryos which had a reduced 
number of neutrophils at 24 h post-transection, compared to control (26 ± 3 cells 
compared to 19 ± 1 in the splice-morpholino group).  
As splice morpholino a appeared most effective at reducing neutrophil 



















Figure 5.2.  Knockdown of CDK9 in zebrafish embryos using morpholinos. 
At 3 dpf, the tailfins of CDK9 splice-blocking morpholino a and b-injected or 
mismatched control sequence-injected embryos underwent tailfin transection, and 
were imaged at various points over time.  Shown is an example of 24 h post-
transection (A).  Transection experiments were performed and quantified using two 
splice-block morpholino sequences (a and b), each shown in (B [i]) and (B [iii]).  
n≥38 fish per group in 3 independent experiments. *p ≤ 0.05, assessed by unpaired 
t-test of 24 h splice blocking morpholino embryos vs 24 h mismatched control 
sequence embryos. Data expressed as ± S.E.M.   
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5.3.3. The effect of CDK9 knockdown on the total neutrophil numbers in 
Tg(mpx:EGFP)i114 embryos 
Whole embryos microinjected with CDK9 splice morpholino a or a control sequence 
were imaged [i, ii] and the total neutrophils quantified by counting the cells in the 
images [iii] in 3 dpf embryo injected with CDK9 splice morpholino a (Fig. 5.3, A, B).  
This showed there was no significant difference (p ≥ 0.05) in neutrophil numbers 
between the two different groups; with 84 ± 7 neutrophils in the control group and 81 
± 7 neutrophils in the CDK9 splice morpholino a group.   
The fish were also digested and the percentage of EGFP+ cells in the total 
embryonic cells was measured by flow cytometry.  There was no significant difference 
(p ≥ 0.05) in the percentage of total cells that were neutrophils in the CDK9 

























Figure 5.3.  Total neutrophils in zebrafish after CDK9 knockdown 
Tg(mpx:EGFP)
i114
 embryos were injected at 0 dpf with a CDK9 splice morpholino 
a or a mismatched control sequence, then raised to 3 dpf.  Entire embryos were 
imaged (A [i, ii] and the cells in each embryo quantified (A [iii]).  Whole embryos 
(10 per group) were also digested, and the amount of EGFP
+
 neutrophils in each 
group was assessed by flow cytometry (B).  Statistical significance was assessed 
by an unpaired t-test. Data are shown as ± S.E.M. 
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5.3.4. The effect of CDK9 on neutrophil apoptosis after tailfin transection 
of Tg(mpx:EGFP)i114 zebrafish embryos 
Tailfin transection was performed on 3 dpf embryos which had been injected at 0 dpf 
with CDK9 splice-blocking morpholino a or a control mismatched morpholino.  Then 
tyramide signal amplification (TSA) and terminal deoxynucleotidyl transferase dUTP 
nick end labelling (TUNEL) was performed on embryos fixed at different time points 
(0, 4, 8, and 24 h) after transection.  The number of TSA+ cells (neutrophils), TUNEL+ 
cells (apoptotic cells) and TSA+TUNEL+ cells were quantified. The double positive 
cells were counted by using  confocal Z-stacks to image co-localisation of TSA and 
TUNEL (rather than just overlap of TSA and TUNEL in different planes). Shown is 
an example of 8 h time point images in control and morpholino groups (Fig. 5.4, A). 
The cell numbers are shown here as percentage of total TSA neutrophils which 
are also TUNEL+, to give a better insight of the contribution of apoptosis at each time 
point (Fig. 5.4, B).  At 8 h post-transection, there was an average of 11 ± 4% apoptotic 
neutrophils in the tailfin in the splice-block morpholino group (black bar), compared 
to 5 ± 4% in the mismatch group (white bar).  At 24 h post-injury, there were 0 
apoptotic neutrophils observed in the splice-block group, but 30 ± 15% of neutrophils 























 embryos which had been microinjected with a morpholino to 
knockdown CDK9 (a), or a mismatch control sequence, underwent tailfin 
transection and fish were fixed at different time points for TSA/TUNEL staining.  
Shown are example images from 8 h post transection in control [i] or morpholino-
injected fish (A [ii]).  Each image was counted and the percentage of total TSA cells 
which were also TUNEL
+
 (assessed by examining confocal Z-stack images) was 
calculated (B).  Green arrows depict neutrophils, red apoptotic nuclei, and green/red 
arrows double positive cells. 3 independent experiments.  *p ≤ 0.05.  Statistical 
significance assessed by ANOVA.  
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5.3.5. CDK9 knockdown effect on macrophage numbers following tailfin 
transection 
The effect of CDK9 knockdown on macrophages was assessed by injecting the CDK9 
splice morpholino a into the Tg(MPEG1:mCherry) line at 0 dpf.  At 3 dpf, the tailfin 
of these embryos was transected and imaged at various time points. 
Shown are the 4 and 24 h time points for the morpholino a- [i] and control-
injected groups [ii, Fig. 5.5, A, B).  The macrophage response to transection was 
significantly lower at 4 h post transection in the splice-injected group (12 ± 1 cells), 
compared to control (20 ± 2 cells); however by 24 h the groups were similar – 24 ± 2 



























Figure 5.5. Effect of CDK9 knockdown on macrophages. 
Newly laid Tg(MPEG1:mCherry) zebrafish eggs were injected with a CDK9 
splice-blocking morpholino a or mismatched control sequence, then raised to 3 dpf.  
The embryo tailfin was transected and the fish imaged at various time points; shown 
are example images of the 4 h (A) and 24 h (B) time points for morpholino [i] and 
control [ii] fish.  Numbers of macrophages at the wound were counted and shown 
graphically (C). n ≥ 20 fish per group in 3 independent experiments.  Data shown 




5.3.6. Utilising CRISPR/cas9 to knockout CDK9 in zebrafish  
Only partial knockdown of CDK9 was achievable in this system by the use of the 
splice-specific morpholinos to target CDK9; the ATG start codon morpholino was 
found to be embryonic lethal, even at very low concentrations of ATG morpholino. 
Therefore, CRISPR/cas9 gene knockout techniques were applied to create 
homozygous and heterozygous CDK9 knockout animals.  Tg(mpx:EGFP)i114 eggs 
were injected with a sequence designed to target exon 2 of CDK9 (all details in Chapter 
2, Methods).  
For genotyping, restriction digestions of a CDK9 PCR product were carried 
out using the Hpy188i enzyme.  The digest site is shown in Figure 2.5. (Chapter 2, 
Methods).  In wild type embryos, the PCR product (415 bp) is fully digested into 270 
bp and 145 bp bands with the Hpy188i restriction enzyme (as the cut site is intact) 
(Fig. 5.6, A[i]).  In heterozygous mutants, the PCR product is partially digested, as the 
cut site is present but not to the same extent as in the wild type.  In homozygous 
mutants, the Hpy188i cut site is completely abolished, resulting in no digestion of the 
PCR product and one 415 bp band.  In fin clips from the F1 Tg(mpx:EGFP)i114 x 
mpx:EFGPi114-CRISPR injected) generation, a mix of wild type and heterozygous 
were present, at a ratio of  1:3 wild type:heterozygous (Fig. 5.6, A[i]). 
The DNA of genotyped adult F1 fish was then sequenced over the CDK9 
region (Fig 5.6, A[ii]).  The heterozygote fish from this batch all had a 5’-3’ GGAC 
base pair deletion, which are the last four base pairs of the CRISPR target site, shown 
in red text.  This was translated to the protein sequence, showing an early stop codon 

















Figure 5.6.  Generating F1 heterozygote CDK9 knockout zebrafish using 
CRISPR/cas9. 
The CDK9 region in these assays was amplified by PCR (undigested [‘Und’] 
bands) and the PCR product digested using Hpy188i restriction enzyme (restriction 
digest ‘RD’ bands).  Fin clips from F1 fish (from a Tg[mpx:EGFP]
i114
 x CRISPR-
injected WIK wild type cross) were digested and PCR and RD was performed (A), 
to show which F0 CRISPR-injected fish were producing heterozygote F1s. Fish 
were designated as heterozygotes when the PCR product was not fully digested into 
2 smaller bands. Each fish was given a code (A-G) and the green ticks designate 
heterozygote fish.  Some of these fin clips were sent for DNA sequencing; the 
sequence of the CDK9 exon 1 region is shown with the CRISPR target sequence in 
red (A [ii]).  The protein sequence was determined from the DNA sequence, 
showing the conserved region between mutant and wild type (WT), and the early 
stop codon and nonsense sequence in the mutant (B).  
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5.3.7. Phenotype of CRISPR/cas9 CDK9 knockout homozygote and 
heterozygote Tg(mpx:EGFP)i114 zebrafish embryos 
Two of the mutant fish were crossed and the resulting embryos genotyped, showing a 
mix of wild type, heterozygote-mutant and homozygote-mutant fish present in the F2 
generation (Fig. 5.7, A).  Embryos were digested for western blotting, showing that 
some of the F2 embryos have ablation of the 42 kDa isoform of CDK9 (Fig. 5.7, B).   
Having confirmed that it was possible to generate homozygote and 
heterozygote CDK9 mutants, the phenotype of these animals was assessed.  The 
homozygote mutants, although viable at the embryonic stage, have a deformed body-
axis morphology and do not swim normally, compared to wild type (Fig 5.7, C[i], 
[iii]).  The heterozygote mutants have normal body morphology with no curvature, 
normal heart function and normal swim behaviour (Fig. 5.7, C[ii]).  Future assays of 





















Figure 5.7.  Generating F2 CDK9 knockout zebrafish using CRISRPR/cas9. 
Heterozygote F1s were crossed and the F2 generation was genotyped using PCR 
and restriction digestion, as in Figure 5.5. (A), and protein expression in a batch of 
embryos measured by western blotting (B).  Representative images of wild type [i], 
heterozygous mutant [ii] and homozygous mutant [iii] embryos (C) were taken to 
assess the morphology of the mutants. 
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5.3.8. Neutrophil numbers in Tg(mpx:EGFP)i114 CRISPR/cas9 CDK9 
knockout homozygote and heterozygote zebrafish embryos 
The total (whole animal) embryonic neutrophils at 3 dpf were assessed in homozygote 
and heterozygote CDK9 mutants, and wild type fish. This showed there were 
significantly less (p ≤ 0.05) total neutrophils between wild type (157 ± 12  cells) and 
heterozygote (131 ± 6 cells) embryos, and wild type and homozygote embryos (60 ± 
6 cells, Fig. 5.8, A).  See also images in Figure 5.7 (C). 
The tail fin of these embryos were transected and the neutrophils at the injury 
site at different times were quantified (Fig. 5.8, B).  This showed that the homozygote 
CDK9 knockout had significantly less (p ≤ 0.05) neutrophils at the wound at 4, 8 and 
24 h post-transection compared with the wild type and heterozygote mutant groups, 
with 4 ± 1 cells at 24 h post-transection compared to 11 ± 2 cells in the wild type group. 
The heterozygote mutants had significantly less (p ≤ 0.05) neutrophils at the 
wound site (and 8 ± 1 cells respectively) compared to wild type embryos (11 ± 2) at 
24 h post-transection, but similar numbers at 0, 4 and 8 h time points.  Images of the 
injured tailfin in wild type, heterozygous and homozygous CDK9 mutants at 24 h post-





















Figure 5.8.  Inflammation in CDK9 homozygote/heterozygote-knockout 
zebrafish embryos 
After imaging, the individual fish were digested and genotyped as in Fig. 5.4., to 
determine if they were wild type, heterozygous or homozygous for the CDK9 
knockout. Total neutrophil numbers in Tg(mpx:EGFP)
i114
 embryos at 3 dpf were 
counted (A).  The tailfin of embryos were transected and imaged at various time 
points after transection.  The neutrophils at the tailfin were quantified (B).  Example 
images shown of the 24 h time point (C).    ≥47 fish per group from 3 independent 
experiments.  *p<0.05.  Statistical significance was assessed by ANOVA followed 
by a post-hoc Newman-Keuls test.  Data are expressed as ± S.E.M. 
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5.3.9. Recruitment of neutrophils to wound site in wild type or 
CRISPR/cas9 CDK9 knockout fish, as a percentage of total 
embryonic neutrophils 
In each fish, the wound-recruited neutrophils as a percentage of total embryonic 
neutrophils was calculated (Fig. 5.9).  There was no significant difference (p ≥ 0.05) 
between wild type, heterozygous and homozygous CDK9 knockouts in percentage of 
neutrophils which are recruited.  For example, at 24 h post-injury, 5 ± 1 % of total 
neutrophils were recruited to the wound, compared to 7 ± 1 % in the heterozygous 



























Figure 5.9.  The percentage of total neutrophils that are recruited to the 
wound in CDK9 knockout embryos 
CRISPR/cas9 was used to generate CDK9 knockout fish. Wild type, heterozygote 
and homozygote CDK9 knockout embryos underwent tailfin transection at 3 dpf. 
In each embryo at each time point post-transection, the total embryonic neutrophils 
and wound site neutrophils are counted and the percentage of total neutrophils 
recruited to the wound was calculated.  No statistical difference was noted using 
ANOVA (p ≥ 0.05) 
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5.3.10. The effect of CDK7 knockdown on neutrophil numbers in 
zebrafish following tailfin transection 
A splice-blocking morpholino to target the CDK7 exon 11/intron 11 boundary was 
injected into newly laid Tg(mpx:EGFP)i114 eggs at 0 dpf, along with a mismatched 
control sequence.  Western blotting showed a reduction in CDK7 protein in embryos 
at 3 dpf injected with the CDK7 morpholino, compared to control sequence or 
untreated embryos (Fig. 5.10, A). 
The 3 dpf morphant embryos underwent tailfin transection and were imaged at 
various time points, as shown in the representative images (Fig. 5.10, B) and the 
neutrophils at the wound site were quantified (Fig. 5.10, C).  Neutrophil numbers were 
not significantly different (p ≥ 0.05) in the CDK7 knockdown group compared to the 
control group; in the CDK7 knockdown group there was a mean of 17 ± 2 neutrophils 
at 24 h post-transection, compared with 18 ± 4 neutrophils in the mismatch-injected 
group.  The 0 and 4 h time points were also not significantly different (p ≥ 0.05) 























Figure 5.10.  CDK7 knockdown in zebrafish embryos using morpholinos 
Zebrafish embryos were microinjected with a CDK7 morpholino or mismatch 
sequence at 0 dpf.  Embryos were digested for western blotting to assess 
knockdown (A).  At 3 dpf, embryo tailfins were transected and the inflammation at 
the tailfin was imaged in control [i] and morpholino [ii] –injected groups (B), and 
then quantified (C).  ≥16 fish per group, from 3 independent experiments. n/s: p ≤ 
0.05, assessed by ANOVA 
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5.3.11. The effect of knocking down CDK7 on macrophage numbers 
A CDK7 splice morpholino or control mismatch sequence was microinjected into 
Tg(MPEG1:mCherry) zebrafish eggs at 0 dpf.  At 3 dpf, successfully-injected embryos 
were selected by fluorescence and underwent tailfin transection. 
At 0, 4 and 24 h the numbers of macrophages were counted, showing no 
significant difference (p ≥ 0.05) in macrophage numbers at any time point after injury 
(Fig. 5.11).  At 4 h, there was a mean of 21 ± 1 macrophages in the CDK7-morpholino 
group, compared to 22 ± 3 cells in the control group.  At 24 h, the CDK7-morpholino 



























Figure 5.11.  The effect of CDK7 knockdown on macrophage numbers. 
CDK7 morpholinos and a control mismatch sequence were microinjected into 
newly laid Tg(MPEG1:mCherry) zebrafish eggs at 0 dpf.  At 3 dpf the tailfin was 
transected and the numbers of macrophages were counted at 0, 4 and 24 h post-
transection.  ≥ 20 embryos per group in 3 independent experiments. 
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5.3.12. The effect of knocking down both CDK9 and CDK7 on 
neutrophilic inflammation post-wounding in zebrafish embryos 
The CDK9 and CDK7 splice morpholinos were co-injected together into 
Tg(mpx:EGFP)i114 eggs (0 dpf).  At 3 dpf, the embryos were transected and the 
inflammation was imaged and quantified at different times (Fig 5.12). 
In the morpholino-injected group there was no significant difference between 
the morpholino and control-injected group, with an average of 18 ± 2 neutrophils at 24 
h post-transection in the morpholino group, compared to the control-injected group 
which had an average of 17 ± 3 neutrophils.  The 0 and 4 h time points did not show a 





























 eggs (0 dpf) were injected with CDK9 splice a and 
CDK7 morpholinos or control mismatch sequences.  The fish were imaged at 
various time points after tailfin transection and the inflammatory response at the 
wound was quantified.  ≥14 fish per group in 3 independent experiments.  Data 
expressed as ± S.E.M.  Statistical significance was assessed by ANOVA followed 
by post-test Newman-Keuls. 
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5.3.13. The effect of knocking down LaRP7 on Tg(mpx:EGFP)i114 
zebrafish embryos post-tailfin transection 
A morpholino was injected into Tg(mpx:EGFP)i114 eggs to knock down LaRP7, or a 
control mismatched sequence.  The success of knockdown of the 70 kDa isoform in 3 
dpf zebrafish was assessed using western blotting (Fig. 5.13, A).  Knockdown of 
LaRP7 significantly increased neutrophilic inflammation at 24 h post-tailfin wounding 
in Tg(mpx:EGFP)i114 zebrafish at 3 dpf, shown by the representative 24 h images (Fig. 
5.13, B) and also when quantified (Fig. 5.13, C[i]). 
At 4 and 8 h post-transection there was not a significant difference (p ≥ 0.05) 
between LaRP7 morpholino and control sequence-injected groups in terms of 
neutrophil numbers.  However, at 24 h post-transection there were significantly more 
neutrophils in the morpholino-injected group (21 ± 4 cells) compared to the control-
treated group (10 ± 43).  There was no significant difference (p ≥ 0.05) between the 
LaRP7 morpholino- and control sequence-injected groups in terms of total neutrophils 























Figure 5.13.  Microinjection of zebrafish eggs with LaRP7 morpholino 
At 0 dpf, Tg(mpx:EGFP)
i114
 zebrafish eggs were injected with a morpholino to 
knock down LaRP7.  Western blotting was performed of embryos injected with the 
LaRP7 morpholino or a control mismatched sequence for LaRP7 and β-actin (A).  
At 3 dpf, morpholino- [ii] or mismatch–injected [i] fish underwent tailfin 
transection.  Images were taken at various time points (shown here are example 
images at 24 h, B) and the inflammatory response was quantified (C [i]).  The total 
neutrophil numbers in whole embryos were quantified (C [ii]).  Data shown as ± 
S.E.M.  ≥10 fish per group in 3 independent experiments.  *p ≤ 0.05. Data analysed 
by ANOVA followed by post-hoc Newman Keuls, or unpaired t-test. 
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5.3.14. The effect of knockdown of LaRP7 and CDK9 morpholinos in 
Tg(mpx:EGFP)i114 zebrafish embryos after tailfin transection 
Next, the LaRP7 and CDK9 (a) splice morpholinos were co-injected, to examine the 
effect of knocking down CDK9 as well as one of its negative regulators (Fig. 5.14, A).  
Western blotting was used to assess successful knockdown of both genes at the 
concentration used (Fig. 5.14, B), which was less than the concentration used for single 
injections, due to toxicity issues when both sequences were co-injected. 
There was no significant difference (p ≥ 0.05) in neutrophil numbers between 
the zebrafish injected with LaRP7 and CDK9 morpholinos, compared to control-
sequence animals injected with two mismatch sequences, at all time points (Fig. 5.14, 
C[i]); for example, in the 24 h post-injury time point with an average of 10 ± 1 
neutrophils at 24 h in the morpholino-treated group and 8 ± 1 neutrophils in the control 
group. 
As a control, zebrafish eggs were injected with the morpholino specific for 
CDK9 or LaRP7, together with the control sequence of the other gene.  In these studies, 
zebrafish injected with the CDK9 morpholino and the LaRP7 mismatch sequence had 
significantly decreased neutrophils (a mean of 8 ± 0.5) at 24 h after tailfin transection 
in comparison to the LaRP7 morpholino with the CDK9 mismatch control (11 ± 1 
cells, Fig. 5.14, C[ii]).  The 24 h time point for all these 4 conditions (LaRP7 and 
CDK9 morpholinos, LaRP7 and CDK9 mismatch sequences, CDK9 morpholino and 



















Figure 5.14.  Co-injection of LaRP7 with CDK9 morpholino 
The CDK9 (a) and LaRP7 morpholinos, or CDK9 and LaRP7 mismatch sequences 
were injected together into 0 dpf Tg(mpx:EGFP)
i114
 zebrafish eggs.  The parts of 
the P-TEFb pathway targeted are depicted in (A).  Western blotting was used to 
show the knockdown levels (B).  Neutrophil migration to sites of wounding in these 
zebrafish was imaged and counted (C [i]).  At 0 dpf, zebrafish eggs were also co-
injected with CDK9 morpholino + LaRP7 mismatch control sequence, or CDK9 
mismatch sequence + LaRP7 morpholino.  At 3 dpf, the zebrafish tailfin was 
transected and the neutrophilic inflammation was imaged and quantified (C [ii]).  
Data expressed as ±S.E.M.  ≥ 30 fish per group in 3 independent experiments.  Data 
analysed by one-way ANOVA followed by post-test Newman Keuls. *p ≤ 0.05. 
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5.3.15. Treatment with AT7519 in LaRP7 knockdown Tg(mpx:EGFP)i114 
embryos that have undergone tailfin transection 
The AT7519 CDKi compound was tested together with the LaRP7 morpholino. 
Zebrafish eggs at 0 dpf were injected with the LaRP7 morpholino or control sequence 
at 0 dpf.  At 3 dpf, the embryos underwent tailfin transection and were then treated 
with AT7419 at 4 h post-transection. 
The addition of AT7519 significantly (p ≤ 0.05) reduced neutrophil numbers 
at 24 h post-transection in the mismatch control injected-group (4 ± 1) compared to 
the morpholino-injected group (9 ± 1 cells, Fig. 5.15, [ii]).  However, the addition of 
AT7519 did not affect LaRP7 splice-morpholino injected fish, which had the same 
neutrophil numbers compared to the control group (9 ± 1 neutrophils, mismatch 
sequence + DMSO, Fig. 5.15, [i]). 
At 4 h post-transection, immediately prior to AT7519 or DMSO treatment, the 
LaRP7 splice-blocking morpholino group had significantly (p ≤ 0.05) more 
neutrophils than the mismatch-injected groups (17 ± 2 and 11 ± 1 cells, respectively.  























Figure 5.15.  Treatment with AT7519 at 4 hpi in LaRP7-morpholino injected 
zebrafish after tailfin transection 
Tg(mpx:EGFP)
i114
 zebrafish eggs were injected with a splice-blocking morpholino 
against LaRP7 or a control mismatch sequence.  At 3 dpf, these zebrafish underwent 
tailfin transection and were treated with AT7519 or DMSO vehicle control at 4 h 
post-transection.  The fish were imaged and tailfin neutrophils were quantified [i].   
The 24 h post-transection time point is highlighted in AT7519-treated fish with 
either LaRP7 splice-blocking- or mismatch control sequence- injected fish [ii].  ≥15 
fish per group in 3 independent experiments.  Data expressed as ± S.E.M.  *p ≤ 
0.05, analysed by ANOVA or unpaired t-test. *p ≤ 0.05 LaRP7 mismatch + AT7519 
vs LaRP7 splice-block +AT7519 and LaRP7 mismatch + DMSO.  #p ≤ 0.05, LaRP7 
splice-block + AT7519 vs LARP7 mismatch + AT7519 
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5.3.16. The effect of knocking down Mcl-1a and/or Mcl-1b on neutrophils 
in Tg(mpx:EGFP)i114 zebrafish embryos 
Due to the fact that Mcl-1 is thought to be transcribed as a result of CDK9 activity, the 
two isoforms of Mcl-1, Mcl-1a and Mcl-1b, were targeted with translation-blocking 
(ATG) morpholinos whose sequences had been previously published (39).  Western 
blotting was used to show successful partial knockdown of Mcl-1a and Mcl-1b, after 
probing with an anti-Mcl-1 antibody and β-actin as loading control (Fig. 16 [A]).   
Knocking down Mcl-1a [i] and Mcl-1b [ii] individually had no significant 
effect (p ≥ 0.05) on the neutrophil numbers at the site of tailfin wounding in 3 dpf fish 
at any time point post-transection (Fig. 5.16, B).  For example, at 24 h post-transection 
in the Mcl-1b knockdown group there was 13 ± 3 cells compared to 10 ± 2 cells in the 
control sequence-injected group.    
Next, the morpholinos were co-injected together, in case one isoform 
compensates for the loss of the other.  In the co-injected fish, no significant difference 
(p ≥ 0.05) was seen in morpholino or control groups in the neutrophilic inflammation 
after wounding (Fig. 5.17, B).  At 24 h, there were 10 ± 1 neutrophils in the control 
group; compared to 11 ± 1 neutrophils in the Mcl-1a and b injected groups.  Example 






















Figure 5.16.  Knocking down Mcl-1a and Mcl-1b using morpholinos 
4.6 ng of Mcl-1a or Mcl-1b ATG morpholino or a control sequence was injected 
into newly laid Tg(mpx:EGFP)
i114
 zebrafish eggs at 0 dpf. The knockdown levels 
were assessed by western blotting and proving with an anti-Mcl-1 antibody and β-
actin antibody as loading control (A).  At 3 dpf the zebrafish underwent tailfin 
transection, the tailfin wound was imaged at various time points and the 
inflammatory response was quantified (B) in Mcl-1a [i] or Mcl-1b [ii] knockdown 
fish.  ≥ 22 fish per group in 3 independent experiments.  Data shown as ± S.E.M. 






Figure 5.17.  Co-injection of morpholinos to knockdown Mcl-1a and Mcl-1b 
4.6 ng of Mcl-1a and Mcl-1b ATG morpholinos were injected together into 
Tg(mpx:EGFP)i114 embryos, and the fish tailfin was transected at 3 dpf and imaged 
at various time points.  The neutrophil inflammatory response was quantified by 
counting cells at the wound. At least 22 fish per group in 3 independent 





Observations from Chapter 5 
 Knocking down CDK9 is possible in zebrafish embryos using morpholinos and 
reduces accumulation of neutrophil numbers at 24 h post-wounding, due to 
increasing neutrophil apoptosis levels post-injury (shown by TUNEL staining). 
 Knocking down CDK9 does not affect total neutrophil numbers. 
 Homozygous CDK9 knockout embryos, and CDK9 ATG morphants exhibit 
significant defective body morphology. 
 Homozygous CDK9 knockout embryos have less neutrophils, both in the 
whole embryo and at the tailfin after wounding. 
 Heterozygous CDK9 knockout animals are viable with a normal morphology, 
have slightly less total neutrophils but have a reduced neutrophil response to 
wounding. 
 CDK9 knockout using CRISPR/cas9 does not affect the percentage of total 
neutrophils that are actually recruited to the wound. 
 Targeting CDK9 using morpholinos does not affect macrophage accumulation 
at the site of injury 24 h post transection, but does affect the initial recruitment. 
 Knockdown of LaRP7 using morpholinos results in an increased neutrophil 
inflammatory response to tailfin wounding. 
 LaRP7 knockdown can reverse the effect of CDK9 morpholino knockdown on 
neutrophil numbers after tailfin wounding, restoring neutrophil numbers to 
normal levels. 
 AT7519 restores neutrophil numbers at the wound site in the LaRP7 splice 
morpholino zebrafish to control levels. 
 Genetic manipulation of CDK7 in zebrafish using morpholinos has no effect 
on neutrophil and macrophage numbers at the wound site post-wounding. 
 Knocking down Mcl-1a or Mcl-1b in zebrafish, or both simultaneously, does 




This section of the project allowed the role of particular genes to be probed in greater 
detail, in particular CDK9, CDK7 and Mcl-1.  These genes have been hypothesised to 
be important in the mechanism by which CDK inhibitor drug targets can drive 
neutrophil apoptosis.  Importantly, it is difficult to target these genes in primary human 
neutrophils, due to the short lifespan of neutrophils in culture, which is an important 
aspect in the choice of zebrafish as an in vivo model system.  
 The main genetic target of these studies was CDK9, as evidence indicates that 
it is an important regulator of neutrophil lifespan.  CDK9 is also known to play a role 
in zebrafish as a regulator of cardiomyocyte proliferation (117).  CDK9 knockdown 
using splice-blocking a and b morpholinos had the effect of attenuating neutrophil 
inflammatory responses at the injury site 24 h following wounding, indicating CDK9 
is important in resolution of inflammation (Fig. 5.2).  Splice morpholino a was more 
effective and therefore was chosen as the focus for the rest of the project.  Interestingly, 
the morpholino did not affect the total neutrophils in the whole embryo, suggesting it 
does not affect haematopoiesis (Fig. 5.3).  This suggests that neutrophils during 
inflammation appear to be more sensitive to the effect of CDK9 splice-blocking 
morpholino knockdown, perhaps relating to the fact that CDK9 is also thought to be 
involved in transcription of inflammatory mediators (212).   
Knocking down CDK9 using splice-blocking morpholinos and treatment with 
CDKi drugs (Chapter 4) has a direct effect on neutrophils at the wound site after tailfin 
transection.  However, the CDK9 ATG morpholino caused developmental defects 
when used here (Fig. 5.1), as it did in the study by Matrone et al (117), making the 
embryos not useful for experimentation purposes.  In this project, the CDK9 ATG-
targeting morpholino caused such drastic side effects that only very low concentrations 
yielded viable embryos.  However, this comes with the disadvantage that the 
fluorescent tag is then heavily diluted, making it difficult to screen for positive 
embryos.  Using western blotting to assess successful knockdown can be done after 
the experiment is run; but this is not so practical for large-scale transection studies, 
and also the morpholino is less effective over time as it is a transient knockdown.  One 
strategy to combat morpholino toxicity is the co-injection of a morpholino against the 
pro-apoptotic protein p53, but this is not suitable in studies where apoptosis is 
important (213).  For this reason, most parts of these studies focused on the use of 
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splice-blocking morpholinos with appropriate controls.  To compensate for the fact 
that CDK9 ATG morpholino was less useful, a second splice-site targeting CDK9 
morpholino was also used.  The Mcl-1 morpholinos targeted the Mcl-1 ATG start 
codons, as they were used in a previous zebrafish study and the gross morphology of 
these animals was well described (39).    
It is sometimes observed that different methods to target a gene result in 
different phenotypes; for example, morphants (where a gene is transiently knocked 
down using techniques like morpholinos) often have a different phenotype to genetic 
knockout mutants.  The techniques differ in the fact that the morpholino causes a 
temporary knockdown which wears off through the various cell divisions.  In one 
study, zebrafish mutants of the egfl7 gene were generated using TALENs.  egfl7 
morphants show vascular defects, whereas the mutants have no such phenotype (214).  
This has been attributed to compensation mechanisms.  Extracellular matrix genes and 
vegfab are up-regulated in these TALEN mutants, but mutants generated by 
CRISPR/cas9 do not have this same gene up-regulation.  Mouse mutants of the same 
gene have no phenotype.  In the same study, in the zebrafish vegfaa mutant there is 
upregulation of the paralogue vegfab, but not so in the morphants (214).  Targeting 
CDK9 in human fibroblasts and astrocytes using a pharmacological inhibitor (FVP), 
or siRNA targeting, or transduction with a dominant negative form of CDK9 all 
resulted in a different global effect on cell gene expression, as measured by microarray 
(215).  It is therefore important to target genes using different methods. 
These types of studies highlight the difficulties in interpretation of genetic 
manipulation data, and made it important to use another genetic method (such as 
CRISPR/cas9) as well as morpholinos to target CDK9, in order to compare the 
phenotype of the mutants and morphants.  There are concerns about non-specificity 
and toxicity of morpholinos at high concentrations, and it is difficult to cause full 
CDK9 knockdown using this method, as the embryos die or do not develop properly 
when the high concentrations likely required to cause complete knockdown are 
injected.  However, a partial knockdown can be achieved with the embryo still 
developing normally (Fig. 5.1). 
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Hence, in this study a CDK9 knockout animal was generated using 
CRISPR/cas9 technology to target CDK9 (160) (Fig. 5.6).  This is described as a good 
system to create stable, heritable knockouts with an efficiency rate of approximately 
70% (159).  In this project, knocking out CDK9 using CRISPR was successfully 
achieved in the neutrophil labelled Tg(mpx:EGFP)i114 zebrafish.  The homozygote 
mutant embryos, however, had a curved body morphology and poor long-term 
survival, although were still viable under 5 dpf (Fig. 5.7).  This is in agreement with 
the morpholino studies, which revealed that only partial splice-site knockdown of 
CDK9 could be achieved in order to have healthy, viable animals, and use of the ATG 
CDK9 morpholino resulted in defective embryonic development.  CDK9 is reported 
to be a master gene regulator, too important for healthy embryo development to be 
completely obliterated, observed also in this study with the CRISPR/cas9 CDK9 
homozygote embryos and when larger amounts of morpholino are injected.  Targeting 
CDK9 in a knockout mouse is embryonically lethal; suggesting it plays an important 
role in mouse development as well (113).  It is known to be important in regulating 
genes during Drosophila melanogaster development (216).  
Whether any of the zebrafish homozygous CDK9 CRISPR/cas9 mutants 
survive to adulthood will be a subject of further studies in the laboratory, including 
histopathological analysis.  A mix of heterozygous and homozygous mutants of the F2 
generation are being raised, and once they have reached adulthood, these fish will be 
fin-clipped and the tissue specimen genotyped using the assay described, to reveal 
whether any of the adult fish carry the homozygous mutation (Fig. 5.6).   
The homozygous mutant embryos had a reduced number of neutrophils at the 
tailfin following transection, compared to wild type Tg(mpx:EGFP)i114 embryos (Fig. 
5.8).  In contrast to the morpholino data, there were also a reduced total number of 
neutrophils in the whole embryo in the CRISPR mutants, particularly in the 
homozygous CDK9 knockout.  This indicates CDK9 is important in haematopoiesis 
in zebrafish. 
Due to the morphology of the homozygous mutants, more specific attention 
was given to the inflammation phenotype of the heterozygous mutants.  The 
heterozygous CDK9 mutant neutrophil response to wounding is similar to that of the 
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CDK9 splice morpholino knockdown animals – there are reduced neutrophils at 24 hpi 
(Fig. 5.8).  This indicates the importance of CDK9 during resolution, and suggests that 
when there is a full CDK9 knockout, all time points of the inflammatory response are 
affected. 
The reduced neutrophil numbers at the wound in homozygote and heterozygote 
mutant knockouts may be attributed to the reduction in total neutrophils seen in these 
embryos (Fig 5.8).  The percentage of the total neutrophils that were actually recruited 
to the wound was calculated, to determine if the function of the neutrophils was 
impaired in the knockout embryos (Fig. 5.9).  However, wild type and hetero-/homo- 
zygote knockout embryos are similar in terms of the percentage of total neutrophils 
that are recruited; suggesting the neutrophils present are functional and migrate.  This 
reduction in total neutrophils is not seen in the CDK9 morpholino-knockdown, 
probably due to the less substantial knockdown in the morphants.  To examine this 
further, tracking individual cells would have to be carried out.   
 Taken together, these data suggest that knocking out CDK9 completely is not 
a suitable resolution strategy, but partial targeting (as a pharmacological agent would 
be) may well be a good option for targeting neutrophilic inflammation.  In addition, 
pharmacological intervention is given at the peak of the inflammatory response rather 
than being present from the beginning.  Understanding the phenotype of the mutants 
will be the source of further study in this project. 
 From the CDK9 morpholino data, it was unclear if the neutrophils were 
more susceptible to apoptosis, or if there was a defect in the migration of the 
neutrophils to the injury site.  To attempt to answer this, TUNEL staining of CDK9 
knockdown embryos was performed to measure apoptosis levels (Fig. 5.4).  There 
were an increased number of apoptotic neutrophils in the tailfin of the CDK9 splice-
blocking morpholino group at 8 h post-transection compared to the control group.  This 
indicates inflammatory neutrophils are more prone to undergo apoptosis when CDK9 
has been knocked down.  This 8 h post-injury time point was similar to the AT7519 
apoptosis data, in which maximum TUNEL staining of neutrophils was seen at 12 h 
post transection (Chapter 4, Fig. 4.6).  This 8 h time point also coincided with the 
beginning of a progressive increase in the presence of macrophage cells at the site of 
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injury in CDK9 knockdown animals; a point which will be expanded on later.  Future 
work will also involve performing TUNEL assays on the CRISPR CDK9 mutants. 
An issue with TUNEL staining is it requires fixing embryos at specific time 
points after transection, making it easy to ‘miss’ apoptotic events.  One other way to 
confirm the possible link of migration or apoptosis would be increased confocal 
microscopy with tracking of individual cells (121).  It has been shown in vivo that it 
takes approximately an hour for a neutrophil in the Tg(mpx:EGFP)i114 line to change 
into apoptotic morphology till the EGFP signal fades.  A good strategy to assess 
apoptosis better would be the generation of a line in which apoptotic cells become 
fluorescently labelled, by apoptosis specific markers (e.g. externalised 
phosphatidylserine).  This would allow definitive assessment of which cells were 
apoptotic.  Previous work from this study and others has shown that maximum 
apoptosis occurs at 12 hours post-treatment with CDKi compounds, but the time 
course of neutrophil apoptosis when morpholinos are used to target molecules 
involved in apoptosis is not previously studied. 
Furthermore, based on the CDK9 homozygous knockout data showing less 
neutrophils through the whole inflammatory response (Fig. 5.8), a future direction to 
this project would be the measurement of neutrophil recruitment.  Although increased 
apoptosis was seen in the CDK9 splice-blocking morpholino group (Fig. 5.4), the 
effect may also be due to defective migratory potential due to the role of CDK9 in 
cytokine and/or adhesion molecule transcription (212).  The CDK9 splice-blocking 
morpholino may affect chemotactic gradients such as H202 gradients or calcium waves, 
which are known to be important in neutrophil chemotaxis in zebrafish (146, 147).  It 
is possible to measure these chemotactic gradients in zebrafish using live imaging, for 
example the HyPer fish allows live imaging of the hydrogen peroxide chemotactic 
gradient by yellow fluorescent protein (YFP) expression (147). 
Cytokines such as TNF and IL-8 are described in zebrafish (217, 218), and 
TNF-transgenic fish have been recently created which may be useful to examine the 
effect of targeting CDK9 on the levels of inflammatory mediators (219).  Expression 
of cytokine mRNA in the tailfin could also be measured by dissecting the wounded 
tailfin area, and using q-PCR to measure the expression of these cytokine transcripts.  
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Zebrafish which express GFP under transcriptional control of NF-κB have also been 
generated, permitting the imaging and measurement of NF-κB activation (220).  This 
would allow the effect of CDK9 inhibition on NF-κB to be assessed; it would be 
expected that reduced NF-κB levels would result in reduced cytokine production. 
 CDK9 knockdown using the splice-blocking morpholino a resulted in a slower 
initial recruitment of macrophages to the wound site, compared to the control groups 
and previously published macrophage recruitment data (127).  This might be due to 
the fact that CDK9 is involved in transcription of macrophage-attracting inflammatory 
mediators (105).  However, by 24 h post-injury, the number of macrophages is not 
significantly different between the CDK9 splice-blocking morpholino- and control 
sequence-injected groups, although there is a non-significant trend of increased 
numbers in the CDK9 splice-blocking morpholino group which may even increase 
further at later time points, and this will be investigated in a future study.  This 
observation could perhaps be attributed to increased apoptosis of the neutrophils, 
resulting in release of factors to attract macrophages (221).  However, previous work 
in LPS-induced lung inflammation in mice has shown that CDKi treatment drives 
macrophages to take up more apoptotic neutrophils rather than there being an increased 
recruitment of macrophages (38).  It is important from a therapeutic point of view that 
targeting CDK9 drives neutrophil apoptosis but does not detrimentally affect 
macrophages during the resolution phase.  This is because macrophages are required 
for effective clearance of apoptotic neutrophils.  As well as the ‘M1’ pro-inflammatory 
phenotype, ‘M2’ pro-healing macrophages are important in clearance during 
resolution.  A way to demonstrate the role of macrophages here would be use of the 
irf8-/- knockout line which lack embryonic macrophages, and test whether this leads to 
persistence of neutrophilic inflammation (222). 
The CRISPR/cas9 mutants were initially made in the Tg(mpx:EGFP)i114 line, 
to examine the effect of CDK9 mutation on neutrophils, since it was hypothesised that 
neutrophils are sensitive to CDK9 inhibition.  A source of further study will be to cross 
the CDK9 CRISPR/cas9 mutants to the macrophage-labelled Tg(MPEG1:mCherry) 
line, to see if there is also a similar initial delay in macrophage recruitment in the 
mutants which becomes similar to baseline by 24 h, as seen with the morphants.  Time-
lapse confocal microscopy may reveal if there is a link between apoptosis and the delay 
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in macrophage recruitment.  In human in vitro studies, CDK inhibitor drugs do not 
drive apoptosis of monocyte-derived macrophages, but the percentage of macrophages 
which have ingested apoptotic bodies is increased (38).  It seems that macrophages are 
able to phagocytose the increased numbers of apoptotic neutrophils present in these 
settings.   
In the future, a CDK9 over-expressing fish could be generated using Tol2 
transgenesis, by driving CDK9 expression under control of neutrophil-specific 
promoter such as myeloperoxidase.  This might be an insightful addition to the 
repertoire, to examine the role of CDK9 in neutrophils in vivo but in the opposite 
manner to knocking CDK9 out.  This would avoid the side-effects of CDK9 global 
knockout, which might be detrimental to other tissues; for example it is known that 
CDK9 is highly expressed in mammalian lung tissue (223).  Although all the roles of 
CDK9 in zebrafish tissue are unclear, it has been shown to be involved in erythroid 
development and cardiomyocyte proliferation, by use of morpholino knockdown of 
CDK9 (224).  Even though it is mainly described as a transcriptional regulator, CDK9 
has also been thought to play a role in the cell cycle with roles in G1 and M phase in 
Drosophila melanogaster, which may also help to explain why it appears necessary 
for development (225).  
As well as the in vivo studies, the genetic targeting of CDK9 also allows for 
potentially useful ex vivo cell studies.  The effect of the CDK9 knockout/knockdown 
on neutrophil characteristics would be interesting to assess in future studies; for 
example: do neutrophils isolated (using FACS) from CDK9 knockout animals still 
migrate, and respond to fMLF stimulation by undergoing shape change, as observed 
in sorted neutrophils in Chapter 1 (Fig. 3.8)? 
 Along with CDK9, another important part of the P-TEFb complex is CDK7, 
which forms part of the TFIIH to helps initiate RNA pol II phosphorylation (226).  For 
this reason, it was also a target of interest in this study.  Knockdown of CDK7 with 
splice-blocking morpholinos did not affect neutrophils or macrophages during tailfin 
inflammation at any time point (Fig. 5.10), despite successful partial knockdown while 
maintaining healthy morphology of the animals.  There could be a several reasons for 
this; the morpholino used was a splice-blocking morpholino, which typically causes a 
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less severe knockdown than ATG (translation-blocking) morpholinos, as ATG 
morpholinos bind to the transcriptional start codon.  Indeed, full CDK7 knockdown 
was not achieved using splice-block morpholinos in these studies.  Due to the toxicity 
of the CDK9 ATG morpholino, a CDK7 ATG morpholino was not tested here, as it 
was hypothesised that CDK7 would similarly be hard to fully knockdown due to its 
role in transcription (226).  Perhaps, therefore, CDK7 does not play a role in 
transcription in zebrafish; very few studies have investigated CDK7 itself in zebrafish, 
however it is known that cyclin H, the binding partner to CDK7, is necessary for 
development.  This was shown in a study in which a dominant negative form of cyclin 
H was expressed in zebrafish (205).  Cyclin H and CDK7 are expressed throughout 
development in zebrafish in tissues such as the brain and liver, shown by in situ 
hybridisation. However, no link has been shown between CDK7 and haematopoiesis 
in any model (mammalian or fish).  To answer questions about the importance of 
CDK7 in this system, a future study could use the CRISPR/cas9 system to generate a 
CDK7 mutant, as opposed to the morpholino strategy of causing transient, partial 
knockdown.   
 It was also hypothesised that CDK7 might work in conjunction with CDK9, 
and that any loss of CDK7 would be masked by compensation by CDK9.  To test this, 
the CDK7 and CDK9 splice-blocking morpholinos were co-injected to investigate if 
the CDK7 morpholino would enhance the effect of the CDK9 morpholino (i.e., did 
CDK7 require the synergistic effect of reduced CDK9 in order to affect neutrophil 
apoptosis?).  However, the co-injection of these morpholinos had no effect on the post-
wounding neutrophil response, compared to control (Fig. 5.12).  This could be 
attributed to the difficulties in establishing the proper concentrations to use.  When 
both are co-injected at the same concentration as the single injection concentration, 
there are off-target toxicity effects which are typical when excess morpholino is 
injected, resulting in death or altered body morphology (227).  Hence lower amounts 
of both morpholinos (compared to the single injection experiments) were injected to 
find concentrations in which the embryo had normal body morphology.  These 
concentrations may not be high enough to cause a noticeable phenotype on the 
zebrafish neutrophils; for example, in this study, there were around 20 neutrophils in 
the CDK9 + CDK7 morpholino group (Fig 5.12) but in the group treated with only a 
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splice-blocking CDK9 morpholino (at a higher concentration), there are much less 
neutrophils (around 10 cells, Fig 5.2).  In addition, the two morpholino sequences may 
be interacting with each other to reduce efficacy.  In the future, the CDK7 morpholino 
could be injected into the CDK9 CRISPR mutants to try and circumvent these 
problems.  In these studies the neutrophil recruitment in these batch of embryos was 
on average slightly higher than normal, strengthening the argument to define a 
“minimum-maximum” neutrophil response criteria to exclude low/high responders. 
In order to further investigate the importance of the P-TEFb complex, the P-
TEFb inhibitor LaRP7 was targeted using splice-blocking morpholinos.  LaRP7 has 
been shown in human cells to act as a negative regulator of P-TEFb (210), and is part 
of the 7SK transcriptionally inactive complex form of P-TEFb.  Driving enhanced 
LaRP7 expression is a potentially good therapeutic strategy as it is a specific 
endogenous regulator of P-TEFb.  Indeed, Larp7 and the 7SK snRNP had anti-tumor 
functions in some kinds of cells, including Drosophila hematopoietic cell lineages 
(228).  LaRP7 has been found in zebrafish and its knockdown destabilises the 7SK 
complex, indicating it works in the same way in fish as mammals (229).  Knockdown 
of LaRP7 has been shown to oppose knockdown of CDK9 in a zebrafish morpholino 
study, resulting in cardiomyocyte proliferation after laser injury of the heart (117).  
Knockdown of LaRP7 using splice-blocking morpholinos induced significant 
developmental defects in the fish in the study by Barboric et al, however the amount 
of morpholino injected in their study was 3 times higher than in this study (229).  
LaRP7 increased neutrophilic inflammation above the baseline level at 24 hpi 
(Fig. 5.13), having reduced the function of this negative regulator.  Although with still 
elevated numbers in the LaRP7 group the difference was not statistically significant at 
4 h and 8 h, possibly due to the increasing importance of CDK9 during resolution 
phase.  The effect of LaRP7 knockdown on macrophages is still to be assessed – does 
more neutrophils result in higher macrophage recruitment?  The amount of LaRP7 
morpholino injected here was optimised so the effects of knockdown can be assessed 
without affecting the morphology of the fish.  Partial LaRP7 knockdown was achieved 
using the morpholino, and this had the effect of increasing the inflammatory response 
higher than baseline (Fig. 5.13). 
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Inhibiting LaRP7 restored a normal neutrophil phenotype to the CDK9 splice-
block morphants, as there was no difference in neutrophils in fish with co-injected 
LaRP7 and CDK9 morpholinos and those injected with controls; however, fish 
injected with only the splice-blocking LaRP7 morpholino (plus control sequence) had 
more neutrophils than fish injected with only the splice-blocking CDK9 morpholino 
(plus control sequence, Fig. 5.14).  The difference between the LaRP7 and CDK9 
single knockdown groups was not as substantial as in previous experiments (Fig 5.2, 
5.13).  This was likely to be because less morpholino of each type was injected in the 
co-injection experiments (due to toxicity issues), and knockdown of both genes was 
probably reduced; similar to the CDK9/CDK7 co-injection study. In the future it might 
be more useful to employ ATG translation-block morpholinos for these experiments, 
which are known to cause more effective knockdown.  Further work will examine if 
LaRP7 knockdown can enhance the expression of CDK9. 
The same strategy was employed with AT7519 used to target CDK9 instead of 
the morpholino, in LaRP7 knockdown or control embryos.  Embryos with the LaRP7 
knockdown (showing enhanced neutrophil numbers) were then treated with AT7519 
at 4 h post-transection, and had similar neutrophil numbers at 24 post-wounding 
compared to control animals (mismatch sequence + DMSO, Fig. 5.15).  However, the 
animals with a mismatch control sequence that were injected with AT7519 had 
reduced neutrophils at 24 h compared to the other groups.  At 4 h post-transection, 
immediately prior to treatment with AT7519, the LaRP7 splice-block treated group 
had an increased number of neutrophils compared to the mismatch sequence-injected 
groups, as would be predicted from the ability of LaRP7 knockdown to increase 
neutrophils numbers.  AT7519 addition returns the enhanced neutrophil numbers in 
the LaRP7 splice morpholino group to the same as the control group.  This sharp 
decrease indicates that the LaRP7 morpholino group are especially sensitive to the 
effect of AT7519.  Over-expression of LaRP7, by addition of a similar small molecule 
or another means of promoting its expression, might be a good future therapy to target 
CDK9 activity.  It would be a useful study to create a LaRP7 CRISPR/cas9 mutant to 
examine its phenotype in comparison to the CDK9 mutant. 
 P-TEFb activity results in transcription of the anti-apoptotic protein Mcl-1 in 
neutrophils. It is known in zebrafish that both Mcl-1 isoforms must be knocked down 
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to affect fish survival (39).  However, targeting Mcl-1a or Mcl-1b with ATG 
morpholinos had no effect on neutrophil numbers following wounding.  This perhaps 
is due to the fact that Mcl-1 is a short lived protein with high turnover in neutrophils, 
and perhaps more is transcribed quite quickly after the morpholino begins to wear off 
(230).  The fact that only partial knockdown was obtained indicates that even more 
morpholino should be injected in the future in the single knockdown embryos.  In 
addition, in the embryos used in the Mcl-1a knockdown experiment, the recruited 
neutrophils was higher than normal and increased towards 24 hpi; even in the control 
group.  This perhaps indicates the batch of fish used doing these studies had an aberrant 
response, validating a future need for defining a ‘maximum’ response. 
Previous work using zebrafish survival as a readout showed that knockdown 
of both Mcl-1a and Mcl-1b is necessary for a phenotype to be seen; and this was the 
case here too.  Single morpholinos can be injected at the highest possible concentration 
(9.2 ng per 1 nL), whereas in co-injected fish, death of eggs was seen when higher 
amounts than 4.6 ng was injected.   
One way to examine the role of Mcl-1 in zebrafish neutrophils would be to 
image the eggs more closely in the first two days after morpholino injection, to 
examine the rate of neutrophil development.  Perhaps other survival proteins are being 
transcribed as a result of the P-TEFb pathway, with Mcl-1 not being so crucial in 
zebrafish neutrophils compared to mammalian neutrophils.  Zebrafish are known to 
possess the full range of Bcl-2 family members described in mammals, and perhaps 
one of these can compensate for loss of Mcl-1 in neutrophils (39).  This could be 
studied by performing qPCR on isolated cells from CDK9 knockdown embryos to 
assess the levels of mRNA of other Bcl-2 family members (e.g. Bcl-2).  Any family 
members which appear to have altered expression after CDK9 knockdown/knockout, 
or knockdown of the P-TEFb inhibitor LaRP7, could then be directly targeted and the 
effect on neutrophil survival assessed.  The role of Mcl-1 will be investigated further 
now an Mcl-1a mutant has recently been obtained from the Wellcome Trust Sanger 
Institute Zebrafish Mutation Project (231), and an Mcl-1b mutant may well be 
discovered in the future or otherwise could be created in the laboratory.   
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 In addition to this, the role of Mcl-1 is beginning to be further probed; during 
the study Mcl-1a/Mcl-1b over-expressing plasmids were created using Tol2 gateway 
cloning, and have been successfully sequenced. Plasmids containing the Mcl-1a and 
Mcl-1b sequence were obtained from Prof. Stephen Renshaw, University of Sheffield.   
They have been found to be integrated into the genome upon microinjection into single 
cell embryos.  The plasmids were designed with the cardiac myosin light chain 2 
(cmlc2)-GFP gene incorporated so successful plasmid integration can be assessed by 
screening for embryos with green fluorescent cardiac myosin cells (Fig. 5.18).  The 
over-expression is driven by the Lysozyme C promoter so therefore should be mainly 
neutrophil-specific (232).  The plasmid was microinjected and the embryos screened 
at 3 dpf.  Those which possess a green heart were selected and are being raised for 
future studies. 
This new line will allow an assessment of how increased Mcl-1 affects 
neutrophil and macrophage recruitment after wounding, as theoretically apoptosis 
should be decreased in these animals.  One immediate study in the laboratory is to 
finish screening Mcl-1 over-expressing founders and breed them with 
Tg(mpx:EGFP)i114 embryos so they can be used in the tailfin transection assay, with 
the opposite hypothesis to the knockdown experiments: over-expression of Mcl-1 









Genetic manipulations in zebrafish allows specific targeting but can also 
present a different set of problems, in particular due to the side-effects of manipulating 
genes in an entire animal.  For now, tissue-specific knockout does not exist in 
zebrafish, due to the lack of identified stem cells; some groups have claimed to have 
identify these in zebrafish but these findings are still unclear (155).  Recent work has 
utilised Tol2 gateway cloning to specifically target CRISPR/cas9 to particular cells, in 
this case the urod heme biosynthesis gene in red blood cells (by using plasmids 
targeting the gata1 gene) (161).  However, not all cells are affected, as this system 
causes different mutations in each individual cell, and several might be silent rather 
than frameshift mutations. 
Figure 5.18.  Generation of Mcl-1 over-expressing zebrafish 
Plasmids containing sequences for Lysozyme C, Mcl-1a:cmlc2:EGFP and a polyA 
3e entry clone, which were recombined into a single plasmid [i].  This was carried 
out for Mcl-1b too.  
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 Taken together, these studies show the importance of CDK9 in resolution of 
inflammation in vivo.  This was shown from both splice morpholino and CRISPR/cas9 
mutant data.  In the mutants but not the morphants, total neutrophils are unaffected.  
The role of CDK7 and Mcl-1 (using morpholinos) in this system are currently less 
clear, but can be a source of future studies.  Knocking down LaRP7 has the opposite 
effect to knocking down CDK9, due to its role as negative regulator of P-TEFb, a role 
which it also seems to perform in zebrafish.  AT7519 treatment reduces the enhanced 








In this study, an in vivo zebrafish injury model was established with which to further 
probe the role of genes of interest in neutrophil apoptosis.  Pharmacological CDKi 
agents known to drive neutrophil apoptosis in vitro in human neutrophils, and in mouse 
inflammatory models, were investigated and some were found to have a similar effect 
in vivo in zebrafish (AT7519, wogonin, FVP) (38, 68, 70, 72) (Fig. 4.2, 4.8, 4.9).  From 
this, it was hypothesised that molecules shown to be important in neutrophil apoptosis 
in vitro (CDK9, CDK7, Mcl-1) might be important in vivo and the zebrafish was an 
ideal model with which to interrogate this possibility (115).  The role of some of these 
genes, investigated in previous studies and this current study, are shown 
diagrammatically (Fig. 6.1).  Overall, the study showed that targeting CDK9 enhanced 
the resolution of neutrophilic inflammation in vivo in the zebrafish (Fig. 5.2, 5.8), 
shown by genetic manipulation using morpholinos and CRISPR/cas9.  Knocking down 
LaRP7, the negative P-TEFb regulator, had the opposite effect and increased 
inflammation post-wounding (Fig. 5.10), and could even reverse the neutrophil-
reducing effect of the CDK9 morpholino post-tailfin transection (Fig. 5.11).  The effect 
of LaRP7 knockdown could be overcome by addition of the CDKi AT7519 at 4 hpi 
(Fig. 5.12).  The role of CDK7 and Mcl-1 in this model was still unclear  at the end of 

















Figure 6.1.  The role of P-TEFb transcription complex in human, mouse and 
zebrafish inflammation and apoptosis. 
Schematic of the P-TEFb transcription pathway.  Green boxes depict important 
proteins and whether or not their role in neutrophil apoptosis has been confirmed in 
vivo in human neutrophil studies, ex vivo in mouse neutrophils, and in vivo in zebrafish. 
‘?’ indicates that the role of this gene in this particular model is still unclear.  
 
 
6.1. CDK9 as a therapeutic target in inflammatory diseases 
In acute inflammatory diseases (e.g. acute lung injury [ALI]), where neutrophilic 
inflammation is an important part of the disease pathology, a sensible strategy would 
be to induce neutrophil apoptosis.  This would reduce numbers of neutrophils 
producing pro-inflammatory factors.  In addition, uptake of apoptotic neutrophils 
exerts an anti-inflammatory phenotype on macrophages, driving them to produce pro-
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resolution cytokines such as IL-10 (45, 212).   Targeting CDK9 and associated family 
members could potentially prove to be a good target for inflammatory diseases, 
particularly those dominated by neutrophils.  P-TEFB is a universal transcription factor 
required for transcription of many genes (223).  Hence, targeting its activity (via 
inhibition of CDK9) would seem like a non-specific therapeutic target.  However, 
CDK9 is expressed most highly in terminally differentiated tissues, suggesting it 
carries out specialised cellular roles (233).  In addition, if there is a redundancy in the 
role of CDK9 in transcribing other genes, it might be possible to target it for particular 
functions (e.g. driving apoptosis) without affecting other cellular functions to a great 
extent.  CDK9 inhibition would be a good strategy for treatment of acute neutrophilic 
inflammatory disease, or for use in chronic situations in which neutrophils contribute 
to disease ‘flares’.  An understanding of the entire P-TEFb complex may well reveal 
other therapeutic targets; for example, LaRP7 is an endogenous inhibitor of the P-
TEFb complex which may increase resolution of inflammation (99, 210).  Perhaps 
enhancement of the actions of LaRP7 could be a therapeutic strategy for the future; by 
administration of LaRP7 or a synthetic small molecule with a similar mode of action. 
In addition to this study, existing data indicate that CDKi drugs might be an 
effective strategy for inducing neutrophil apoptosis.  In many mouse models of 
inflammation in different tissues, CDKi drugs have been shown to induce neutrophil 
apoptosis (38, 68).  In diseases such as acute lung injury, patients usually present when 
inflammation is at its peak.  This means that targeting neutrophil migration alone may 
not be a successful strategy; possible therapeutics should target neutrophils that are 
already there (and also perhaps enhance reverse migration).  In the drug treatment 
tailfin injury experiments, this scenario was mirrored by administration of CDKi drugs 
at 4 h post-transection; the peak of neutrophilic inflammation in zebrafish (9).   
 
6.2. Zebrafish as a model for inflammatory diseases 
Zebrafish are a good model for investigating many aspects of neutrophil biology (115, 
234).  The ease of imaging of neutrophil behaviour is unprecedented in any other 
animal model.  The injury model selected here proved to be a robust assay for 
measuring neutrophil inflammation, which occurs rapidly similar to mammalian 
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inflammation.  Aside from this, the neutrophils themselves appear to share 
characteristics with mammalian cells.  Sections of the haematopoietic site (the kidney) 
in adult fish reveal cells bearing hallmarks of neutrophils (multi-lobed nuclei) and 
macrophages (phagosomes in cytoplasm) (125).  Coupled with the transparency of the 
embryo, they are an ideal model to image the real time behaviours of neutrophil and 
macrophages in vivo.  Some disadvantages are that these are embryonic animals, and 
therefore these cells might not be fully developed.  Presumably the environment of 
haematopoietic development in the kidney in the adult differs from that of the embryo, 
which has a pronephros embryonic kidney at these early stages. (235).  The high degree 
of conservation in cells (for example the response to fMLF, shown in Fig. 3.8) 
indicates that many of the lessons learned in zebrafish can be applicable to mammalian 
models.  Additionally, many genes such as CDK9 have high levels of conservation 
(Introduction, Table 1.2). 
 One drawback to this model is that mouse models can give information about 
the impact on individual organs compared to the embryo of the zebrafish, which has 
some still undeveloped organs (e.g. the kidney).  In a lung inflammation experiment 
in mice, lung tissue, BAL, blood and lymphoid tissue such as the spleen can all be 
harvested for the measurement of parameters such as cell numbers and histological 
sections for analysis of tissue structure (38).  This allows the effect of pharmacological 
treatments on these many different tissues to be assessed.  However, in rodent systems 
the subtle cell-cell interactions are difficult to image in vivo, and simple genetic 
manipulations are not possible.   
Like zebrafish, using primary isolated human neutrophils is a relatively simple 
and quick way to assess the effect of pharmacological manipulations on neutrophils 
directly (1).  However, the short-lived nature of neutrophils is not amenable to genetic 
manipulation; they die within 24 h in culture.  Hence, using both human, rodent and 
zebrafish models concurrently can give complementary data that can inform future 
experiments, as we have previously demonstrated using the compound wogonin, 
which proved to be effective in reducing mouse lung inflammation following initial 
trials in isolated human neutrophils and zebrafish (72) (38). 
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 One issue, common to all transgenic lines in all models, is the specificity of 
cell labelling.  Traditionally myeloperoxidase (labelled in Tg[mpx:EGFP]i114 
zebrafish) is thought to be specific to neutrophils; however, it has been shown that 
macrophages in atheroma appear to express myeloperoxidase (236). In the 
MPEG1:mCherry line, perforin-2 expression labels macrophages (237), however, 
perforin-2 expression has been shown to be inducible in other cells such as fibroblasts 
(238).  It is likely that there exists no perfect marker for individual cell types. 
 
6.3. Pharmacological versus genetic approaches to investigate the role 
of CDK9 and P-TEFb in inflammation 
In these studies, pharmacological and genetic approaches were used to target the same 
pathways.  Some parallels could be drawn between the phenotype of the fish injected 
with the CDKi compounds, and the morpholino-injected fish (Chapter 4 and 5 data).  
Both manipulations reduced neutrophil numbers by increasing apoptosis, indicating 
the importance of CDK9 in neutrophil apoptotic pathways.  There are important 
differences, in that the CDK9 morpholino is present from the 1-cell stage of the 
embryo.  The drug and morpholino experiments are therefore not directly comparable, 
as the morpholino/CRISPR targeting is present from the beginning of development, 
whereas the drug treatments are present from the peak of inflammation (after tailfin 
transection).  However, AT7519 pre-treatment prior to transection could also affect 
recruitment to the wound site.  Whether this is down to effects on neutrophil apoptosis 
or migration is still unclear.  This experiment was only carried out to 4 h post-
transection, but it would be interesting to image these fish for longer and determine 
whether AT7519 pre-treatment results in a similar phenotype to the CDK9 knockdown 
animals. 
One possible direction for the future is to examine CDK9 knockout from 3 dpf 
(the time of transection) would be the creation of a conditional knockout mutant, for 
example using a Cre Lox system (239).  This could help to overcome issues of 
embryonic lethality, such as the phenotype of the homozygote embryos. 
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Despite the fact that the genetic manipulations can have off-target effects, this 
is also true of treatments with drugs and other compounds, and for drug usage in 
humans, a full understanding of the side effects is important.  CDK inhibitor drugs 
generally target a range of CDKs in a variety of different potencies.  Future therapies 
would hopefully target CDK9 active sites more specifically, which is made more 
possible with the development of small molecule inhibitors.  It should be noted that 
morpholinos can also result in off-target effects; for example, by non-specific binding 
to other sequences.  Hence, it is considered important to assess genetic manipulation 
via a second method. 
Small molecule inhibitors of Mcl-1 itself have been challenging to create due 
to the need to disrupt high affinity bonds in Mcl-1, however these inhibitors are 
beginning to emerge (240).  Hence, upstream molecules such as P-TEFb have 
generally been targeted in order to target Mcl-1 (241).  Mcl-1 knockout mice are 
embryonically unviable (207).  In this way, the use of the zebrafish might be a good 
strategy for investigating Mcl-1, as there exist two isoforms of Mcl-1 in zebrafish, and 
individual isoforms can be targeted (39). 
The effect of CDK9 inhibition on neutrophil migration will be examined in the 
future, by measuring parameters such as the production of pro-inflammatory 
chemotactic agents at the tailfin post-injury (147).  Alternatively, fluorescence 
activated cell sorting could be used to sort neutrophils from CDK9 
knockout/knockdown zebrafish, then stimulating them ex vivo with a substance such 
as fMLF, to see if they respond, for example, by alteration in their forward scatter by 
flow cytometry measurement (see Chapter 3, Fig. 3.8).  Alternatively, the effect of this 
stimulation could be measured ex vivo by imaging cell morphology and migration. 
 Taken together, the pharmacological studies allow the assessment of the effects 
of compounds on cell populations of interest in the zebrafish.  The genetic studies here 
give insight in the role of specifically CDK9 and other genes in a way which 





6.4. CDK9 in other model systems 
In the future it will be interesting to examine the role of CDK9 in other inflammation 
models apart from the wounding model used in the thesis, to ensure the pro-resolution 
role of CDK9 occurs in other examples of inflammation.  For example, an 
investigation of the phenotype of CDK9 knockdown/knockout zebrafish upon 
response to infection would be an interesting experiment.  Targeting CDK9 in mice 
pharmacologically has been shown to have beneficial effects on bacterial clearance in 
the lung, and even resulted in a reduced bacterial load, even with the effect on driving 
neutrophil apoptosis (38). This could be possibly due to increased phagocytosis of 
bacteria by macrophages, which may be enhanced by increased apoptotic neutrophil 
numbers.  This hypothesis could be carefully examined in fish, using fluorescently-
labelled bacteria in Tg(mpx:EGFP)i114 and Tg(MPEG1:mCherry), allowing real-time 
imaging of what happens to the bacteria after CDK inhibitor treatment.  Several 
infection models have been established in zebrafish, such as E. Coli and M. Marinum 
infection (137, 242).  In addition to this, different methods of injuries could be used; 
for example, cryoinjury can be used to induce tissue damage (243).  This injury is not 
localised like tailfin injury, so would be a system for examination of the role of CDK9 
in a more diffuse injury. 
 
6.5. Does targeting CDK9 affect reverse migration of neutrophils? 
Neutrophil reverse migration is an umbrella term to describe the migration of 
neutrophils away from an inflammatory site, but sometimes also migration across the 
endothelium in the bloodstream, and sometimes appearing at a site remote from the 
original inflammatory site (29).  This was first reported by Brown et al in 2007.  The 
contribution of reverse migration to mammalian resolution remains unclear.  It is 
thought that the majority of neutrophils will undergo apoptosis at the site of 
inflammation.  However, studies in vitro and in mouse intravital imaging wound 
models have demonstrated that transendothelial migration of neutrophils can occur 
(27, 244), with around 10% of neutrophils shown to do this.  The function of this is 
still unknown but may influence the adaptive immune response in lymphatic sites 
remote from the original inflammation site.  Reverse transmigrated neutrophils may 
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also contribute to inflammation in organs separate from the inflammatory site.  Some 
of the mechanisms of this are being delineated; for example, LTB4 is thought to 
mediate the ability of neutrophils to reverse transmigrate, via stimulation of neutrophil 
elastase which cleaves JAM-C adhesion molecules (28).  
Investigation of neutrophil reverse migration can be performed effectively in 
zebrafish, using the mpx:kaede transgenic line (115, 122).  In this line, EGFP+ 
neutrophils can be photoconverted to RFP+ neutrophils.  Hence, EGFP+ neutrophils at 
the wound at the peak of inflammation (4 h) can be photoconverted, and then the RFP+ 
neutrophils can be tracked – as RFP+ neutrophils not present at the wound anymore 
must have reverse migrated.  A recent study used this system to examine the phenotype 
of reverse migrated neutrophils (245).  This revealed that reverse-migrated neutrophils 
had less spherical, more ‘activated’ morphologies, and mount normal responses to 
secondary insults.   
Interestingly, a recent zebrafish study showed that reverse migration of 
neutrophils can be pharmacologically enhanced by the compound Tanshinone IIA. 
(122).  Tanshinone IIA is an anti-inflammatory compound derived from a Chinese 
medicinal herb.  It also has pro-apoptotic effects on neutrophils.  This suggests that a 
good pharmacological strategy would be one that targets both apoptosis and reverse 
migration.  In this study, a further step will be to investigate the effect of the CDKi 
drugs and genetic targeting of CDKs on parameters such as reverse migration.  It 
would also be interesting to assess what happens to the excess neutrophils in the LaRP7 
morpholino-injected animals- do they undergo enhanced reverse migration? 
 
6.6. Does targeting CDK9 affect regeneration of the tailfin? 
The zebrafish has become a popular model to investigate tissue regeneration, due to 
its ability to regenerate a large range of tissues such as the heart and spinal cord after 
lesioning; which does not occur in mammals (246).  Similarly, the tailfin is able to 
grow back following transection.  In tailfin injury models, new genes important in 
regeneration have been identified, such as fibroblast growth factor 20 (fgf20).  Due to 
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the role of CDK9 in transcription, it would be interesting to assess how targeting 
CDK9 using morpholinos or pharmacological agents will affect the ability of tissues 
to regenerate after tailfin transection.  An adverse effect on regeneration/healing would 
affect the possible therapeutic usage of the drug.  It was shown that macrophages are 
key to tailfin regeneration (138, 139), and as the CDK9 manipulations do not affect 
macrophages, it is hypothesised the manipulations would not affect regeneration.  It 
was even shown that removing neutrophils could accelerate tailfin regeneration (247)  
Hence, enhancing the resolution of inflammation using CDK inhibition may also affect 
tissue regeneration. 
 
6.7. Ablating cell populations of interest 
A powerful strategy to investigate cellular roles in the resolution of inflammation is to 
ablate specific cell populations, as described above in the regeneration studies (247).  
A future direction of this project could be to examine the effects of macrophage 
ablation on the resolution of inflammation after CDK inhibitor drug treatment or 
CDK9 knockdown.  This would reveal the contribution of macrophages to resolving 
inflammation in this model.  A number of questions arise including: i) does 
neutrophilic inflammation resolve differently without the presence of macrophages to 
clear apoptotic debris, especially when an external apoptosis-driving drug is added?  
Or ii) would other mechanisms such as reverse migration be able to compensate for 
this? 
Knockouts of specific cells can be made on the basis of driving deletion of 
particular promoters.  A macrophage deficient fish has been made by mutating the 
interferon regulatory factor 8 (irf8) (248).  Irf8 was shown to regulate macrophage 
development (222).  These fish later develop macrophages at later stages, suggesting 
irf8 only plays a role in primitive macrophage formation.  These animals could be used 
to assess the contribution of macrophage phagocytosis to the resolution of 
inflammation induced by targeting CDK9. 
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One approach to target specific cells can be made by linking cell-specific 
promoters to the nitroreductase gene (nfsB) (166).  The pro-drug metronidazole is 
converted to a cytotoxic drug upon nitroreductase expression.  Addition of 
metronidazole to fish expressing LysC (labelling mainly neutrophils) or fms (labelling 
mainly macrophages) together with nfsB results in a good ablation of neutrophils and 
macrophages, respectively (138).  The advantage of this is that the cell populations are 
not absent from the beginning of development, and therefore any unforeseen 
consequences on development can be avoided.  However, these strategies rely on 
addition of a drug, which may in itself be having other side effects; and the drug may 
not fully reach the areas which require depletion (166).  Some cells require longer 
incubations to be depleted than others.  These animals were used to show the 
Straphylococcus aureus is likely to use neutrophils as a pathogen reservoir (249). 
 Another clever strategy to affect neutrophils previously used was the creation 
of CXCR4 mutants, which results in a retention of neutrophils in the haematopoietic 
site.  This is true in both mammals and zebrafish (250).  Knocking down stromal cell-
derived factor 1 (SDF1) could reverse this phenotype in fish, suggesting that SDF1 
was responsible for this retention.  This is the mutation present in the 
immunodeficiency syndrome WHIM (warts, hypogammaglobulinemia, infections and 
myelokathexis).  This mutation in zebrafish provides a way to examine ‘neutropenia’ 
and hence macrophage behaviour without the presence of neutrophils; however of 
course there is a defect in an important chemokine receptor in this system. 
 
6.8. Conclusions 
The zebrafish is a powerful model system, used here to examine the role of CDKs and 
neutrophil apoptosis in resolution of inflammation.  Drugs that inhibit CDK9 may 
prove to be a good strategy to dampen down the inflammatory response.  Evidence 
from mouse models supports this hypothesis, and the ability of CDK9-targeting drugs 
was shown here to have a neutrophil-reducing effect in vivo in the zebrafish.  The 
genetic evidence presented in this study allows us to pinpoint exactly which genes are 
involved in this, giving justification for more specific targeting of CDK9 in the future.  
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The synthesis of new small molecules allows the creation of more selective inhibitors, 
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8. Appendix A 
 
8.1. General materials 
 Petri Dishes – Corning 60mm x 15mm (Corning) or 100mm x 15mm tissue 
culture treated, polystyrene cell culture dish (Thermo Scientific) 
 Plastic Pasteur pastettes (Scientific Labs) 
 Tricaine Solution (see Appendix B) 
 Methylene Blue Solution (see Appendix B) 
 Embryo Medium Solution (see Appendix B) 
 System Water (see Appendix B) 
 0.5mL, 1mL, 2mL Microcentrifuge Tubes (Eppendorf) 
 Falcon 15mL and 50mL Conical Centrifuge Tubes (Bectin Dickinson) 
 0.2mL 8-strip PCR Tubes and Caps (Starlab Group) 
 UltraPureTM Agarose (Life Technologies) 
 Ethanol (Molecular Biology Grade, Sigma Aldrich) 
 Glycerol solution (Sigma Aldrich) 
 Tris-Buffered Saline (TBS, see Appendix B) 
 Tris-Buffered Saline-Tween (TBS, see Appendix B) 
 Mastercycler PCR machine (Eppendorf) 
 Horizontal DNA Gel Apparatus (BioRad) 
 Nanodrop machine (to assess DNA concentration) 
 












8.3. Zebrafish husbandry and breeding 
 Pair-mating boxes 
 Sieves 
 28°C Incubator 
 
8.4. Zebrafish tailfin injury 
 Sterile Scalpel #23 (Swann Morton)  
 19 G Needle (Bectin Dickinson Microlance)  
 48 well cell culture flat-bottomed plate (Costar) 
 
8.5. Imaging, measuring and analysis of inflammation 
 LabTekII 8 chambered #1.5 cover glass slide (Nunc) 
 Leica MZ16F dissecting scope with Green Fluorescent Protein (Ex. 488) and 
Texas Red (Ex. 596) filters 
 Leica DFC300 FX Digital Colour Camera 
 Leica sp5 Confocal Microscope 
 Zeiss LSM 510 Meta Microscope 
 
8.6. Digestion of whole embryos and isolation of neutrophils by FACS 
 40μM Nylon Cell Strainer (Corning) 
 Trypsin/EDTA 
 Rosewell Park Memorial Institute (RPMI) 1640 Medium (Gibco) 
 Foetal Bovine Serum (Sigma Aldrich) 
 FACS Aria II Cell Sorter (Bectin Dickinson) 
 
8.7. Stimluation of FACS-isolated EGFP+ cells using N-formyl-Met-Leu-Phe 
(fMLF) 
 N-Formyl-Met-Leu-Phe (fMLF) 
 Phosphate-Buffered Saline (PBS) containing Ca2+ and Mg2+ (Gibco) 
 Phosphate-Buffered Saline (PBS) without Ca2+ and Mg2+ (Gibco) 
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 LSR Fortessa Flow Cytometer (Bectin Dickinson) 
 
8.8. Drug treatment of zebrafish embryos 
 
Table A.1. Compound Manufacturers 
Drug Manufacturer 
AT7519 Astex Therapeutics 
Wogonin Sigma Aldrich 
Luteolin Sigma Aldrich 
Apigenin Sigma Aldrich 
FVP Sigma Aldrich 
SNS-032 Selleckchem 
zVAD-fmk Tocris Bioscience 
QVD-OPh R & D 
 
8.9. Incubation of zebrafish embryos with compounds 
 48 well cell culture flat-bottomed plate (Costar) 
 Dimethyl Sulfoxide (DMSO, Sigma Aldrich) 
 
8.10. Injection of zebrafish with compounds or morpholinos 
 Microloader Pipette Tips 0.5-20µL (Eppendorf) 
 Microcapillary needles, pulled on a Flaming Brown Needle Puller. Typical 
needle settings: Heat 580, Pull 100, Velocity 55, Time 250.  (TW100F-4 
Borosilicate thin-wall glass capillary, 1mm OD with filament 
microcapillaries). 
 Micromanipulator (Narishige) 
 Microinjecter (Narishige) 
 1mm Stage Micrometer (Pyser SGI) 
 Morpholinos were dissolved in sterile dH20 to 1µM stock then diluted to 
desired concentration in dH20. 
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 All morpholinos (Table 2.3, Methods Chapter 2) were ordered from Gene 
Tools LLC and were designed using the Gene Tools software design tool. 
 
 
8.11. Fixing embryos for staining 
 1.5mL microcentrifuge tube (Eppendorf) 
 Tris Buffered Saline (see Appendix B for recipe) 
 Paraformaldehyde Solution (PFA, 4%, Chem Cruz) 
 Methanol (Fisher Chemicals) 
 
8.12. TSA/TUNEL staining 
 Tyramide Signal Amplication kit (Perkin Elmer), containing Amplification 
Diluent and Fluorescein dye. 
 ApopTag Red In Situ  Apoptosis Detection Kit (Millipore), containing TdT 
enzyme, Reaction Buffer, Stop Buffer, anti-Dig Rhodamine, Blocking 
Solution  
 Proteinase K from Tritirachium album (Sigma Aldrich) 
 Paraformaldehyde Solution (PFA, 4%, Chem Cruz) 
 Fluorescent Microscope (EVOS FL Cell Imaging System) 
 Acetone 
 
8.13. Western blotting  
 Radioimmunoprecipitation Assay (RIPA) buffer (Sigma Aldrich) 
 Protease Inhibitor Cocktail (Sigma Aldrich) 
 Pestle for 1.5mL/2mL microcentrifuge tubes (Eppendorf) 
 SoniPrep 150 Sonicator (MSE) 
 BCA Protein Assay Kit, consisting of Reagent A, Regent B and Protein 
Standards (Thermo Scientific) 
 Synergy HT Plate Reader (BioTek) 
 Sample Buffer (4x, See Appendix B) 
 Bromophenol blue (Sigma Aldrich) 
231 
 
 β-mercaptoethanol (Sigma Aldrich) 
 Novex Tris-Glycine gel (4-12%, Life Technologies) 
 Gel Running and Transfer Tanks (Biorad) 
 Running Buffer (see Appendix B) 
 Methanol (Fisher Chemicals) 
 Transfer Buffer (See Appendix B) 
 Immobilon Polyvinylidene fluoride (PVDF) Transfer Membrane, Pore Size 
45um (Millipore) 
 Dried milk powder (Marvel) 
 Electrochemiluminescence Prime Western Blotting Detection Reagent (GE 
Healthcare), containing Solution A and Solution B. 
 SRX-101A Developer (Konika) 
 Biomax Light Film (Kodak) 
 
Table A.2. Western Blotting Antibodies 
Antibody Company 
CDK9 Santa Cruz Biotechnology 
CDK7 Santa Cruz Biotechnology 
Mcl-1 Santa Cruz Biotechnology 
LaRP7 Sigma Aldrich 
Goat Anti-Rabbit DAKO 
Goat Anti Mouse DAKO 
 
 
8.14. Heritable gene knockdown using CRISPR/cas9 
 Guide Oligonucleotides (Eurofins) 
 Primers (Invitrogen) 
 Ambion MEGAscript T7 kit (containing 10x Reaction Buffer, Enzyme Mix, 
dNTPs, and Turbo DNAse) 
 MEGAclear kit (containing Elution Solution, Binding Solution Concentrate, 
Wash Solution, collection tubes and filters) 
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 Phenol Red solution (Sigma Aldrich) 
 Proteinase K from Tritirachium album (Sigma Aldrich) 
 Tris-Acetate EDTA Buffer (50x, Life Technologies) 
 OneTaq Quick Load Master Mix with Standard Buffer (New England 
Biolabs) 
 Primers (Life Technologies) 
 Hpy188I (New England Biolabs) 
 Hpy99I (New England Biolabs) 
 Cutsmart Buffer (New England Biolabs) 
 SYBR® Safe DNA Gel Stain (Life Technologies) 
 Gene Ruler 100bp plus DNA ladder (Thermo Scientific) 
 
8.15. Creation of Mcl-1 over-expressing zebrafish using Tol2 gateway 
cloning 
 Primers (Life Technologies) 
 OneShot Top10TM chemically competent E. Coli (Life Technologies) 
 S.O.C. medium (Life Technologies) 
 Kanamycin antibiotic (Sigma Aldrich) 
 Lysogeny Broth (LB) medium 
 Glycerol (Sigma) 
 Qiagen Spin-Miniprep Kit (containing Buffer P1, Buffer P2, Buffer N3, 
Buffer PB, Buffer PE, QIAprep spin columns and collecting tubes) 
 Pyrococcus furiosus (PFU) DNA Polymerase (Promega) 
 Loading dye 6x (Thermo Scientific) 
 QIAquick Gel Extraction Kit, containing buffer QG, isopropanol, spin 
columns (Qiagen) 
 BP Clonase II Enzyme Mix (Life Technologies) 
 LR Clonase II Enzyme Mix (Life Technologies) 
 SeqSmart Sequencing kit (Eurofins) 




8.16. Isolating neutrophils from peripheral blood and assessing apoptosis 
after CDKi treatment 
 
 Iscove's Modified Dulbecco's Medium (IMDM)  
 Penicillin / Streptomycin (Thermo Scientific) 
 96-well flat bottomed plate (CoStar) 
 Dulbecco’s Phosphate-Buffered Saline (DPBS) 
 Cytocentrifuge chambers, filter cards, glass slides, and coverslips  
 Diff-Quik™ stains (Thermo Scientific) 
 DPX mounting medium (Sigma Aldrich) 
 Annexin-V conjugated to fluorescein isothiocynate (FITC, Abcam) 
 AnnV binding buffer, - Hanks balanced salt solution (HBSS) with 5mM Ca2+ 
(Stored at 4oC) 





9. Appendix B 
 
9.1. Embryo medium solution 
 1.0 mL Hank's Solution #1  
 0.1 mL Hank's Solution #2  
 1.0 mL Hank's Solution #4  
 1.0 mL Hank's Solution #5  
 1.0 mL fresh Hank's Solution #6  
 95.9 mL ddH20  
 Use about 10 drops 1 M NaOH to pH 7.2  
 
Hank's Solution #1: 8.0 g NaCl, 0.4 g KCl, 100 mL ddH20  
Hank's Solution #2: 0.358 g Na2HPO4 anhydrous, 0.6 g KH2PO4, 100 mL ddH20  
Hank's Solution #4: 0.72 g CaCl2, 50 mL ddH20  
Hank's Solution #5: 1.23 g MgSO4 x7 H2O in 50 mL ddH2O 
Hank's Solution #6: made fresh: 0.35 g NaHCO3, 10 mL ddH20 
 
9.2. Methylene blue solution  
Make Conditioned H20: 0.8 g sodium bicarbonate, 4.5 mL Marine Salts (Tropic 
Marin®), 750 L H20.  Then add 0.6 mL methylthioninium chloride (methylene blue) 
per 10 L of conditioned water (equivalent to 0.5 mg/mL) 
 
9.3. System water solution 
0.03% salt (Tropic Marin®) in dH20 
 
9.4. Danieau’s solution 
58 mM NaCl  
0.7 mM KCl  
0.4 mM MgSO4  
235 
 
0.6 mM Ca(NO3)2  
5.0 mM HEPES 
 
9.5. Tricaine solution 
400 mg Tricaine powder in 97.9 mL embryo medium 
0.26 g Tris in 2.1 mL embryo medium  
Adjust pH to pH 7. 
 
 
9.6. Western Blotting Reagents 
All chemicals below obtained from Sigma Aldrich 
9.6.1. Running buffer 
121 g Tris Base 
238 g HEPES 
10 g SDS 
9.6.2. Transfer buffer (Western blotting) 
 (x10 stock) 
30.3 g Tris Base 
144.12 g Glycine 
Make up to 1l with dH2O (no need to pH) 
 (x1) 
100ml of 10x transfer buffer stock 
200ml methanol 
700ml dH2O 
9.6.3. Tris-buffered saline (pH 7.4) 
 (x10 stock) 
24.22g Tris Base 
 87.66g NaCl 
Dissolve in ~800ml dH2O, pH with HCl (~15.61ml of 11.4M HCl) 




100ml of 10x TBS stock 
899ml dH2O 
1ml Tween-20 
9.6.4. Sample buffer 
4ml 20% SDS 
4ml Glycerol 
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10.2. Conference Contributions 
 
10.2.1. Oral Presentations 
 
 25th UK Adhesion Society meeting, University of Birmingham, 25th November 
2013: Investigating the Role and Function of Cyclin-Dependent Kinases in the 
Resolution of Innate Inflammation in vivo using the Zebrafish Tailfin 
Transection Model. Hoodless LJ, Lucas CD, Duffin R, Haslett C, Tucker CS, 
Rossi AG. 
 
10.2.2. Poster Presentations 
 
 Banff Inflammation Workshop, Calgary, Canada. 30th January – 1st February 
2015: The Role of Cyclin-Dependent Kinase 9 in the Resolution of Innate 
Inflammation in a Zebrafish Model. Hoodless LJ, Lucas CD, Duffin R, Haslett 
C, Tucker CS, Rossi AG. 
 British Society for Immunology Inflammation & Disease Meeting, University 
of Manchester, 9-10th September 2014: Investigating cyclin-dependent kinases 
in the resolution of innate inflammation using zebrafish tailfin injury. Hoodless 
LJ, Lucas CD, Duffin R, Haslett C, Tucker CS, Rossi AG. 
 8th European ZebraFish Meeting 9-13th July 2013, Barcelona: Investigating 
cyclin-dependent kinases in the resolution of innate inflammation using 
zebrafish tailfin injury.  Hoodless LJ, Lucas CD, Duffin R, Haslett C, Tucker 




 UK Home Office License for rodent and zebrafish handling. 
 Various Institute for Academic Development training courses, including 
writing and science communication workshops.  
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 Running workshops for children aged 6-11 at the annual Edinburgh 
International Science Festival 
 Demonstrator at the 2014 Zebrafish Transgenesis Workshop in Edinburgh. 
 Assisting with mentoring two Masters degree students 
